<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>1100</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="1100"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=1100&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=1000&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=1200&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928733435"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928733435?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928733435&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928733435&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0141813015002615"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928733435</prism:url><dc:identifier>SCOPUS_ID:84928733435</dc:identifier><eid>2-s2.0-84928733435</eid><dc:title>Human urinary renalase lacks the N-terminal signal peptide crucial for accommodation of its FAD cofactor</dc:title><dc:creator>Fedchenko V.</dc:creator><prism:publicationName>International Journal of Biological Macromolecules</prism:publicationName><prism:issn>01418130</prism:issn><prism:eIssn>18790003</prism:eIssn><prism:volume>78</prism:volume><prism:pageRange>347-353</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>July 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijbiomac.2015.04.023</prism:doi><pii>S0141813015002615</pii><dc:description>© 2015 Elsevier B.V. Renalase is a recently discovered secretory protein involved in the regulation of blood pressure. Cells synthesize all known isoforms of human renalase (1 and 2) as flavoproteins. Accommodation of FAD in the renalase protein requires the presence of its N-terminal peptide. However, in secretory proteins, such peptides are usually cleaved during their export from the cell. In the present study, we have isolated human renalase from urinary samples of healthy volunteers and human recombinant renalases 1 and 2 expressed in Escherichia coli cells. In these proteins, we investigated the presence of the renalase N-terminal peptide and the FAD cofactor and performed computer-aided molecular analysis of the renalase crystal structure to evaluate possible consequences of removal of the N-terminal peptide. In contrast to human recombinant renalase isoforms 1 and 2 containing non-covalently bound FAD and clearly detectable N-terminal peptide, renalase purified from human urine lacks both the N-terminal signal peptide and FAD. The computer-aided analysis indicates that the removal of this peptide results in inability of the truncated renalase to bind the FAD cofactor. Thus, our results indicate that human renalase secreted in urine lacks its N-terminal peptide, and therefore catalytic activities of urinary renalase reported in the literature cannot be attributed to FAD-dependent mechanisms. We suggest that FAD-dependent catalytic functions are intrinsic properties of intracellular renalases, whereas extracellular renalases act in FAD- and possibly catalytic-independent manner.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069638</affiliation-url><afid>60069638</afid><affilname>Institute of Biomedical Chemistry, Russian Academy of Medical Sciences</affilname><name-variant>Institute of Biomedical Chemistry</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6701446828</author-url><authid>6701446828</authid><authname>Fedchenko V.</authname><surname>Fedchenko</surname><given-name>Valerii I.</given-name><initials>V.I.</initials><afid>60069638</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602680161</author-url><authid>6602680161</authid><authname>Buneeva O.</authname><surname>Buneeva</surname><given-name>Olga A.</given-name><initials>O.A.</initials><afid>60069638</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:22980421100</author-url><authid>22980421100</authid><authname>Kopylov A.</authname><surname>Kopylov</surname><given-name>Arthur T.</given-name><initials>A.T.</initials><afid>60069638</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701511242</author-url><authid>6701511242</authid><authname>Veselovsky A.</authname><surname>Veselovsky</surname><given-name>Alexander V.</given-name><initials>A.V.</initials><afid>60069638</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602917155</author-url><authid>6602917155</authid><authname>Zgoda V.</authname><surname>Zgoda</surname><given-name>Victor G.</given-name><initials>V.G.</initials><afid>60069638</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7202004215</author-url><authid>7202004215</authid><authname>Medvedev A.</authname><surname>Medvedev</surname><given-name>Alexei E.</given-name><initials>A.E.</initials><afid>60069638</afid></author><authkeywords>FAD cofactor | N-terminal signaling peptide | Renalase</authkeywords><intid>35839786</intid><source-id>17544</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928138505"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928138505?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928138505&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928138505&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0022098115000520"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928138505</prism:url><dc:identifier>SCOPUS_ID:84928138505</dc:identifier><eid>2-s2.0-84928138505</eid><dc:title>Warmer water temperature results in oxidative damage in an antarctic fish, the bald notothen</dc:title><dc:creator>Carney Almroth B.</dc:creator><prism:publicationName>Journal of Experimental Marine Biology and Ecology</prism:publicationName><prism:issn>00220981</prism:issn><prism:volume>468</prism:volume><prism:pageRange>130-137</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>July 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jembe.2015.02.018</prism:doi><pii>S0022098115000520</pii><dc:description>© 2015 Elsevier B.V. Global climate change is predicted to result in increases in water temperature in the polar regions, but the full consequences of this for marine fish species are not understood, especially with regard to cellular mechanisms underlying oxidative stress. Warmer temperatures could potentially result in increased oxidative stress, and it is not known whether stenothermal fish can cope with this on a cellular and physiological level. In order to address this, we exposed bald notothen (. Pagothenia borchgrevinki), a fish species endemic to Antarctica, to an increase in temperature from -. 1.6. °C to 4. °C and measured the effects on oxidative stress including antioxidant defenses, oxidative damage in proteins and lipids, and transcriptional regulation of involved genes. We show that the fish responds to an acute (12. h) temperature increase with increased antioxidant defenses. However, these antioxidant defenses were similar to basal levels following long-term (3. weeks) exposure to the higher temperature and moreover, these individuals also had higher levels of oxidative damage. These results indicate that this species has the ability to alter levels of endogenous antioxidants, but that this response is transient and insufficient to protect against oxidative damage. These effects may have serious consequences for these fish in a warmer future since long-term consequences of this accumulation of damaged lipids and proteins are associated with aging and known to include decreased cellular function, disease and eventually cell death.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016437</affiliation-url><afid>60016437</afid><affilname>Goteborgs Universitet</affilname><name-variant>Göteborg University</name-variant><affiliation-city>Goteborg</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027152</affiliation-url><afid>60027152</afid><affilname>Sveriges lantbruksuniversitet</affilname><name-variant>Swedish University of Agricultural Sciences</name-variant><affiliation-city>Uppsala</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56600765200</author-url><authid>56600765200</authid><authname>Carney Almroth B.</authname><surname>Carney Almroth</surname><given-name>Bethanie</given-name><initials>B.</initials><afid>60016437</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603287865</author-url><authid>6603287865</authid><authname>Asker N.</authname><surname>Asker</surname><given-name>Noomi</given-name><initials>N.</initials><afid>60016437</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23036976500</author-url><authid>23036976500</authid><authname>Wassmur B.</authname><surname>Wassmur</surname><given-name>Britt</given-name><initials>B.</initials><afid>60016437</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55270712500</author-url><authid>55270712500</authid><authname>Rosengren M.</authname><surname>Rosengren</surname><given-name>Malin</given-name><initials>M.</initials><afid>60016437</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23018844700</author-url><authid>23018844700</authid><authname>Jutfelt F.</authname><surname>Jutfelt</surname><given-name>Fredrik</given-name><initials>F.</initials><afid>60016437</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24773121600</author-url><authid>24773121600</authid><authname>Gräns A.</authname><surname>Gräns</surname><given-name>Albin</given-name><initials>A.</initials><afid>60027152</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35474405800</author-url><authid>35474405800</authid><authname>Sundell K.</authname><surname>Sundell</surname><given-name>Kristina</given-name><initials>K.</initials><afid>60016437</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8668720400</author-url><authid>8668720400</authid><authname>Axelsson M.</authname><surname>Axelsson</surname><given-name>Michael</given-name><initials>M.</initials><afid>60016437</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6603241289</author-url><authid>6603241289</authid><authname>Sturve J.</authname><surname>Sturve</surname><given-name>Joachim</given-name><initials>J.</initials><afid>60016437</afid></author><authkeywords>Fish | Global warming | Oxidative damage | Oxidative stress | Polar</authkeywords><intid>1035728761</intid><source-id>29606</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928723655"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928723655?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928723655&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928723655&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0925443915001118"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928723655</prism:url><dc:identifier>SCOPUS_ID:84928723655</dc:identifier><eid>2-s2.0-84928723655</eid><dc:title>Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice</dc:title><dc:creator>Chan S.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Molecular Basis of Disease</prism:publicationName><prism:issn>09254439</prism:issn><prism:eIssn>1879260X</prism:eIssn><prism:volume>1852</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:pageRange>1511-1519</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>July 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbadis.2015.04.005</prism:doi><pii>S0925443915001118</pii><dc:description>© 2015 Elsevier B.V. Hepatic steatosis is often associated with insulin resistance as a hallmark of the metabolic syndrome in the liver. The present study investigated the effects of PPARα activation induced by fenofibrate (FB) on the relationship of insulin resistance and hepatic steatosis in mice fed a high-fat (HF) diet, which increases lipid influx into the liver. Mice were fed HF diet to induce insulin resistance and hepatic steatosis with or without FB. FB activated PPARα and ameliorated HF diet-induced glucose intolerance and hepatic insulin resistance without altering either hepatic steatosis or inflammation signaling (JNK or IKK). Interestingly, FB treatment simultaneously increased fatty acid (FA) synthesis (50%) and oxidation (66%, both p&lt;. 0.01) into intermediate lipid metabolites, suggesting a FA oxidation-synthesis cycling in operation. Associated with these effects, diacylglycerols (DAGs) were sequestered within the lipid droplet/ER compartment, thus reducing their deposition in the cellular membrane, which is known to impair insulin signal transduction. These findings suggest that the reduction in membrane DAGs (rather than total hepatic steatosis) may be critical for the protection by fenofibrate-induced PPARα activation against hepatic insulin resistance induced by dietary fat.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011362</affiliation-url><afid>60011362</afid><affilname>Royal Melbourne Institute of Technology University</affilname><name-variant>RMIT University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019578</affiliation-url><afid>60019578</afid><affilname>Monash University</affilname><name-variant>Monash University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55455843200</author-url><authid>55455843200</authid><authname>Chan S.</authname><surname>Chan</surname><given-name>Stanley M H</given-name><initials>S.M.H.</initials><afid>60011362</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36090560300</author-url><authid>36090560300</authid><authname>Zeng X.</authname><surname>Zeng</surname><given-name>Xiao Yi</given-name><initials>X.Y.</initials><afid>60011362</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:54994554600</author-url><authid>54994554600</authid><authname>Sun R.</authname><surname>Sun</surname><given-name>Ruo Qiong</given-name><initials>R.Q.</initials><afid>60011362</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56366149500</author-url><authid>56366149500</authid><authname>Jo E.</authname><surname>Jo</surname><given-name>Eunjung</given-name><initials>E.</initials><afid>60011362</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7410093065</author-url><authid>7410093065</authid><authname>Zhou X.</authname><surname>Zhou</surname><given-name>Xiu</given-name><initials>X.</initials><afid>60011362</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55748383600</author-url><authid>55748383600</authid><authname>Wang H.</authname><surname>Wang</surname><given-name>Hao</given-name><initials>H.</initials><afid>60011362</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56366149300</author-url><authid>56366149300</authid><authname>Li S.</authname><surname>Li</surname><given-name>Songpei</given-name><initials>S.</initials><afid>60011362</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56611283700</author-url><authid>56611283700</authid><authname>Xu A.</authname><surname>Xu</surname><given-name>Aimin</given-name><initials>A.</initials><afid>60006541</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56448217200</author-url><authid>56448217200</authid><authname>Watt M.</authname><surname>Watt</surname><given-name>Matthew J.</given-name><initials>M.J.</initials><afid>60019578</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7403237496</author-url><authid>7403237496</authid><authname>Ye J.</authname><surname>Ye</surname><given-name>Ji Ming</given-name><initials>J.M.</initials><afid>60011362</afid></author><authkeywords>DAG repartitioning | FA oxidation | FA synthesis | Insulin signaling | PPARα</authkeywords><intid>1785840157</intid><source-id>21722</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929484434"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929484434?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929484434&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929484434&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1353829215000507"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929484434</prism:url><dc:identifier>SCOPUS_ID:84929484434</dc:identifier><eid>2-s2.0-84929484434</eid><dc:title>"Nature is there; its free": Urban greenspace and the social determinants of health of immigrant families</dc:title><dc:creator>Hordyk S.</dc:creator><prism:publicationName>Health and Place</prism:publicationName><prism:issn>13538292</prism:issn><prism:eIssn>18732054</prism:eIssn><prism:volume>34</prism:volume><prism:pageRange>74-82</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>July 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.healthplace.2015.03.016</prism:doi><pii>S1353829215000507</pii><dc:description>© 2015 Elsevier Ltd. In this article, we draw on a 2012 Montreal-based study that examined the embodied, every day practices of immigrant children and families in the context of urban greenspaces such as parks, fields, backyards, streetscapes, gardens, forests and rivers. Results suggest that activities in the natural environment serve as a protective factor in the health and well-being of this population, providing emotional and physical nourishment in the face of adversity. Using the Social Determinants of Health model adopted by the World Health Organization (WHO, 1998), we analyze how participants accessed urban nature to minimize the effects of inadequate housing, to strengthen social cohesion and reduce emotional stress. We conclude with a discussion supporting the inclusion of the natural environment in the Social Determinants of Health Model.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002494</affiliation-url><afid>60002494</afid><affilname>McGill University</affilname><name-variant>McGill University</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115250279</affiliation-url><afid>115250279</afid><affilname>Les Amis de la Montagne</affilname><name-variant>Les Amis de la Montagne</name-variant><affiliation-city/><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55485973600</author-url><authid>55485973600</authid><authname>Hordyk S.</authname><surname>Hordyk</surname><given-name>Shawn Renee</given-name><initials>S.R.</initials><afid>60002494</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:16238393800</author-url><authid>16238393800</authid><authname>Hanley J.</authname><surname>Hanley</surname><given-name>Jill</given-name><initials>J.</initials><afid>60002494</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56647715500</author-url><authid>56647715500</authid><authname>Richard É.</authname><surname>Richard</surname><given-name>Éric</given-name><initials>É.</initials><afid>115250279</afid></author><authkeywords>Families | Immigration | Nature | Social determinants of health</authkeywords><intid>35964039</intid><source-id>29102</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927633586"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927633586?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927633586&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927633586&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S8756328215001143"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927633586</prism:url><dc:identifier>SCOPUS_ID:84927633586</dc:identifier><eid>2-s2.0-84927633586</eid><dc:title>Loss of milk fat globule-epidermal growth factor 8 (MFG-E8) in mice leads to low bone mass and accelerates ovariectomy-associated bone loss by increasing osteoclastogenesis</dc:title><dc:creator>Sinningen K.</dc:creator><prism:publicationName>Bone</prism:publicationName><prism:issn>87563282</prism:issn><prism:volume>76</prism:volume><prism:pageRange>107-114</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>July 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bone.2015.04.003</prism:doi><pii>S8756328215001143</pii><dc:description>© 2015 Elsevier Inc. Milk fat globule-epidermal growth factor 8 (MFG-E8) is a glycoprotein that controls the engulfment of apoptotic cells and exerts inflammation-modulatory effects. Recently, it has been implicated in osteoclastogenesis and the pathogenesis of inflammatory periodontal bone loss, but its role in physiological bone homeostasis is still not well defined. Here, we evaluated the influence of MFG-E8 on osteoblasts and osteoclasts and its impact on bone remodeling in healthy and ovariectomized mice as a model for post-menopausal osteoporosis.Total and trabecular bone mineral densities at the lumbar spine in 6-week-old MFG-E8 KO mice were reduced by 11% (p. &lt;. 0.05) and 17% (p. &lt;. 0.01), respectively, as compared to wild-type (WT) mice. Accordingly, serum levels of the bone formation marker P1NP were decreased by 37% (p. &lt;. 0.01) in MFG-E8 KO mice as were the ex vivo mineralization capacity and expression of osteoblast genes (Runx2, alkaline phosphatase, osteocalcin) in MFG-E8 KO osteoblasts. In contrast, serum bone resorption markers CTX1 and TRAP5b were increased by 30% and 60% (p. &lt;. 0.05), respectively, in MFG-E8 KO mice. Furthermore, bone marrow macrophages from MFG-E8-KO mice differentiated more effectively into osteoclasts, as compared to WT cells. MFG-E8-deficient osteoclasts displayed increased bone resorption ex vivo, which could be reversed by the presence of recombinant MFG-E8. To determine the significance of the enhanced osteoclastogenesis in MFG-E8 KO mice, we performed an ovariectomy, which is associated with bone loss due to increased osteoclast activity. Indeed, MFG-E8 KO mice lost 12% more trabecular bone density than WT mice after ovariectomy.Together, these data indicate that MFG-E8 controls steady-state and pathological bone turnover and may therefore represent a new target gene in the treatment of bone diseases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018353</affiliation-url><afid>60018353</afid><affilname>Technische Universitat Dresden</affilname><name-variant>Technische Universität Dresden</name-variant><affiliation-city>Dresden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018353</affiliation-url><afid>60018353</afid><affilname>Technische Universitat Dresden</affilname><name-variant>Technische Universität Dresden</name-variant><affiliation-city>Dresden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102531</affiliation-url><afid>60102531</afid><affilname>Center for Regenerative Therapies Dresden</affilname><name-variant>Center for Regenerative Therapies</name-variant><affiliation-city>Dresden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013409</affiliation-url><afid>60013409</afid><affilname>National Cancer Institute</affilname><name-variant>NIH</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102531</affiliation-url><afid>60102531</afid><affilname>Center for Regenerative Therapies Dresden</affilname><name-variant>Center for Regenerative Therapies</name-variant><affiliation-city>Dresden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025310</affiliation-url><afid>60025310</afid><affilname>Heinrich Heine Universitat</affilname><affiliation-city>Dusseldorf</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54382510800</author-url><authid>54382510800</authid><authname>Sinningen K.</authname><surname>Sinningen</surname><given-name>Kathrin</given-name><initials>K.</initials><afid>60018353</afid><afid>60025310</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54382510800</author-url><authid>54382510800</authid><authname>Sinningen K.</authname><surname>Sinningen</surname><given-name>Kathrin</given-name><initials>K.</initials><afid>60018353</afid><afid>60025310</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56593160700</author-url><authid>56593160700</authid><authname>Albus E.</authname><surname>Albus</surname><given-name>Elise</given-name><initials>E.</initials><afid>60018353</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37032104500</author-url><authid>37032104500</authid><authname>Thiele S.</authname><surname>Thiele</surname><given-name>Sylvia</given-name><initials>S.</initials><afid>60018353</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:49461196100</author-url><authid>49461196100</authid><authname>Grossklaus S.</authname><surname>Grossklaus</surname><given-name>Sylvia</given-name><initials>S.</initials><afid>60018353</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56592100200</author-url><authid>56592100200</authid><authname>Kurth T.</authname><surname>Kurth</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60102531</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006032452</author-url><authid>7006032452</authid><authname>Udey M.</authname><surname>Udey</surname><given-name>Mark C.</given-name><initials>M.C.</initials><afid>60013409</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004264075</author-url><authid>7004264075</authid><authname>Chavakis T.</authname><surname>Chavakis</surname><given-name>Triantafyllos</given-name><initials>T.</initials><afid>60018353</afid><afid>60102531</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004264075</author-url><authid>7004264075</authid><authname>Chavakis T.</authname><surname>Chavakis</surname><given-name>Triantafyllos</given-name><initials>T.</initials><afid>60018353</afid><afid>60102531</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006185414</author-url><authid>7006185414</authid><authname>Hofbauer L.</authname><surname>Hofbauer</surname><given-name>Lorenz C.</given-name><initials>L.C.</initials><afid>60018353</afid><afid>60102531</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006185414</author-url><authid>7006185414</authid><authname>Hofbauer L.</authname><surname>Hofbauer</surname><given-name>Lorenz C.</given-name><initials>L.C.</initials><afid>60018353</afid><afid>60102531</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35488927400</author-url><authid>35488927400</authid><authname>Rauner M.</authname><surname>Rauner</surname><given-name>Martina</given-name><initials>M.</initials><afid>60018353</afid></author><authkeywords>Bone homeostasis | MFG-E8 | Osteoblast | Osteoclast</authkeywords><intid>1535645435</intid><source-id>29551</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928790572"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928790572?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928790572&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928790572&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0196978115001308"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928790572</prism:url><dc:identifier>SCOPUS_ID:84928790572</dc:identifier><eid>2-s2.0-84928790572</eid><dc:title>Angiotensin-(1-7) through Mas receptor activation induces peripheral antinociception by interaction with adrenoreceptors</dc:title><dc:creator>Castor M.</dc:creator><prism:publicationName>Peptides</prism:publicationName><prism:issn>01969781</prism:issn><prism:eIssn>18735169</prism:eIssn><prism:volume>69</prism:volume><prism:pageRange>80-85</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>1 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.peptides.2015.04.011</prism:doi><pii>S0196978115001308</pii><dc:description>© 2015 Elsevier Inc. Angiotensin-(1-7) [Ang-(1-7)] develops its functions interacting with Mas receptor. Mas receptor was recently identified in the DRG and its activation by Ang-(1-7) resulted in peripheral antinociception against PGE&lt;inf&gt;2&lt;/inf&gt; hyperalgesia in an opioid-independent pathway. Nevertheless, the mechanism by which Ang-(1-7) induce peripheral antinociception was not yet elucidated. Considering that endogenous noradrenaline could induce antinociceptive effects by activation of the adrenoceptors the aim of this study was verify if the Ang-(1-7) is able to induce peripheral antinociception by interacting with the endogenous noradrenergic system. Hyperalgesia was induced by intraplantar injection of prostaglandin E&lt;inf&gt;2&lt;/inf&gt; (2 μg). Ang-(1-7) was administered locally into the right hindpaw alone and after either agents, α&lt;inf&gt;2&lt;/inf&gt;-adrenoceptor antagonist, yohimbine (5, 10 and 20 μg/paw), α&lt;inf&gt;2C&lt;/inf&gt;-adrenoceptor antagonist rauwolscine (10, 15 and 20 μg/paw), α&lt;inf&gt;1&lt;/inf&gt;-adrenoceptor antagonist prazosin (0.5, 1 and 2 μg/paw), β-adrenoceptor antagonist propranolol (150, 300 and 600 ng/paw). Noradrenaline (NA) reuptake inhibitor reboxetine (30 μg/paw) was administered prior to Ang-(1-7) low dose (20 ng) and guanetidine 3 days prior to experiment (30 mg/kg/animal, once a day), depleting NA storage. Intraplantar Ang-(1-7) induced peripheral antinociception against hyperalgesia induced by PGE&lt;inf&gt;2&lt;/inf&gt;. This effect was reversed, in dose dependent manner, by intraplantar injection of yohimbine, rauwolscine, prazosin and propranolol. Reboxetine intensified the antinociceptive effects of low-dose of Ang-(1-7) and guanethidine, which depletes peripheral sympathomimetic amines, reversed almost 70% the Ang-(1-7)-induced peripheral antinociception. Then, this study provides evidence that Ang-(1-7) induce peripheral antinociception stimulating an endogenous noradrenaline release that activates peripheral adrenoceptors inducing antinociception.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030074</affiliation-url><afid>60030074</afid><affilname>Universidade Federal de Minas Gerais</affilname><name-variant>Universidade Federal de Minas Gerais</name-variant><affiliation-city>Belo Horizonte</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030074</affiliation-url><afid>60030074</afid><affilname>Universidade Federal de Minas Gerais</affilname><name-variant>Universidade Federal de Minas Gerais</name-variant><affiliation-city>Belo Horizonte</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35739958800</author-url><authid>35739958800</authid><authname>Castor M.</authname><surname>Castor</surname><given-name>Marina G M</given-name><initials>M.G.M.</initials><afid>60030074</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8952484300</author-url><authid>8952484300</authid><authname>Santos R.</authname><surname>Santos</surname><given-name>Robson A S</given-name><initials>R.A.S.</initials><afid>60030074</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7007025426</author-url><authid>7007025426</authid><authname>Duarte I.</authname><surname>Duarte</surname><given-name>Igor D G</given-name><initials>I.D.G.</initials><afid>60030074</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:34873293700</author-url><authid>34873293700</authid><authname>Romero T.</authname><surname>Romero</surname><given-name>Thiago R L</given-name><initials>T.R.L.</initials><afid>60030074</afid></author><authkeywords>Adrenergic system | Adrenoceptor | Angiotensin 1-7 | Noradrenaline | Peripheral antinociception</authkeywords><intid>1035847560</intid><source-id>14222</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225547"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225547?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225547&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225547&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225547</prism:url><dc:identifier>SCOPUS_ID:84930225547</dc:identifier><eid>2-s2.0-84930225547</eid><dc:title>Clinical and biochemical effects of a 3-week program of diet combined with spa therapy in obese and diabetic patients: a pilot open study</dc:title><dc:creator>Fioravanti A.</dc:creator><prism:publicationName>International Journal of Biometeorology</prism:publicationName><prism:issn>00207128</prism:issn><prism:volume>59</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:pageRange>783-789</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>1 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s00484-014-0894-5</prism:doi><dc:description>© 2014, ISB. Obesity is a major risk factor for arterial hypertension, coronary artery disease, dyslipidemias, and type 2 diabetes. Spa therapy has long been used for treating obesity and its comorbidities. Enlargement of adipose tissue has been linked to a dysregulation of adipokine secretion and adipose tissue inflammation. Adipokines are currently investigated as potential drug targets in these conditions. Our primary aim was to assess the clinical efficacy of a 3-week program of diet combined with spa therapy in obese patients with and without type 2 diabetes. The secondary aim was to examine whether this combined program influences the response of serum levels of leptin, adiponectin, visfatin, and high-sensitivity C-reactive protein. Fifty obese males were enrolled and 21 of these featured a type 2 diabetes. During the 3-week period of the study, the patients were on a 1,000-kcal diet and were involved in mineral bath and total body’s mud-pack applications (15 procedures). Patients were assessed at baseline and at the end of the therapy for clinical and biochemical parameters (total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glycemia, and adipokines). We showed that a 3-week program of spa therapy in obese patients induced significant decrease of body weight, body mass index, triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, glycemia, and serum levels of leptin and high-sensitivity C-reactive protein. So, a cycle of mud-bath therapy associated with a controlled diet may be a promising treatment for obesity and type 2 diabetes decreasing body weight and many risk factors for atherosclerosis and metabolic syndrome.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002838</affiliation-url><afid>60002838</afid><affilname>Universita degli Studi di Siena</affilname><name-variant>Università di Siena</name-variant><affiliation-city>Siena</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293806</affiliation-url><afid>115293806</afid><affilname>Thermal Hospital</affilname><name-variant>Thermal Hospital</name-variant><affiliation-city>Ciechocinek</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002838</affiliation-url><afid>60002838</afid><affilname>Universita degli Studi di Siena</affilname><name-variant>Università di Siena</name-variant><affiliation-city>Siena</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024615</affiliation-url><afid>60024615</afid><affilname>Ludwik Rydygier Collegium Medicum in Bydgoszcz</affilname><name-variant>Nicolaus Copernicus University</name-variant><affiliation-city>Bydgoszcz</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56283748400</author-url><authid>56283748400</authid><authname>Fioravanti A.</authname><surname>Fioravanti</surname><given-name>Antonella</given-name><initials>A.</initials><afid>60002838</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35745682100</author-url><authid>35745682100</authid><authname>Adamczyk P.</authname><surname>Adamczyk</surname><given-name>Przemysław</given-name><initials>P.</initials><afid>115293806</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:20734913600</author-url><authid>20734913600</authid><authname>Pascarelli N.</authname><surname>Pascarelli</surname><given-name>Nicola Antonio</given-name><initials>N.A.</initials><afid>60002838</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25649683600</author-url><authid>25649683600</authid><authname>Giannitti C.</authname><surname>Giannitti</surname><given-name>Chiara</given-name><initials>C.</initials><afid>60002838</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003762624</author-url><authid>7003762624</authid><authname>Urso R.</authname><surname>Urso</surname><given-name>Renato</given-name><initials>R.</initials><afid>60002838</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56603204500</author-url><authid>56603204500</authid><authname>Tołodziecki M.</authname><surname>Tołodziecki</surname><given-name>Michał</given-name><initials>M.</initials><afid>60024615</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003990726</author-url><authid>7003990726</authid><authname>Ponikowska I.</authname><surname>Ponikowska</surname><given-name>Irena</given-name><initials>I.</initials><afid>60024615</afid></author><authkeywords>Adipokines | Body mass index | Obesity | Spa therapy | Type 2 diabetes | Weight</authkeywords><intid>536087159</intid><source-id>13506</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929093799"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929093799?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929093799&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929093799&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929093799</prism:url><dc:identifier>SCOPUS_ID:84929093799</dc:identifier><eid>2-s2.0-84929093799</eid><dc:title>The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease</dc:title><dc:creator>Kim T.</dc:creator><prism:publicationName>Journal of Cellular Biochemistry</prism:publicationName><prism:issn>07302312</prism:issn><prism:eIssn>10974644</prism:eIssn><prism:volume>116</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:pageRange>1171-1178</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>1 July 2015</prism:coverDisplayDate><prism:doi>10.1002/jcb.25077</prism:doi><dc:description>© 2014 Wiley Periodicals, Inc. © 2014 Wiley Periodicals, Inc. The important changes in body composition associated with aging are a decline in skeletal muscle mass and an increase in body fat. Body fat distribution also changes with age; subcutaneous fat decreases and visceral abdominal fat increase, which contributes to numerous cardiometabolic diseases (CMDs) such as type 2 diabetes, dyslipidemia, and cardiovascular disease (CVD). Sarcopenia often accompanied by an increase in body fat and vice versa, a scenario termed sarcopenic obesity (SO), which might lead to the cumulative risk of both sarcopenia and obesity. However, there is still no consensus regarding the definition and consequences of SO. The lack of a unified definition for SO might contribute to inconsistent findings about the association of SO with CMD. Complex etiologies are associated with development of SO. A vicious cycle between the loss of muscle and the accumulation of ectopic fat might be associated with CMD via an intricate interplay of factors including proinflammatory cytokines, oxidative stress, mitochondrial dysfunction, insulin resistance, dietary energy, physical activity, mitochondrial dysfunction, and other factors that have yet to be identified. Moreover, recent epidemiological studies suggest that SO is related to CVD and mortality. This review focuses on the current literature with regard to the association between sarcopenia, dynapenia, and obesity, as well as their implications for CMD. The ultimate goal of this Prospects is to encourage conduct of well-designed future studies that elucidate the relationship among sarcopenia, SO, and CMD. J. Cell. Biochem. 116: 1171-1178, 2015.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005273</affiliation-url><afid>60005273</afid><affilname>Korea University</affilname><name-variant>Korea University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015143</affiliation-url><afid>60015143</afid><affilname>Inje University</affilname><name-variant>Inje University</name-variant><affiliation-city>Gimhae</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56470027700</author-url><authid>56470027700</authid><authname>Kim T.</authname><surname>Kim</surname><given-name>Tae Nyun</given-name><initials>T.N.</initials><afid>60005273</afid><afid>60015143</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56470027700</author-url><authid>56470027700</authid><authname>Kim T.</authname><surname>Kim</surname><given-name>Tae Nyun</given-name><initials>T.N.</initials><afid>60005273</afid><afid>60015143</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7403949874</author-url><authid>7403949874</authid><authname>Choi K.</authname><surname>Choi</surname><given-name>Kyung Mook</given-name><initials>K.M.</initials><afid>60005273</afid></author><authkeywords>CARDIOMETABOLIC DISEASE | SARCOPENIA | SARCOPENIC OBESITY | VISCERAL OBESITY</authkeywords><intid>1785902099</intid><source-id>17598</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225651"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225651?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225651&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225651&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225651</prism:url><dc:identifier>SCOPUS_ID:84930225651</dc:identifier><eid>2-s2.0-84930225651</eid><dc:title>Automated discovery of lead users and latent product features by mining large scale social media networks</dc:title><dc:creator>Tuarob S.</dc:creator><prism:publicationName>Journal of Mechanical Design, Transactions of the ASME</prism:publicationName><prism:issn>10500472</prism:issn><prism:volume>137</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>1 July 2015</prism:coverDisplayDate><prism:doi>10.1115/1.4030049</prism:doi><dc:description>Copyright © 2015 by ASME. Lead users play a vital role in next generation product development, as they help designers discover relevant product feature preferences months or even years before they are desired by the general customer base. Existing design methodologies proposed to extract lead user preferences are typically constrained by temporal, geographic, size, and heterogeneity limitations. To mitigate these challenges, the authors of this work propose a set of mathematical models that mine social media networks for lead users and the product features that they express relating to specific products. The authors hypothesize that: (i) lead users are discoverable from large scale social media networks and (ii) product feature preferences, mined from lead user social media data, represent product features that do not currently exist in product offerings but will be desired in future product launches. An automated approach to lead user product feature identification is proposed to identify latent features (product features unknown to the public) from social media data. These latent features then serve as the key to discovering innovative users from the ever increasing pool of social media users. The authors collect 2.1×10&lt;sup&gt;9&lt;/sup&gt; social media messages in the United States during a period of 31 months (from March 2011 to September 2013) in order to determine whether lead user preferences are discoverable and relevant to next generation cell phone designs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001439</affiliation-url><afid>60001439</afid><affilname>Pennsylvania State University</affilname><name-variant>Pennsylvania State University</name-variant><affiliation-city>State College</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001439</affiliation-url><afid>60001439</afid><affilname>Pennsylvania State University</affilname><name-variant>Pennsylvania State University</name-variant><affiliation-city>State College</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:43661605700</author-url><authid>43661605700</authid><authname>Tuarob S.</authname><surname>Tuarob</surname><given-name>Suppawong</given-name><initials>S.</initials><afid>60001439</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15833577900</author-url><authid>15833577900</authid><authname>Tucker C.</authname><surname>Tucker</surname><given-name>Conrad S.</given-name><initials>C.S.</initials><afid>60001439</afid></author><intid>1786087436</intid><article-number>071402</article-number><source-id>20979</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929208465"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929208465?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929208465&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929208465&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315008219"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929208465</prism:url><dc:identifier>SCOPUS_ID:84929208465</dc:identifier><eid>2-s2.0-84929208465</eid><dc:title>Introducing bioresorbable scaffolds into the show. A potential adjunct to resuscitate Ross procedure</dc:title><dc:creator>Spadaccio C.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>50-52</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>1 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.098</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103293</affiliation-url><afid>60103293</afid><affilname>Golden Jubilee National Hospital</affilname><name-variant>Golden Jubilee National Hospital</name-variant><affiliation-city>Clydebank</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017293</affiliation-url><afid>60017293</afid><affilname>Universita degli Studi di Napoli Federico II</affilname><name-variant>University of Naples Federico II</name-variant><affiliation-city>Naples</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015622</affiliation-url><afid>60015622</afid><affilname>Hopital Pitie Salpetriere</affilname><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114802780</affiliation-url><afid>114802780</afid><affilname>Cardiac Surgery Centre Cardiologique du Nord de Saint-Denis</affilname><name-variant>Cardiac Surgery Centre Cardiologique du Nord de Saint-Denis</name-variant><affiliation-city/><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15061886300</author-url><authid>15061886300</authid><authname>Spadaccio C.</authname><surname>Spadaccio</surname><given-name>Cristiano</given-name><initials>C.</initials><afid>60103293</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6604046422</author-url><authid>6604046422</authid><authname>Montagnani S.</authname><surname>Montagnani</surname><given-name>Stefania</given-name><initials>S.</initials><afid>60017293</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56207622700</author-url><authid>56207622700</authid><authname>Acar C.</authname><surname>Acar</surname><given-name>Christophe</given-name><initials>C.</initials><afid>60015622</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603639321</author-url><authid>6603639321</authid><authname>Nappi F.</authname><surname>Nappi</surname><given-name>Francesco</given-name><initials>F.</initials><afid>114802780</afid></author><authkeywords>Bioresorbable scaffolds | Elastic remodeling | Ross operation</authkeywords><intid>1035912358</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926490101"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926490101?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926490101&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926490101&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S016748891500097X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926490101</prism:url><dc:identifier>SCOPUS_ID:84926490101</dc:identifier><eid>2-s2.0-84926490101</eid><dc:title>PKC theta and p38 MAPK activate the EBV lytic cycle through autophagy induction</dc:title><dc:creator>Gonnella R.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Molecular Cell Research</prism:publicationName><prism:issn>01674889</prism:issn><prism:eIssn>18792596</prism:eIssn><prism:volume>1853</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:pageRange>1586-1595</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>July 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbamcr.2015.03.011</prism:doi><pii>S016748891500097X</pii><dc:description>© 2015 Elsevier B.V. PKC activation by combining TPA with sodium butyrate (T/B) represents the most effective and widely used strategy to induce the Epstein-Barr virus (EBV) lytic cycle. The results obtained in this study show that novel PKCθ is involved in such process and that it acts through the activation of p38 MAPK and autophagy induction. Autophagy, a mechanism of cellular defense in stressful conditions, is manipulated by EBV to enhance viral replication. Besides promoting the EBV lytic cycle, the activation of p38 and autophagy resulted in a pro-survival effect, as indicated by p38 or ATG5 knocking down experiments. However, this pro-survival role was counteracted by a pro-death activity of PKCθ, due to the dephosphorylation of AKT. In conclusion, this study reports, for the first time, that T/B activates a PKCθ-p38 MAPK axis in EBV infected B cells, that promotes the viral lytic cycle and cell survival and dephosphorylates AKT, balancing cell life and cell death.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602365853</author-url><authid>6602365853</authid><authname>Gonnella R.</authname><surname>Gonnella</surname><given-name>Roberta</given-name><initials>R.</initials><afid>60032350</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8205213900</author-url><authid>8205213900</authid><authname>Granato M.</authname><surname>Granato</surname><given-name>Marisa</given-name><initials>M.</initials><afid>60032350</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202992415</author-url><authid>7202992415</authid><authname>Farina A.</authname><surname>Farina</surname><given-name>Antonella</given-name><initials>A.</initials><afid>60032350</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003648319</author-url><authid>7003648319</authid><authname>Santarelli R.</authname><surname>Santarelli</surname><given-name>Roberta</given-name><initials>R.</initials><afid>60032350</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006907188</author-url><authid>7006907188</authid><authname>Faggioni A.</authname><surname>Faggioni</surname><given-name>Alberto</given-name><initials>A.</initials><afid>60032350</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004592650</author-url><authid>7004592650</authid><authname>Cirone M.</authname><surname>Cirone</surname><given-name>Mara</given-name><initials>M.</initials><afid>60032350</afid></author><authkeywords>Autophagy | EBV | LC3 | Lytic cycle | P38 MAPK | PKCθ</authkeywords><intid>2035447462</intid><source-id>18408</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924674610"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924674610?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924674610&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924674610&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0309174015000522"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924674610</prism:url><dc:identifier>SCOPUS_ID:84924674610</dc:identifier><eid>2-s2.0-84924674610</eid><dc:title>Enzyme immunoassay and proteomic characterization of troponin I as a marker of mammalian muscle compounds in raw meat and some meat products</dc:title><dc:creator>Zvereva E.</dc:creator><prism:publicationName>Meat Science</prism:publicationName><prism:issn>03091740</prism:issn><prism:volume>105</prism:volume><prism:pageRange>46-52</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>July 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.meatsci.2015.03.001</prism:doi><pii>S0309174015000522</pii><dc:description>© 2015. The skeletal muscle protein troponin I (TnI) has been characterized as a potential thermally stable and species-specific biomarker of mammalian muscle tissues in raw meat and meat products. This study proposed a technique for the quantification of TnI comprising protein extraction and sandwich enzyme-linked immunosorbent assay (ELISA). The technique is characterized by a TnI detection limit of 4.8. ng/ml with quantifiable concentrations ranging from 8.7 to 52. ng/ml. The method was shown to be suitable for detection of TnI in mammalian (beef, pork, lamb, and horse) meat but not in poultry (chicken, turkey, and duck) meat. In particular, the TnI content in beef was 0.403. ±. 0.058. mg/g of wet tissue. The TnI estimations obtained for the pork and beef samples using ELISA were comparable to the proteomic analysis results. Thus, the quantitative study of TnI can be a convenient way to assess the mammalian muscle tissue content of various meat products.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021331</affiliation-url><afid>60021331</afid><affilname>Russian Academy of Sciences</affilname><name-variant>Russian Academy of Sciences</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115049639</affiliation-url><afid>115049639</afid><affilname>All-Russian Research Institute of Meat Industry named after V.M. Gorbatov</affilname><name-variant>All-Russian Research Institute of Meat Industry named after V.M. Gorbatov</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005763426</author-url><authid>7005763426</authid><authname>Zvereva E.</authname><surname>Zvereva</surname><given-name>Elena A.</given-name><initials>E.A.</initials><afid>60021331</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004540939</author-url><authid>7004540939</authid><authname>Kovalev L.</authname><surname>Kovalev</surname><given-name>Leonid I.</given-name><initials>L.I.</initials><afid>60021331</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56547892000</author-url><authid>56547892000</authid><authname>Ivanov A.</authname><surname>Ivanov</surname><given-name>Alexei V.</given-name><initials>A.V.</initials><afid>60021331</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701467064</author-url><authid>6701467064</authid><authname>Kovaleva M.</authname><surname>Kovaleva</surname><given-name>Marina A.</given-name><initials>M.A.</initials><afid>60021331</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35608006700</author-url><authid>35608006700</authid><authname>Zherdev A.</authname><surname>Zherdev</surname><given-name>Anatoly V.</given-name><initials>A.V.</initials><afid>60021331</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7102549922</author-url><authid>7102549922</authid><authname>Shishkin S.</authname><surname>Shishkin</surname><given-name>Sergey S.</given-name><initials>S.S.</initials><afid>60021331</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56525000800</author-url><authid>56525000800</authid><authname>Lisitsyn A.</authname><surname>Lisitsyn</surname><given-name>Andrey B.</given-name><initials>A.B.</initials><afid>115049639</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56413067100</author-url><authid>56413067100</authid><authname>Chernukha I.</authname><surname>Chernukha</surname><given-name>Irina M.</given-name><initials>I.M.</initials><afid>115049639</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7006549067</author-url><authid>7006549067</authid><authname>Dzantiev B.</authname><surname>Dzantiev</surname><given-name>Boris B.</given-name><initials>B.B.</initials><afid>60021331</afid></author><authkeywords>ELISA | Meat products | Proteomic study | Troponin I</authkeywords><intid>1535188198</intid><source-id>21219</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928665904"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928665904?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928665904&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928665904&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0091743515001073"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928665904</prism:url><dc:identifier>SCOPUS_ID:84928665904</dc:identifier><eid>2-s2.0-84928665904</eid><dc:title>Sedentary behavior and indicators of mental health in school-aged children and adolescents: A systematic review</dc:title><dc:creator>Suchert V.</dc:creator><prism:publicationName>Preventive Medicine</prism:publicationName><prism:issn>00917435</prism:issn><prism:eIssn>10960260</prism:eIssn><prism:volume>76</prism:volume><prism:pageRange>48-57</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>July 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ypmed.2015.03.026</prism:doi><pii>S0091743515001073</pii><dc:description>© 2015 Elsevier Inc. Objective: The presented systematic review aims at giving a comprehensive overview of studies assessing the relationship between sedentary behavior and indicators of mental health in school-aged children and adolescents. Methods: Six online databases (MEDLINE, EMBASE, PsycINFO, PsycARTICLES, CINAHL and SPORTDiscus) as well as personal libraries and reference lists of existing literature were searched for eligible studies. Results: Ninety-one studies met all inclusion criteria. There was strong evidence that high levels of screen time were associated with more hyperactivity/inattention problems and internalizing problems as well as with less psychological well-being and perceived quality of life. Concerning depressive symptoms, self-esteem, eating disorder symptoms, and anxiety symptoms, no clear conclusion could be drawn. But, taking quality assessment into account, self-esteem was negatively associated with sedentary behavior, i.e. high levels of time engaging in screen-based sedentary behavior were linked to lower scores in self-esteem. Conclusions: Overall, the association between sedentary behavior and mental health indicators was rather indeterminate. Future studies of high quality and with an objective measure of sedentary behavior will be necessary to further examine this association as well as to investigate longitudinal relationships and the direction of causality. Furthermore, more studies are needed to identify moderating and mediating variables.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60074872</affiliation-url><afid>60074872</afid><affilname>Institut fur Therapie- und Gesundheitsforschung (IFT-Nord)</affilname><name-variant>Institut für Therapie- und Gesundheitsforschung</name-variant><affiliation-city>Kiel</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55949146200</author-url><authid>55949146200</authid><authname>Suchert V.</authname><surname>Suchert</surname><given-name>Vivien</given-name><initials>V.</initials><afid>60074872</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701391249</author-url><authid>6701391249</authid><authname>Hanewinkel R.</authname><surname>Hanewinkel</surname><given-name>Reiner</given-name><initials>R.</initials><afid>60074872</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507188114</author-url><authid>6507188114</authid><authname>Isensee B.</authname><surname>Isensee</surname><given-name>Barbara</given-name><initials>B.</initials><afid>60074872</afid></author><authkeywords>Adolescent | Child | Mental health | Sedentary lifestyle | Systematic review</authkeywords><intid>1785824245</intid><source-id>17665</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926151461"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926151461?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926151461&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926151461&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0166432815001849"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926151461</prism:url><dc:identifier>SCOPUS_ID:84926151461</dc:identifier><eid>2-s2.0-84926151461</eid><dc:title>Increased palatable food intake and response to food cues in intrauterine growth-restricted rats are related to tyrosine hydroxylase content in the orbitofrontal cortex and nucleus accumbens</dc:title><dc:creator>Alves M.</dc:creator><prism:publicationName>Behavioural Brain Research</prism:publicationName><prism:issn>01664328</prism:issn><prism:eIssn>18727549</prism:eIssn><prism:volume>287</prism:volume><prism:pageRange>73-81</prism:pageRange><prism:coverDate>2015-07-01</prism:coverDate><prism:coverDisplayDate>July 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbr.2015.03.019</prism:doi><pii>S0166432815001849</pii><dc:description>© 2015 Elsevier B.V. Intrauterine growth restriction (IUGR) is associated with altered food preferences, which may contribute to increased risk of obesity. We evaluated the effects of IUGR on attention to a palatable food cue, as well as tyrosine hydroxylase (TH) content in the orbitofrontal cortex (OFC) and nucleus accumbens (NAcc) in response to sweet food intake. From day 10 of gestation and through lactation, Sprague-Dawley rats received either an ad libitum (Adlib) or a 50% food-restricted (FR) diet. At birth, pups were cross-fostered, generating four groups (gestation/lactation): Adlib/Adlib (control), FR/Adlib (intrauterine growth-restricted), Adlib/FR, and FR/FR. Adult attention to palatable food cues was measured using the Attentional Set-Shifting Task (ASST), which uses a sweet pellet as reward. TH content in the OFC and NAcc was measured at baseline and in response to palatable food intake. At 90 days of age, FR/Adlib males ate more sweet food than controls, without differences in females. However, when compared to Controls, FR/Adlib females needed fewer trials to reach criterion in the ASST (p= 0.04) and exhibited increased TH content in the OFC in response to sweet food (p= 0.03). In the NAcc, there was a differential response of TH content after sweet food intake in both FR/Adlib males and females (p&lt;. 0.05). Fetal programming of adult food preferences involves the central response to palatable food cues and intake, affecting dopamine release in select structures of the brain reward system.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006726</affiliation-url><afid>60006726</afid><affilname>Universidade Federal do Rio Grande do Sul</affilname><name-variant>Universidade Federal do Rio Grande do Sul</name-variant><affiliation-city>Porto Alegre</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014120</affiliation-url><afid>60014120</afid><affilname>Hospital de Clinicas de Porto Alegre</affilname><name-variant>Universidade Federal do Rio Grande do Sul</name-variant><affiliation-city>Porto Alegre</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016081</affiliation-url><afid>60016081</afid><affilname>Los Angeles County Harbor-UCLA Med Center</affilname><name-variant>Harbor-UCLA Medical Center</name-variant><affiliation-city>Torrance</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005247</affiliation-url><afid>60005247</afid><affilname>David Geffen School of Medicine at UCLA</affilname><name-variant>University of California</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56070228800</author-url><authid>56070228800</authid><authname>Alves M.</authname><surname>Alves</surname><given-name>Márcio Bonesso</given-name><initials>M.B.</initials><afid>60006726</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55505133600</author-url><authid>55505133600</authid><authname>Dalle Molle R.</authname><surname>Dalle Molle</surname><given-name>Roberta</given-name><initials>R.</initials><afid>60014120</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7201841080</author-url><authid>7201841080</authid><authname>Desai M.</authname><surname>Desai</surname><given-name>Mina</given-name><initials>M.</initials><afid>60016081</afid><afid>60005247</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7201841080</author-url><authid>7201841080</authid><authname>Desai M.</authname><surname>Desai</surname><given-name>Mina</given-name><initials>M.</initials><afid>60016081</afid><afid>60005247</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35464768900</author-url><authid>35464768900</authid><authname>Ross M.</authname><surname>Ross</surname><given-name>Michael G.</given-name><initials>M.G.</initials><afid>60016081</afid><afid>60005247</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35464768900</author-url><authid>35464768900</authid><authname>Ross M.</authname><surname>Ross</surname><given-name>Michael G.</given-name><initials>M.G.</initials><afid>60016081</afid><afid>60005247</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35944403200</author-url><authid>35944403200</authid><authname>Silveira P.</authname><surname>Silveira</surname><given-name>Patrícia Pelufo</given-name><initials>P.P.</initials><afid>60006726</afid><afid>60014120</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35944403200</author-url><authid>35944403200</authid><authname>Silveira P.</authname><surname>Silveira</surname><given-name>Patrícia Pelufo</given-name><initials>P.P.</initials><afid>60006726</afid><afid>60014120</afid></author><authkeywords>Attention | Dopamine | Feeding | Fetal growth restriction | Rats</authkeywords><intid>535407316</intid><source-id>14285</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930205298"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930205298?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930205298&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930205298&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930205298</prism:url><dc:identifier>SCOPUS_ID:84930205298</dc:identifier><eid>2-s2.0-84930205298</eid><dc:title>Around and around the merry-go-round: multiple implantations of short- and long-term ventricular assist devices in a patient with severe heart failure</dc:title><dc:creator>Sabashnikov A.</dc:creator><prism:publicationName>Journal of Artificial Organs</prism:publicationName><prism:issn>14347229</prism:issn><prism:eIssn>16190904</prism:eIssn><prism:volume>18</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>166-169</prism:pageRange><prism:coverDate>2015-06-30</prism:coverDate><prism:coverDisplayDate>30 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10047-014-0809-6</prism:doi><dc:description>© 2014, The Japanese Society for Artificial Organs. Multiple implantations of left ventricular assist devices over a period of three years were performed in a 17-year-old gentleman with non-ischaemic dilated cardiomyopathy and congestive cardiac failure. The first device (HeartMate II) was implanted as a bridge to transplantation. However, after few months of support the patient showed signs of myocardial recovery and the device was successfully explanted. After 2 years of uneventful follow-up, the patient’s condition deteriorated requiring further mechanical support. Due to the elevated risk associated with a redo full-support LVAD implantation, we decided to implant a partial support device (Synergy&lt;sup&gt;®&lt;/sup&gt; CircuLite). Because of recurrent pump thrombosis requiring device exchange, the final weeks to transplantation were bridged with CentriMag&lt;sup&gt;®&lt;/sup&gt; short-term LVAD. After successful cardiac transplantation the patient required further temporary extracorporeal membrane oxygenation support which was weaned off and explanted on the fourth postoperative day. After further uncomplicated postoperative recovery the patient was discharged and has been doing well for 1 year of follow-up.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024930</affiliation-url><afid>60024930</afid><affilname>Harefield Hospital</affilname><name-variant>Harefield Hospital</name-variant><affiliation-city>Harefield</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008658</affiliation-url><afid>60008658</afid><affilname>Uniklinik Koln</affilname><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:53464306800</author-url><authid>53464306800</authid><authname>Sabashnikov A.</authname><surname>Sabashnikov</surname><given-name>Anton</given-name><initials>A.</initials><afid>60024930</afid><afid>60008658</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:53464306800</author-url><authid>53464306800</authid><authname>Sabashnikov A.</authname><surname>Sabashnikov</surname><given-name>Anton</given-name><initials>A.</initials><afid>60024930</afid><afid>60008658</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56304970200</author-url><authid>56304970200</authid><authname>Butters T.</authname><surname>Butters</surname><given-name>Tom</given-name><initials>T.</initials><afid>60024930</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55978636800</author-url><authid>55978636800</authid><authname>Högerle B.</authname><surname>Högerle</surname><given-name>Benjamin</given-name><initials>B.</initials><afid>60024930</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36637326100</author-url><authid>36637326100</authid><authname>Hedger M.</authname><surname>Hedger</surname><given-name>Mike</given-name><initials>M.</initials><afid>60024930</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506399801</author-url><authid>6506399801</authid><authname>Zeriouh M.</authname><surname>Zeriouh</surname><given-name>Mohamed</given-name><initials>M.</initials><afid>60008658</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55979021800</author-url><authid>55979021800</authid><authname>Fatullayev J.</authname><surname>Fatullayev</surname><given-name>Javid</given-name><initials>J.</initials><afid>60024930</afid><afid>60008658</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55979021800</author-url><authid>55979021800</authid><authname>Fatullayev J.</authname><surname>Fatullayev</surname><given-name>Javid</given-name><initials>J.</initials><afid>60024930</afid><afid>60008658</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36899452500</author-url><authid>36899452500</authid><authname>Weymann A.</authname><surname>Weymann</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60024930</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:14008276900</author-url><authid>14008276900</authid><authname>Choi Y.</authname><surname>Choi</surname><given-name>Yeong Hoon</given-name><initials>Y.H.</initials><afid>60008658</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7005549835</author-url><authid>7005549835</authid><authname>Wahlers T.</authname><surname>Wahlers</surname><given-name>Thorsten</given-name><initials>T.</initials><afid>60008658</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55552579500</author-url><authid>55552579500</authid><authname>Popov A.</authname><surname>Popov</surname><given-name>Aron Frederik</given-name><initials>A.F.</initials><afid>60024930</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7401894717</author-url><authid>7401894717</authid><authname>Simon A.</authname><surname>Simon</surname><given-name>André R.</given-name><initials>A.R.</initials><afid>60024930</afid></author><authkeywords>Bridge to transplantation | Left ventricular assist device (LVAD) | LVAD thrombosis</authkeywords><intid>2036082495</intid><source-id>27215</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930081097"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930081097?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930081097&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930081097&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930081097</prism:url><dc:identifier>SCOPUS_ID:84930081097</dc:identifier><eid>2-s2.0-84930081097</eid><dc:title>The Association of Duration of Residence in the United States with Cardiovascular Disease Risk Factors Among South Asian Immigrants</dc:title><dc:creator>Bharmal N.</dc:creator><prism:publicationName>Journal of Immigrant and Minority Health</prism:publicationName><prism:issn>15571912</prism:issn><prism:eIssn>15571920</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>781-790</prism:pageRange><prism:coverDate>2015-06-30</prism:coverDate><prism:coverDisplayDate>30 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10903-013-9973-7</prism:doi><dc:description>© 2013, Springer Science+Business Media New York. South Asians are disproportionately impacted by cardiovascular disease (CVD). Our objective was to examine the association between duration of residence in the US and CVD risk factors among South Asian adult immigrants. Multivariate logistic regression analyses using pooled data from the 2005, 2007, 2009 California Health Interview Surveys. Duration of residence in the US &lt;15 years was significantly associated with overweight/obese BMI (OR 0.59; 95 % CI 0.35, 0.98 for 5 to &lt;10 years), daily consumption of 5+  servings of fruits/vegetables (OR 0.37; 95 % CI 0.15, 0.94 for 10 to &lt;15 years), and sedentary lifestyle (OR 2.11; 95 % CI 1.17, 3.81 for 10 to &lt;15 years) compared with duration of residence ≥15 years after adjusting for illness burden, healthcare access, and socio-demographic characteristics. Duration of residence was not significantly associated with other CVD risk factors. Duration of residence is an important correlate of overweight/obesity and other risk factors among South Asian immigrants.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031203</affiliation-url><afid>60031203</afid><affilname>University of California System</affilname><name-variant>Univ of California</name-variant><affiliation-city>Oakland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006577</affiliation-url><afid>60006577</afid><affilname>National Institutes of Health, Bethesda</affilname><name-variant>National Institute of Health</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029270</affiliation-url><afid>60029270</afid><affilname>UCLA School of Public Health</affilname><name-variant>University of California</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029270</affiliation-url><afid>60029270</afid><affilname>UCLA School of Public Health</affilname><name-variant>University of California</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005247</affiliation-url><afid>60005247</afid><affilname>David Geffen School of Medicine at UCLA</affilname><name-variant>University of California</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:49862618400</author-url><authid>49862618400</authid><authname>Bharmal N.</authname><surname>Bharmal</surname><given-name>Nazleen</given-name><initials>N.</initials><afid>60031203</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55584776930</author-url><authid>55584776930</authid><authname>Kaplan R.</authname><surname>Kaplan</surname><given-name>Robert M.</given-name><initials>R.M.</initials><afid>60006577</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7402159104</author-url><authid>7402159104</authid><authname>Shapiro M.</authname><surname>Shapiro</surname><given-name>Martin F.</given-name><initials>M.F.</initials><afid>60031203</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006355538</author-url><authid>7006355538</authid><authname>Mangione C.</authname><surname>Mangione</surname><given-name>Carol M.</given-name><initials>C.M.</initials><afid>60031203</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:34569678700</author-url><authid>34569678700</authid><authname>Kagawa-Singer M.</authname><surname>Kagawa-Singer</surname><given-name>Marjorie</given-name><initials>M.</initials><afid>60029270</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7403908593</author-url><authid>7403908593</authid><authname>Wong M.</authname><surname>Wong</surname><given-name>Mitchell D.</given-name><initials>M.D.</initials><afid>60031203</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102471160</author-url><authid>7102471160</authid><authname>McCarthy W.</authname><surname>McCarthy</surname><given-name>William J.</given-name><initials>W.J.</initials><afid>60029270</afid><afid>60005247</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102471160</author-url><authid>7102471160</authid><authname>McCarthy W.</authname><surname>McCarthy</surname><given-name>William J.</given-name><initials>W.J.</initials><afid>60029270</afid><afid>60005247</afid></author><authkeywords>Acculturation | Asian Americans | Cardiovascular disease | Immigrants | Risk factors | United States</authkeywords><intid>36062059</intid><source-id>2700147401</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930198919"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930198919?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930198919&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930198919&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930198919</prism:url><dc:identifier>SCOPUS_ID:84930198919</dc:identifier><eid>2-s2.0-84930198919</eid><dc:title>Iatrogenic-related transplant injuries: The role of the interventional radiologist</dc:title><dc:creator>Copelan A.</dc:creator><prism:publicationName>Seminars in Interventional Radiology</prism:publicationName><prism:issn>07399529</prism:issn><prism:eIssn>10988963</prism:eIssn><prism:volume>32</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>133-155</prism:pageRange><prism:coverDate>2015-06-30</prism:coverDate><prism:coverDisplayDate>30 June 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0035-1549842</prism:doi><dc:description>© 2015 by Thieme Medical Publishers, Inc. As advances in surgical techniques and postoperative care continue to improve outcomes, the use of solid organ transplants as a treatment for end-stage organ disease is increasing. With the growing population of transplant patients, there is an increasing need for radiologic diagnosis and minimally invasive procedures for the management of posttransplant complications. Typical complications may be vascular or nonvascular. Vascular complications include arterial stenosis, graft thrombosis, and development of fistulae. Common nonvascular complications consist of leaks, abscess formation, and stricture development. The use of interventional radiology in the management of these problems has led to better graft survival and lower patient morbidity and mortality. An understanding of surgical techniques, postoperative anatomy, radiologic findings, and management options for complications is critical for proficient management of complex transplant cases. This article reviews these factors for kidney, liver, pancreas, islet cell, lung, and small bowel transplants.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020117</affiliation-url><afid>60020117</afid><affilname>William Beaumont Hospital</affilname><name-variant>William Beaumont Hospital</name-variant><affiliation-city>Royal Oak</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029278</affiliation-url><afid>60029278</afid><affilname>University of Chicago</affilname><name-variant>University of Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006404</affiliation-url><afid>60006404</afid><affilname>CASE School of Medicine</affilname><name-variant>Case Western Reserve University School of Medicine</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24554070900</author-url><authid>24554070900</authid><authname>Copelan A.</authname><surname>Copelan</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60020117</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662739500</author-url><authid>56662739500</authid><authname>George D.</authname><surname>George</surname><given-name>Daniel</given-name><initials>D.</initials><afid>60020117</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005505558</author-url><authid>7005505558</authid><authname>Kapoor B.</authname><surname>Kapoor</surname><given-name>Baljendra</given-name><initials>B.</initials><afid>60021160</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662868800</author-url><authid>56662868800</authid><authname>Nghiem H.</authname><surname>Nghiem</surname><given-name>Hahn Vu</given-name><initials>H.V.</initials><afid>60020117</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7201873772</author-url><authid>7201873772</authid><authname>Lorenz J.</authname><surname>Lorenz</surname><given-name>Jonathan M.</given-name><initials>J.M.</initials><afid>60029278</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56663258300</author-url><authid>56663258300</authid><authname>Erly B.</authname><surname>Erly</surname><given-name>Brian</given-name><initials>B.</initials><afid>60021160</afid><afid>60006404</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56663258300</author-url><authid>56663258300</authid><authname>Erly B.</authname><surname>Erly</surname><given-name>Brian</given-name><initials>B.</initials><afid>60021160</afid><afid>60006404</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56549666200</author-url><authid>56549666200</authid><authname>Wang W.</authname><surname>Wang</surname><given-name>Weiping</given-name><initials>W.</initials><afid>60021160</afid></author><authkeywords>angioplasty | complications | interventional radiology | organ transplantation | percutaneous</authkeywords><intid>36086488</intid><source-id>17891</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209896"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209896?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209896&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209896&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209896</prism:url><dc:identifier>SCOPUS_ID:84930209896</dc:identifier><eid>2-s2.0-84930209896</eid><dc:title>Iatrogenic percutaneous vascular injuries: Clinical presentation, imaging, and management</dc:title><dc:creator>Ge B.</dc:creator><prism:publicationName>Seminars in Interventional Radiology</prism:publicationName><prism:issn>07399529</prism:issn><prism:eIssn>10988963</prism:eIssn><prism:volume>32</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>108-122</prism:pageRange><prism:coverDate>2015-06-30</prism:coverDate><prism:coverDisplayDate>30 June 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0035-1549375</prism:doi><dc:description>© 2015 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Vascular interventional radiology procedures are relatively safe compared with analogous surgical procedures, with overall major complication rates of less than 1%. However, major vascular injuries resulting from these procedures may lead to significant morbidity and mortality. This review will discuss the etiology, clinical presentation, diagnosis, and management of vascular complications related to percutaneous vascular interventions. Early recognition of these complications and familiarity with treatment options are essential skills for the interventional radiologist.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023009</affiliation-url><afid>60023009</afid><affilname>University of Pennsylvania, Health System</affilname><name-variant>Hospital of the University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020117</affiliation-url><afid>60020117</afid><affilname>William Beaumont Hospital</affilname><name-variant>William Beaumont Hospital</name-variant><affiliation-city>Royal Oak</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662769500</author-url><authid>56662769500</authid><authname>Ge B.</authname><surname>Ge</surname><given-name>Benjamin H.</given-name><initials>B.H.</initials><afid>60023009</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24554070900</author-url><authid>24554070900</authid><authname>Copelan A.</authname><surname>Copelan</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60020117</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662886200</author-url><authid>56662886200</authid><authname>Scola D.</authname><surname>Scola</surname><given-name>Dominic</given-name><initials>D.</initials><afid>60020117</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662761900</author-url><authid>56662761900</authid><authname>Watts M.</authname><surname>Watts</surname><given-name>Micah M.</given-name><initials>M.M.</initials><afid>60023009</afid></author><authkeywords>endovascular management of vascular injury | iatrogenic vascular injury | interventional radiology</authkeywords><intid>1536086973</intid><source-id>17891</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929300632"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929300632?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929300632&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929300632&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929300632</prism:url><dc:identifier>SCOPUS_ID:84929300632</dc:identifier><eid>2-s2.0-84929300632</eid><dc:title>Taxonomic relationships of pollens from matrix-assisted laser desorption/ionization time-of-flight mass spectrometry data using multivariate statistics</dc:title><dc:creator>Seifert S.</dc:creator><prism:publicationName>Rapid Communications in Mass Spectrometry</prism:publicationName><prism:issn>09514198</prism:issn><prism:eIssn>10970231</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>1145-1154</prism:pageRange><prism:coverDate>2015-06-30</prism:coverDate><prism:coverDisplayDate>30 June 2015</prism:coverDisplayDate><prism:doi>10.1002/rcm.7207</prism:doi><dc:description>Copyright © 2015 John Wiley &amp; Sons, Ltd. Copyright © 2015 John Wiley &amp; Sons, Ltd. Rationale Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) has been suggested as a promising tool for the investigation of pollen, but the usefulness of this approach for classification and identification of pollen species has to be proven by an application to samples of varying taxonomic relations. Method MALDI-MS in combination with hierarchical cluster analysis (HCA) and principal component analysis (PCA) was used to delineate taxonomic relations between plants based on pollen biochemistry. To assess the robustness of the approach, pollen of 74 species of the plant orders Fagales and Coniferales were probed. Results Discrimination at the levels of plant order and genus were achieved using the whole spectral range. In many cases, different species of the same genus could be distinguished. The sources of the spectral/chemical differences at the genus level can be understood using PCA. Specifically, typical mass regions for exact genus detection were identified. Conclusions Our results indicate that the chemical information represented by MALDI-TOFMS data is useful for reconstructing taxonomic relationships and is complementary to other chemical information on pollen from other spectroscopic data.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000762</affiliation-url><afid>60000762</afid><affilname>Humboldt-Universitat zu Berlin</affilname><name-variant>Humboldt University</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072294</affiliation-url><afid>60072294</afid><affilname>Federal Institute for Materials Research and Testing Berlin</affilname><name-variant>BAM Federal Institute for Materials Research and Testing</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55162525700</author-url><authid>55162525700</authid><authname>Seifert S.</authname><surname>Seifert</surname><given-name>Stephan</given-name><initials>S.</initials><afid>60000762</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7007145090</author-url><authid>7007145090</authid><authname>Weidner S.</authname><surname>Weidner</surname><given-name>Steffen M.</given-name><initials>S.M.</initials><afid>60072294</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55162009300</author-url><authid>55162009300</authid><authname>Panne U.</authname><surname>Panne</surname><given-name>Ulrich</given-name><initials>U.</initials><afid>60000762</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8350232400</author-url><authid>8350232400</authid><authname>Kneipp J.</authname><surname>Kneipp</surname><given-name>Janina</given-name><initials>J.</initials><afid>60000762</afid></author><intid>535946067</intid><source-id>24088</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930196831"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930196831?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930196831&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930196831&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930196831</prism:url><dc:identifier>SCOPUS_ID:84930196831</dc:identifier><eid>2-s2.0-84930196831</eid><dc:title>Transjugular intrahepatic portosystemic shunt complications: Prevention and management</dc:title><dc:creator>Suhocki P.</dc:creator><prism:publicationName>Seminars in Interventional Radiology</prism:publicationName><prism:issn>07399529</prism:issn><prism:eIssn>10988963</prism:eIssn><prism:volume>32</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>123-132</prism:pageRange><prism:coverDate>2015-06-30</prism:coverDate><prism:coverDisplayDate>30 June 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0035-1549376</prism:doi><dc:description>© 2015 by Thieme Medical Publishers, Inc. Transjugular intrahepatic portosystemic shunt (TIPS) insertion has been well established as an effective treatment in the management of sequelae of portal hypertension. There are a wide variety of complications that can be encountered, such as hemorrhage, encephalopathy, TIPS dysfunction, and liver failure. This review article summarizes various approaches to preventing and managing these complications.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005200</affiliation-url><afid>60005200</afid><affilname>Duke University School of Medicine</affilname><name-variant>Duke University Medical Center</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015615</affiliation-url><afid>60015615</afid><affilname>Stanford University Medical Center</affilname><name-variant>Stanford University Medical Center</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003897193</author-url><authid>7003897193</authid><authname>Suhocki P.</authname><surname>Suhocki</surname><given-name>Paul V.</given-name><initials>P.V.</initials><afid>60005200</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36729660500</author-url><authid>36729660500</authid><authname>Lungren M.</authname><surname>Lungren</surname><given-name>Matthew P.</given-name><initials>M.P.</initials><afid>60015615</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005505558</author-url><authid>7005505558</authid><authname>Kapoor B.</authname><surname>Kapoor</surname><given-name>Baljendra</given-name><initials>B.</initials><afid>60021160</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35484393400</author-url><authid>35484393400</authid><authname>Kim C.</authname><surname>Kim</surname><given-name>Charles Y.</given-name><initials>C.Y.</initials><afid>60005200</afid></author><authkeywords>complications | encephalopathy | interventional radiology | portal hypertension | transjugular intrahepatic portosystemic shunt</authkeywords><intid>536087786</intid><source-id>17891</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930207431"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930207431?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930207431&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930207431&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930207431</prism:url><dc:identifier>SCOPUS_ID:84930207431</dc:identifier><eid>2-s2.0-84930207431</eid><dc:title>A practical review of the use of stents for the maintenance of hemodialysis access</dc:title><dc:creator>Ginsburg M.</dc:creator><prism:publicationName>Seminars in Interventional Radiology</prism:publicationName><prism:issn>07399529</prism:issn><prism:eIssn>10988963</prism:eIssn><prism:volume>32</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>217-224</prism:pageRange><prism:coverDate>2015-06-30</prism:coverDate><prism:coverDisplayDate>30 June 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0035-1549844</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012708</affiliation-url><afid>60012708</afid><affilname>Stanford University</affilname><name-variant>Stanford University</name-variant><affiliation-city>Palo Alto</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029278</affiliation-url><afid>60029278</afid><affilname>University of Chicago</affilname><name-variant>University of Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005290</affiliation-url><afid>60005290</afid><affilname>University of Illinois</affilname><name-variant>University of Illinois</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:17034631500</author-url><authid>17034631500</authid><authname>Ginsburg M.</authname><surname>Ginsburg</surname><given-name>Michael</given-name><initials>M.</initials><afid>60012708</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7201873772</author-url><authid>7201873772</authid><authname>Lorenz J.</authname><surname>Lorenz</surname><given-name>Jonathan M.</given-name><initials>J.M.</initials><afid>60029278</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56001552500</author-url><authid>56001552500</authid><authname>Zivin S.</authname><surname>Zivin</surname><given-name>Sean P.</given-name><initials>S.P.</initials><afid>60005290</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507731237</author-url><authid>6507731237</authid><authname>Zangan S.</authname><surname>Zangan</surname><given-name>Steven</given-name><initials>S.</initials><afid>60029278</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662731500</author-url><authid>56662731500</authid><authname>Martinez D.</authname><surname>Martinez</surname><given-name>Don</given-name><initials>D.</initials><afid>60029278</afid></author><intid>1036082647</intid><source-id>17891</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929952249"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929952249?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929952249&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929952249&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929952249</prism:url><dc:identifier>SCOPUS_ID:84929952249</dc:identifier><eid>2-s2.0-84929952249</eid><dc:title>Patients with reduced heart rate response to adenosine infusion have low myocardial flow reserve in &lt;sup&gt;13&lt;/sup&gt;N-ammonia PET studies</dc:title><dc:creator>Tomiyama T.</dc:creator><prism:publicationName>International Journal of Cardiovascular Imaging</prism:publicationName><prism:issn>15695794</prism:issn><prism:eIssn>15730743</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>1089-1095</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10554-015-0654-6</prism:doi><dc:description>© 2015, The Author(s). To assess the effect of adenosine infusion by evaluating the relationship between heart rate (HR) response to adenosine and myocardial flow reserve (MFR) of remote regions supplied by normal coronary arteries in &lt;sup&gt;13&lt;/sup&gt;N-ammonia PET. Thirty-one consecutive subjects (20 known coronary artery disease patients, 4 chronic heart failure patients, and 7 normal volunteers) except cases having 3-vessel disease underwent rest and adenosine stress &lt;sup&gt;13&lt;/sup&gt;N-ammonia myocardial perfusion PET. Semi-quantitative, quantitative, and gated analyses were performed. Subjects were divided into two groups with regard to HR response to adenosine. Twenty-two subjects had normal HR response (peak/rest HR &gt; 1.20), while reduced HR response (≤1.20) was observed in nine subjects. There were no differences in rest myocardial blood flow (MBF) of remote regions between the groups. Subjects with reduced HR response had significantly lower stress MBF and MFR of remote regions than those with normal HR response (stress MBF: 1.559 ± 0.517 vs. 2.279 ± 0.530, p = 0.004, MFR: 1.59 ± 0.36 vs. 2.35 ± 0.53, p = 0.001). There were no significant differences between the groups by means of semi-quantitative scoring. Rest and stress ejection fraction (EF) in the reduced HR response group was lower than that in the normal HR response group. In a multiple stepwise regression analysis, HR ratio, dyslipidemia, and Brinkman index were identified as predictors of the change in MFR of remote regions. Subjects with reduced HR response to adenosine had lower stress MBF and MFR of remote regions and lower EF. Moreover, HR response was one of the predictors of the change in MFR of remote regions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018600</affiliation-url><afid>60018600</afid><affilname>Nippon Medical School</affilname><name-variant>Nippon Medical School</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018600</affiliation-url><afid>60018600</afid><affilname>Nippon Medical School</affilname><name-variant>Nippon Medical School</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018600</affiliation-url><afid>60018600</afid><affilname>Nippon Medical School</affilname><name-variant>Nippon Medical School</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55348855000</author-url><authid>55348855000</authid><authname>Tomiyama T.</authname><surname>Tomiyama</surname><given-name>Takeshi</given-name><initials>T.</initials><afid>60018600</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005408122</author-url><authid>7005408122</authid><authname>Kumita S.</authname><surname>Kumita</surname><given-name>Shin ichiro</given-name><initials>S.i.</initials><afid>60018600</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24460259300</author-url><authid>24460259300</authid><authname>Ishihara K.</authname><surname>Ishihara</surname><given-name>Keiichi</given-name><initials>K.</initials><afid>60018600</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55770838800</author-url><authid>55770838800</authid><authname>Suda M.</authname><surname>Suda</surname><given-name>Masaya</given-name><initials>M.</initials><afid>60018600</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36884449000</author-url><authid>36884449000</authid><authname>Sakurai M.</authname><surname>Sakurai</surname><given-name>Minoru</given-name><initials>M.</initials><afid>60018600</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8897661800</author-url><authid>8897661800</authid><authname>Hakozaki K.</authname><surname>Hakozaki</surname><given-name>Kenta</given-name><initials>K.</initials><afid>60018600</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56585223700</author-url><authid>56585223700</authid><authname>Hashimoto H.</authname><surname>Hashimoto</surname><given-name>Hidenobu</given-name><initials>H.</initials><afid>60018600</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55684314200</author-url><authid>55684314200</authid><authname>Takahashi N.</authname><surname>Takahashi</surname><given-name>Naoto</given-name><initials>N.</initials><afid>60018600</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7401826299</author-url><authid>7401826299</authid><authname>Takano H.</authname><surname>Takano</surname><given-name>Hitoshi</given-name><initials>H.</initials><afid>60018600</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:54391286500</author-url><authid>54391286500</authid><authname>Kobayashi Y.</authname><surname>Kobayashi</surname><given-name>Yasuhiro</given-name><initials>Y.</initials><afid>60018600</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56567707300</author-url><authid>56567707300</authid><authname>Kiriyama T.</authname><surname>Kiriyama</surname><given-name>Tomonari</given-name><initials>T.</initials><afid>60018600</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56585349300</author-url><authid>56585349300</authid><authname>Fukushima Y.</authname><surname>Fukushima</surname><given-name>Yoshimitsu</given-name><initials>Y.</initials><afid>60018600</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7005452152</author-url><authid>7005452152</authid><authname>Shimizu W.</authname><surname>Shimizu</surname><given-name>Wataru</given-name><initials>W.</initials><afid>60018600</afid></author><authkeywords>&lt;sup&gt;13&lt;/sup&gt;N-ammonia | Adenosine | Heart rate response | Myocardial blood flow (MBF) | Myocardial flow reserve (MFR) | Positron emission tomography (PET)</authkeywords><intid>36041517</intid><source-id>37971</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929956758"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929956758?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929956758&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929956758&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929956758</prism:url><dc:identifier>SCOPUS_ID:84929956758</dc:identifier><eid>2-s2.0-84929956758</eid><dc:title>Hand-held echocardiography in the setting of pre-operative cardiac evaluation of patients undergoing non-cardiac surgery: results from a randomized pilot study</dc:title><dc:creator>Cavallari I.</dc:creator><prism:publicationName>International Journal of Cardiovascular Imaging</prism:publicationName><prism:issn>15695794</prism:issn><prism:eIssn>15730743</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>995-1000</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10554-015-0656-4</prism:doi><dc:description>© 2015, Springer Science+Business Media Dordrecht. Transthoracic echocardiography is not a routine test in the pre-operative cardiac evaluation of patients undergoing non-cardiac surgery but may be considered in those with known heart failure and valvular heart disease or complaining cardiac symptoms. In this setting, hand-held echocardiography (HHE) could find a potential application as an alternative to standard echocardiography in selected patients; however, its utility in this context has not been investigated. The aim of this pilot study was to evaluate the conclusiveness of HHE compared to standard echocardiography in this subset of patients. 100 patients scheduled for non-cardiac surgery were randomized to receive a standard exam with a Philips Ie33 or a bedside evaluation with a pocket-size imaging device (Opti-Go, Philips Medical System). The primary endpoint was the percentage of satisfactory diagnosis at the end of the examination referred as conclusiveness. Secondary endpoints were the mean duration time and the mean waiting time to perform the exams. No significant difference in terms of conclusiveness between HHE and standard echo was found (86 vs 96 %; P = 0.08). Mean duration time of the examinations was 6.1 ± 1.2 min with HHE and 13.1 ± 2.6 min with standard echocardiography (P &lt; 0.001). HHE resulted in a consistent save of waiting time because it was performed the same day of clinical evaluation whereas patients waited 10.1 ± 6.1 days for a standard echocardiography (P &lt; 0.001). This study suggests the potential role of HHE for pre-operative evaluation of selected patients undergoing non-cardiac surgery, since it provided similar information but it was faster and earlier performed compared to standard echocardiography.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Campus Bio-Medico University</affilname><name-variant>Department of Cardiovascular Sciences</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56023619700</author-url><authid>56023619700</authid><authname>Cavallari I.</authname><surname>Cavallari</surname><given-name>Ilaria</given-name><initials>I.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8315239300</author-url><authid>8315239300</authid><authname>Mega S.</authname><surname>Mega</surname><given-name>Simona</given-name><initials>S.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:9736245200</author-url><authid>9736245200</authid><authname>Goffredo C.</authname><surname>Goffredo</surname><given-name>Costanza</given-name><initials>C.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003940338</author-url><authid>7003940338</authid><authname>Patti G.</authname><surname>Patti</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003658668</author-url><authid>7003658668</authid><authname>Chello M.</authname><surname>Chello</surname><given-name>Massimo</given-name><initials>M.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006231137</author-url><authid>7006231137</authid><authname>Di Sciascio G.</authname><surname>Di Sciascio</surname><given-name>Germano</given-name><initials>G.</initials><afid/></author><authkeywords>Echocardiography | Non-cardiac surgery | pocket-sized ultrasound | Pre-operative care</authkeywords><intid>1786042901</intid><source-id>37971</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930193066"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930193066?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930193066&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930193066&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930193066</prism:url><dc:identifier>SCOPUS_ID:84930193066</dc:identifier><eid>2-s2.0-84930193066</eid><dc:title>News from NIH: a center for translation research and implementation science</dc:title><dc:creator>Mensah G.</dc:creator><prism:publicationName>Translational Behavioral Medicine</prism:publicationName><prism:issn>18696716</prism:issn><prism:eIssn>16139860</prism:eIssn><prism:volume>5</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>127-130</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13142-015-0310-7</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006577</affiliation-url><afid>60006577</afid><affilname>National Institutes of Health, Bethesda</affilname><name-variant>National Institute of Health</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006775989</author-url><authid>7006775989</authid><authname>Mensah G.</authname><surname>Mensah</surname><given-name>George A.</given-name><initials>G.A.</initials><afid>60006577</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005006597</author-url><authid>7005006597</authid><authname>Engelgau M.</authname><surname>Engelgau</surname><given-name>Michael</given-name><initials>M.</initials><afid>60006577</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003454494</author-url><authid>7003454494</authid><authname>Stoney C.</authname><surname>Stoney</surname><given-name>Catherine</given-name><initials>C.</initials><afid>60006577</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663243700</author-url><authid>56663243700</authid><authname>Mishoe H.</authname><surname>Mishoe</surname><given-name>Helena</given-name><initials>H.</initials><afid>60006577</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662759500</author-url><authid>56662759500</authid><authname>Kaufmann P.</authname><surname>Kaufmann</surname><given-name>Peter</given-name><initials>P.</initials><afid>60006577</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56656434900</author-url><authid>56656434900</authid><authname>Freemer M.</authname><surname>Freemer</surname><given-name>Michelle</given-name><initials>M.</initials><afid>60006577</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56662825500</author-url><authid>56662825500</authid><authname>Fine L.</authname><surname>Fine</surname><given-name>Lawrence</given-name><initials>L.</initials><afid>60006577</afid></author><authkeywords>Behavior change | Implementation science | NIH funding opportunity | Population health impact | Prevention | Systems science | Translation research</authkeywords><intid>2036081631</intid><source-id>21100199546</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930212888"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930212888?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930212888&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930212888&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930212888</prism:url><dc:identifier>SCOPUS_ID:84930212888</dc:identifier><eid>2-s2.0-84930212888</eid><dc:title>An optically coupled sensor for the measurement of currents induced by MRI gradient fields into endocardial leads</dc:title><dc:creator>Mattei E.</dc:creator><prism:publicationName>Magnetic Resonance Materials in Physics, Biology and Medicine</prism:publicationName><prism:issn>09685243</prism:issn><prism:volume>28</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>291-303</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10334-014-0463-2</prism:doi><dc:description>© 2014, ESMRMB. Object: The gradient fields generated during magnetic resonance imaging (MRI) procedures have the potential to induce electrical current on implanted endocardial leads. Whether this current can result in undesired cardiac stimulation is unknown. Materials and methods: This paper provides a detailed description of how to construct an optically coupled sensor for the measurement of gradient-field–induced currents into endocardial leads. The system is based on a microcontroller that works as analog-to-digital converter and sends the current signal acquired from the lead to an optical high-speed, light-emitting diode transmitter. A plastic fiber guides the light outside the MRI chamber to a photodiode receiver and then to an acquisition board connected to a PC laptop. Results: The performance of the system has been characterized in terms of power consumption (8 mA on average), sampling frequency (20.5 kHz), measurement range (−12.8 to 10.3 mA) and resolution (22.6 µA). Results inside a 3 T MRI scanner are also presented. Conclusions: The detailed description of the current sensor could permit more standardized study of MRI gradient current induction in pacemaker systems. Results show the potential of gradient currents to affect the pacemaker capability of triggering a heartbeat, by modifying the overall energy delivered by the stimulator.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010062</affiliation-url><afid>60010062</afid><affilname>Istituto Superiore Di Sanita, Rome</affilname><name-variant>Istituto Superiore di Sanita</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017905</affiliation-url><afid>60017905</afid><affilname>IRCCS Ospedale Pediatrico Bambino Gesu</affilname><name-variant>Bambino Gesù Children's Hospital</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:22935173800</author-url><authid>22935173800</authid><authname>Mattei E.</authname><surname>Mattei</surname><given-name>Eugenio</given-name><initials>E.</initials><afid>60010062</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56240603000</author-url><authid>56240603000</authid><authname>Censi F.</authname><surname>Censi</surname><given-name>Federica</given-name><initials>F.</initials><afid>60010062</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:22936348600</author-url><authid>22936348600</authid><authname>Triventi M.</authname><surname>Triventi</surname><given-name>Michele</given-name><initials>M.</initials><afid>60010062</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55215552000</author-url><authid>55215552000</authid><authname>Napolitano A.</authname><surname>Napolitano</surname><given-name>Antonio</given-name><initials>A.</initials><afid>60017905</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36476423700</author-url><authid>36476423700</authid><authname>Genovese E.</authname><surname>Genovese</surname><given-name>Elisabetta</given-name><initials>E.</initials><afid>60017905</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16244373000</author-url><authid>16244373000</authid><authname>Cannatà V.</authname><surname>Cannatà</surname><given-name>Vittorio</given-name><initials>V.</initials><afid>60017905</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005890135</author-url><authid>7005890135</authid><authname>Calcagnini G.</authname><surname>Calcagnini</surname><given-name>Giovanni</given-name><initials>G.</initials><afid>60010062</afid></author><authkeywords>Electromagnetic fields | Pacemaker | Safety of implantable devices | Sensor design and characterization</authkeywords><intid>1036083084</intid><source-id>40970</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930199665"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930199665?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930199665&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930199665&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930199665</prism:url><dc:identifier>SCOPUS_ID:84930199665</dc:identifier><eid>2-s2.0-84930199665</eid><dc:title>Neuroimaging of Headaches Associated with Vascular Disorders</dc:title><dc:creator>Natarajan S.</dc:creator><prism:publicationName>Current Pain and Headache Reports</prism:publicationName><prism:issn>15313433</prism:issn><prism:eIssn>15343081</prism:eIssn><prism:volume>19</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11916-015-0489-9</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Headaches from vascular causes need to be differentiated from primary headaches because a misdiagnosis may lead to dire consequences for the patient. Neuroimaging is critical in identifying patients with vascular headaches and identifying the nature of the pathologic disorder causing these headaches. In addition, the imaging findings guide the physician regarding the optimal treatment modality for these lesions. This review summarizes the nuances of differentiating patients with secondary headaches related to vascular disease and discusses pertinent neuroimaging studies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032083</affiliation-url><afid>60032083</afid><affilname>University at Buffalo State University of New York</affilname><name-variant>State University of New York at Buffalo</name-variant><affiliation-city>Buffalo</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019049</affiliation-url><afid>60019049</afid><affilname>Kaleida Health</affilname><name-variant>Kaleida Health System</name-variant><affiliation-city>Buffalo</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011951</affiliation-url><afid>60011951</afid><affilname>University of South Florida College of Medicine</affilname><name-variant>University of South Florida College of Medicine</name-variant><affiliation-city>Tampa</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032083</affiliation-url><afid>60032083</afid><affilname>University at Buffalo State University of New York</affilname><name-variant>State University of New York at Buffalo</name-variant><affiliation-city>Buffalo</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032083</affiliation-url><afid>60032083</afid><affilname>University at Buffalo State University of New York</affilname><name-variant>State University of New York at Buffalo</name-variant><affiliation-city>Buffalo</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14013402000</author-url><authid>14013402000</authid><authname>Natarajan S.</authname><surname>Natarajan</surname><given-name>Sabareesh K.</given-name><initials>S.K.</initials><afid>60032083</afid><afid>60019049</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14013402000</author-url><authid>14013402000</authid><authname>Natarajan S.</authname><surname>Natarajan</surname><given-name>Sabareesh K.</given-name><initials>S.K.</initials><afid>60032083</afid><afid>60019049</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55448264000</author-url><authid>55448264000</authid><authname>Mokin M.</authname><surname>Mokin</surname><given-name>Maxim</given-name><initials>M.</initials><afid>60032083</afid><afid>60019049</afid><afid>60011951</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55448264000</author-url><authid>55448264000</authid><authname>Mokin M.</authname><surname>Mokin</surname><given-name>Maxim</given-name><initials>M.</initials><afid>60032083</afid><afid>60019049</afid><afid>60011951</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55448264000</author-url><authid>55448264000</authid><authname>Mokin M.</authname><surname>Mokin</surname><given-name>Maxim</given-name><initials>M.</initials><afid>60032083</afid><afid>60019049</afid><afid>60011951</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55364196800</author-url><authid>55364196800</authid><authname>Sonig A.</authname><surname>Sonig</surname><given-name>Ashish</given-name><initials>A.</initials><afid>60032083</afid><afid>60019049</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55364196800</author-url><authid>55364196800</authid><authname>Sonig A.</authname><surname>Sonig</surname><given-name>Ashish</given-name><initials>A.</initials><afid>60032083</afid><afid>60019049</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:13105759200</author-url><authid>13105759200</authid><authname>Levy E.</authname><surname>Levy</surname><given-name>Elad I.</given-name><initials>E.I.</initials><afid>60032083</afid><afid>60019049</afid><afid>60032083</afid><afid>60032083</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:13105759200</author-url><authid>13105759200</authid><authname>Levy E.</authname><surname>Levy</surname><given-name>Elad I.</given-name><initials>E.I.</initials><afid>60032083</afid><afid>60019049</afid><afid>60032083</afid><afid>60032083</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:13105759200</author-url><authid>13105759200</authid><authname>Levy E.</authname><surname>Levy</surname><given-name>Elad I.</given-name><initials>E.I.</initials><afid>60032083</afid><afid>60019049</afid><afid>60032083</afid><afid>60032083</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:13105759200</author-url><authid>13105759200</authid><authname>Levy E.</authname><surname>Levy</surname><given-name>Elad I.</given-name><initials>E.I.</initials><afid>60032083</afid><afid>60019049</afid><afid>60032083</afid><afid>60032083</afid></author><authkeywords>Cervical dissection | Headache | Neuroimaging | Vascular disorders | Vascular malformations</authkeywords><intid>1536087909</intid><article-number>16</article-number><source-id>14995</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929966490"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929966490?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929966490&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929966490&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929966490</prism:url><dc:identifier>SCOPUS_ID:84929966490</dc:identifier><eid>2-s2.0-84929966490</eid><dc:title>Role of tissue characterization by Cardiac Magnetic Resonance in the diagnosis of constrictive pericarditis</dc:title><dc:creator>Aquaro G.</dc:creator><prism:publicationName>International Journal of Cardiovascular Imaging</prism:publicationName><prism:issn>15695794</prism:issn><prism:eIssn>15730743</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>1021-1031</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10554-015-0648-4</prism:doi><dc:description>© 2015, Springer Science+Business Media Dordrecht. Cardiac Magnetic Resonance (CMR) allows evaluation of the functional and flow changes in pericardial constriction as well as detection of acute pericardial inflammation, fusion and thickening of pericardial layers and pericardial effusion. We sought to evaluate the diagnostic role of tissue characterization by CMR in constrictive pericarditis (CP). We performed a CMR exam in 70 patients (mean age 58 ± 16) with clinical suspicion of constrictive pericarditis and constrictive pattern at echocardiography and/or catheterization. A multiparametric CMR approach was used to evaluate the initial diagnostic suspicion. A clinical follow-up was performed in all patients for a median of 551 days. The diagnosis of CP was confirmed in 53 patients while 12 patients presented signs of predominant pericardial active inflammation suggesting a diagnosis of transient constrictive pericarditis and five presented effusive-constrictive pericarditis. Patients with a final diagnosis of CP had worse prognosis than those with transient constrictive or effusive constrictive pericarditis. The presence of myocardial late gadolinium enhancement was associated to adverse events. Results of the current study confirmed the value of CMR in the differential diagnosis of pericardial disease. A multiparametric CMR approach allowed to distinguish between active inflammation, chronic pericarditis with constriction and effusion without inflammation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115278665</affiliation-url><afid>115278665</afid><affilname>Fondazione CNR-Regione Toscana</affilname><name-variant>Fondazione CNR-Regione Toscana</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114746151</affiliation-url><afid>114746151</afid><affilname>Multimodality Cardiac Imaging Section</affilname><name-variant>Multimodality Cardiac Imaging Section</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35279306300</author-url><authid>35279306300</authid><authname>Aquaro G.</authname><surname>Aquaro</surname><given-name>Giovanni Donato</given-name><initials>G.D.</initials><afid>115278665</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24597524200</author-url><authid>24597524200</authid><authname>Barison A.</authname><surname>Barison</surname><given-name>Andrea</given-name><initials>A.</initials><afid>115278665</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55556219100</author-url><authid>55556219100</authid><authname>Cagnolo A.</authname><surname>Cagnolo</surname><given-name>Alessandro</given-name><initials>A.</initials><afid>115278665</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35390317100</author-url><authid>35390317100</authid><authname>Todiere G.</authname><surname>Todiere</surname><given-name>Giancarlo</given-name><initials>G.</initials><afid>115278665</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102494982</author-url><authid>7102494982</authid><authname>Lombardi M.</authname><surname>Lombardi</surname><given-name>Massimo</given-name><initials>M.</initials><afid>114746151</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005694410</author-url><authid>7005694410</authid><authname>Emdin M.</authname><surname>Emdin</surname><given-name>Michele</given-name><initials>M.</initials><afid>115278665</afid></author><authkeywords>Acute pericarditis | Cardiac Magnetic Resonance | Constrictive pericarditis | Pericardial effusion</authkeywords><intid>1786043052</intid><source-id>37971</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930200693"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930200693?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930200693&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930200693&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930200693</prism:url><dc:identifier>SCOPUS_ID:84930200693</dc:identifier><eid>2-s2.0-84930200693</eid><dc:title>Characterizing blood oxygen level-dependent (BOLD) response following in-magnet quadriceps exercise</dc:title><dc:creator>Caterini J.</dc:creator><prism:publicationName>Magnetic Resonance Materials in Physics, Biology and Medicine</prism:publicationName><prism:issn>09685243</prism:issn><prism:volume>28</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>271-278</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10334-014-0461-4</prism:doi><dc:description>© 2014, ESMRMB. Object: There have been no studies to investigate the effects of cycling exercise protocols, as well as repeated bouts of exercise, on the blood oxygen level-dependent (BOLD) response in the quadriceps muscles. This study characterized BOLD signal recovery following non-ischemic bouts of exercise in the quadriceps muscles of healthy adults in order to provide a basis for application of a protocol for clinical populations. Materials and methods: Healthy male subjects (23.7 ± 2.0 years of age, n = 10) completed three cycles of one-minute exercise (65 % of maximum workload), with two  minutes of rest between each bout, on an MRI-compatible ergometer. The BOLD responses during recovery were fitted to a sigmoid model, and response kinetics (post-exercise intensity [S&lt;inf&gt;0&lt;/inf&gt;]), response time (α), change in baseline BOLD signal (κ), and inflection point (β)] were measured. Results: The sigmoid function fit well to the post-exercise BOLD data (r&lt;sup&gt;2&lt;/sup&gt; = 0.95 ± 0.04). The mean response time was 10.5 ± 3.8 seconds, change in baseline BOLD intensity was 0.15 ± 0.068, and time to half-peak was 20.2 ± 8.6 seconds. Conclusion: The proposed sigmoid model is a robust method for quantifying quadriceps BOLD response post-exercise without induced ischemia. Extension of this model to evaluate microvascular responses in patients with chronic disease could improve our understanding of exercise intolerance.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030319</affiliation-url><afid>60030319</afid><affilname>Hospital for Sick Children University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030319</affiliation-url><afid>60030319</afid><affilname>Hospital for Sick Children University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031828</affiliation-url><afid>60031828</afid><affilname>McMaster University</affilname><name-variant>McMaster University</name-variant><affiliation-city>Hamilton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55754578200</author-url><authid>55754578200</authid><authname>Caterini J.</authname><surname>Caterini</surname><given-name>Jessica E.</given-name><initials>J.E.</initials><afid>60016849</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36126105900</author-url><authid>36126105900</authid><authname>Elzibak A.</authname><surname>Elzibak</surname><given-name>Alyaa H.</given-name><initials>A.H.</initials><afid>60030319</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662799700</author-url><authid>56662799700</authid><authname>Michel E.</authname><surname>Michel</surname><given-name>Emilie Jean St</given-name><initials>E.J.S.</initials><afid>60030319</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005952744</author-url><authid>7005952744</authid><authname>McCrindle B.</authname><surname>McCrindle</surname><given-name>Brian W.</given-name><initials>B.W.</initials><afid>60030319</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102622991</author-url><authid>7102622991</authid><authname>Redington A.</authname><surname>Redington</surname><given-name>Andrew N.</given-name><initials>A.N.</initials><afid>60030319</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55754883500</author-url><authid>55754883500</authid><authname>Thompson S.</authname><surname>Thompson</surname><given-name>Sara</given-name><initials>S.</initials><afid>60016849</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6701776288</author-url><authid>6701776288</authid><authname>Noseworthy M.</authname><surname>Noseworthy</surname><given-name>Michael D.</given-name><initials>M.D.</initials><afid>60031828</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:24069546500</author-url><authid>24069546500</authid><authname>Wells G.</authname><surname>Wells</surname><given-name>Greg D.</given-name><initials>G.D.</initials><afid>60030319</afid><afid>60016849</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:24069546500</author-url><authid>24069546500</authid><authname>Wells G.</authname><surname>Wells</surname><given-name>Greg D.</given-name><initials>G.D.</initials><afid>60030319</afid><afid>60016849</afid></author><authkeywords>BOLD imaging | Exercise | Skeletal muscle</authkeywords><intid>1536087313</intid><source-id>40970</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930194168"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930194168?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930194168&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930194168&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930194168</prism:url><dc:identifier>SCOPUS_ID:84930194168</dc:identifier><eid>2-s2.0-84930194168</eid><dc:title>Free-breathing, zero-TE MR lung imaging</dc:title><dc:creator>Gibiino F.</dc:creator><prism:publicationName>Magnetic Resonance Materials in Physics, Biology and Medicine</prism:publicationName><prism:issn>09685243</prism:issn><prism:volume>28</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>207-215</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10334-014-0459-y</prism:doi><dc:description>© 2014, ESMRMB. Object: The investigation of three-dimensional radial, zero-echo time (TE) imaging for high-resolution, free-breathing magnetic resonance (MR) lung imaging using prospective and retrospective motion correction. Materials and methods: Zero-TE was implemented similarly to the rotating-ultra-fast-imaging-sequence, providing 3D, isotropic, radial imaging with proton density contrast. Respiratory motion was addressed using prospective triggering (PT), prospective gating (PG) and retrospective gating (RG) with physiological signals obtained from a respiratory belt and interleaved pencil beam and DC navigators. The methods were demonstrated on four healthy volunteers at 3T. Results: 3D, radial zero-TE imaging with high imaging bandwidth and nominally zero echo-time enables efficient capture of short-lived signals from the lung parenchyma and the vessels. Compared to Cartesian encoding, unaccounted for free-breathing respiration resulted in only benign blurring artifacts confined to the origin of motion. Breath holding froze respiration but achieved only limited image resolution (~1.8 mm, 30 s). PT and PG obtained similar quality expiratory-phase images at 1.2 mm resolution in ~6 min scan time. RG allowed multi-phase imaging in ~15 min, derived from eight individually stored averages. Conclusion: Zero-TE appears to be an attractive pulse sequence for 3D isotropic lung imaging. Prospective and retrospective approaches provide high-quality, free-breathing MR lung imaging within reasonable scan time.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028868</affiliation-url><afid>60028868</afid><affilname>Universita di Pisa</affilname><name-variant>University of Pisa</name-variant><affiliation-city>Pisa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021211</affiliation-url><afid>60021211</afid><affilname>GE Global Research</affilname><name-variant>General Electric Research and Development Center</name-variant><affiliation-city>Niskayuna</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023843</affiliation-url><afid>60023843</afid><affilname>GE Healthcare, Sweden</affilname><name-variant>GE Healthcare ^</name-variant><affiliation-city>Uppsala</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021199</affiliation-url><afid>60021199</afid><affilname>Consiglio Nazionale delle Ricerche</affilname><name-variant>CNR</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009071</affiliation-url><afid>60009071</afid><affilname>Istituto di Fisiologia Clinica del CNR</affilname><name-variant>CNR</name-variant><affiliation-city>Pisa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55331915000</author-url><authid>55331915000</authid><authname>Gibiino F.</authname><surname>Gibiino</surname><given-name>Fabio</given-name><initials>F.</initials><afid>60028868</afid><afid>60021211</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55331915000</author-url><authid>55331915000</authid><authname>Gibiino F.</authname><surname>Gibiino</surname><given-name>Fabio</given-name><initials>F.</initials><afid>60028868</afid><afid>60021211</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:10045393400</author-url><authid>10045393400</authid><authname>Sacolick L.</authname><surname>Sacolick</surname><given-name>Laura</given-name><initials>L.</initials><afid>60023843</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55561198100</author-url><authid>55561198100</authid><authname>Menini A.</authname><surname>Menini</surname><given-name>Anne</given-name><initials>A.</initials><afid>60021211</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25422522900</author-url><authid>25422522900</authid><authname>Landini L.</authname><surname>Landini</surname><given-name>Luigi</given-name><initials>L.</initials><afid>60028868</afid><afid>60021199</afid><afid>60009071</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25422522900</author-url><authid>25422522900</authid><authname>Landini L.</authname><surname>Landini</surname><given-name>Luigi</given-name><initials>L.</initials><afid>60028868</afid><afid>60021199</afid><afid>60009071</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25422522900</author-url><authid>25422522900</authid><authname>Landini L.</authname><surname>Landini</surname><given-name>Luigi</given-name><initials>L.</initials><afid>60028868</afid><afid>60021199</afid><afid>60009071</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602498937</author-url><authid>6602498937</authid><authname>Wiesinger F.</authname><surname>Wiesinger</surname><given-name>Florian</given-name><initials>F.</initials><afid>60021211</afid></author><authkeywords>Lung imaging | Navigators | Respiratory motion | Zero echo-time | Zero TE</authkeywords><intid>2036082052</intid><source-id>40970</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930208275"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930208275?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930208275&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930208275&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930208275</prism:url><dc:identifier>SCOPUS_ID:84930208275</dc:identifier><eid>2-s2.0-84930208275</eid><dc:title>Theory-based approach for maintaining resistance training in older adults with prediabetes: adherence, barriers, self-regulation strategies, treatment fidelity, costs</dc:title><dc:creator>Winett R.</dc:creator><prism:publicationName>Translational Behavioral Medicine</prism:publicationName><prism:issn>18696716</prism:issn><prism:eIssn>16139860</prism:eIssn><prism:volume>5</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>149-159</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13142-015-0304-5</prism:doi><dc:description>© 2015, Society of Behavioral Medicine. Effectively preventing and treating chronic diseases through health behavior changes often require intensive theory- and evidence-based intervention including long-term maintenance components. We assessed the efficacy of theory-based maintenance approaches varying by dose for persistently performing resistance training (RT) with the hypothesis that a higher-dose social cognitive theory (SCT) approach would produce greater RT adherence than lower-dose Standard. The Resist-Diabetes study first established 2×/week resistance training (RT) in a 3-month supervised intervention in older (50–69 years, N = 170), overweight to obese (BMI 25–39.9 kg/m&lt;sup&gt;2&lt;/sup&gt;) previously inactive adults who fit prediabetes criteria (fasting glucose concentration = 95–125 mg/dl; oral glucose tolerance test 2-h glucose concentration = 140–199 mg/dl or both). After the supervised phase, participants (N = 159) were then randomly assigned to one of two conditions for transition (3 weeks) and then RT alone in community settings for extended contact, maintenance (6 months), and then no contact (6 months). SCT featured continued tailored, interactive personal, and web-based check-ups focused on RT, self-regulation, and a barrier/strategies approach. Standard involved low-dose, generic personal, and web-based check-ups within the same theoretical approach. SCT and Standard both resulted in similar RT, 2×/week adherence during maintenance (74.4 %) and no-contact phases (53.1 %). Cost analysis indicated the Standard intervention for transition and maintenance was inexpensive ($160). Standard can be translated into practice with the potential for continuous contact and persistence in RT beyond the typical program maintenance phase.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027090</affiliation-url><afid>60027090</afid><affilname>Virginia Polytechnic Institute and State University</affilname><name-variant>Virginia Polytechnic Institute and State University</name-variant><affiliation-city>Blacksburg</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027090</affiliation-url><afid>60027090</afid><affilname>Virginia Polytechnic Institute and State University</affilname><name-variant>Virginia Polytechnic Institute and State University</name-variant><affiliation-city>Blacksburg</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027090</affiliation-url><afid>60027090</afid><affilname>Virginia Polytechnic Institute and State University</affilname><name-variant>Virginia Polytechnic Institute and State University</name-variant><affiliation-city>Blacksburg</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114275216</affiliation-url><afid>114275216</afid><affilname>Personal Computer Resources, Inc.</affilname><name-variant>Personal Computer Resources, Inc.</name-variant><affiliation-city>Blacksburg</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011460</affiliation-url><afid>60011460</afid><affilname>Brown University</affilname><name-variant>Brown University</name-variant><affiliation-city>Providence</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005010246</author-url><authid>7005010246</authid><authname>Winett R.</authname><surname>Winett</surname><given-name>Richard A.</given-name><initials>R.A.</initials><afid>60027090</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003555184</author-url><authid>7003555184</authid><authname>Davy B.</authname><surname>Davy</surname><given-name>Brenda M.</given-name><initials>B.M.</initials><afid>60027090</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8659041600</author-url><authid>8659041600</authid><authname>Savla J.</authname><surname>Savla</surname><given-name>Jyoti</given-name><initials>J.</initials><afid>60027090</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:13403401900</author-url><authid>13403401900</authid><authname>Marinik E.</authname><surname>Marinik</surname><given-name>Elaina L.</given-name><initials>E.L.</initials><afid>60027090</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26659789300</author-url><authid>26659789300</authid><authname>Kelleher S.</authname><surname>Kelleher</surname><given-name>Sarah A.</given-name><initials>S.A.</initials><afid>60027090</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6506820055</author-url><authid>6506820055</authid><authname>Winett S.</authname><surname>Winett</surname><given-name>Sheila G.</given-name><initials>S.G.</initials><afid>114275216</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:38961352000</author-url><authid>38961352000</authid><authname>Halliday T.</authname><surname>Halliday</surname><given-name>Tanya M.</given-name><initials>T.M.</initials><afid>60027090</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7406554123</author-url><authid>7406554123</authid><authname>Williams D.</authname><surname>Williams</surname><given-name>David M.</given-name><initials>D.M.</initials><afid>60011460</afid></author><authkeywords>Behavioral maintenance | Cost | Diabetes | Health behavior change | Resistance training | Social cognitive theory | Treatment fidelity</authkeywords><intid>36085692</intid><source-id>21100199546</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930197669"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930197669?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930197669&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930197669&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930197669</prism:url><dc:identifier>SCOPUS_ID:84930197669</dc:identifier><eid>2-s2.0-84930197669</eid><dc:title>Proton spectroscopic imaging of brain metabolites in basal ganglia of healthy older adults</dc:title><dc:creator>Parikh J.</dc:creator><prism:publicationName>Magnetic Resonance Materials in Physics, Biology and Medicine</prism:publicationName><prism:issn>09685243</prism:issn><prism:volume>28</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>251-257</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10334-014-0465-0</prism:doi><dc:description>© 2014, The Author(s). Object: We sought to measure brain metabolite levels in healthy older people. Materials and methods: Spectroscopic imaging at the level of the basal ganglia was applied in 40 participants aged 73–74 years. Levels of the metabolites N-acetyl aspartate (NAA), choline, and creatine were determined in "institutional units" (IU) corrected for T1 and T2 relaxation effects. Structural imaging enabled determination of grey matter (GM), white matter (WM), and cerebrospinal fluid content. ANOVA analysis was carried out for voxels satisfying quality criteria. Results: Creatine levels were greater in GM than WM (57 vs. 44 IU, p &lt; 0.001), whereas choline and NAA levels were greater in WM than GM [13 vs. 10 IU (p &lt; 0.001) and 76 versus 70 IU (p = 0.03), respectively]. The ratio of NAA/cre was greater in WM than GM (2.1 vs. 1.4, p = 0.001) as was that of cho/cre (0.32 vs. 0.16, p &lt; 0.001). A low voxel yield was due to brain atrophy and the difficulties of shimming over an extended region of brain. Conclusion: This study addresses the current lack of information on brain metabolite levels in older adults. The normal features of ageing result in a substantial loss of reliable voxels and should be taken into account when planning studies. Improvements in shimming are also required before the methods can be applied more widely.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027272</affiliation-url><afid>60027272</afid><affilname>University of Edinburgh</affilname><name-variant>University of Edinburgh</name-variant><affiliation-city>Edinburgh</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027272</affiliation-url><afid>60027272</afid><affilname>University of Edinburgh</affilname><name-variant>University of Edinburgh</name-variant><affiliation-city>Edinburgh</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001881</affiliation-url><afid>60001881</afid><affilname>University of Sheffield</affilname><name-variant>University of Sheffield</name-variant><affiliation-city>Sheffield</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027272</affiliation-url><afid>60027272</afid><affilname>University of Edinburgh</affilname><name-variant>University of Edinburgh</name-variant><affiliation-city>Edinburgh</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027272</affiliation-url><afid>60027272</afid><affilname>University of Edinburgh</affilname><name-variant>University of Edinburgh</name-variant><affiliation-city>Edinburgh</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7101714163</author-url><authid>7101714163</authid><authname>Parikh J.</authname><surname>Parikh</surname><given-name>Jehill</given-name><initials>J.</initials><afid>60027272</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56635811800</author-url><authid>56635811800</authid><authname>Thrippleton M.</authname><surname>Thrippleton</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60027272</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35773520400</author-url><authid>35773520400</authid><authname>Murray C.</authname><surname>Murray</surname><given-name>Catherine</given-name><initials>C.</initials><afid>60027272</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103166287</author-url><authid>7103166287</authid><authname>Armitage P.</authname><surname>Armitage</surname><given-name>Paul A.</given-name><initials>P.A.</initials><afid>60001881</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8270690500</author-url><authid>8270690500</authid><authname>Harris B.</authname><surname>Harris</surname><given-name>Bridget A.</given-name><initials>B.A.</initials><afid>60027272</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56511083000</author-url><authid>56511083000</authid><authname>Andrews P.</authname><surname>Andrews</surname><given-name>Peter J D</given-name><initials>P.J.D.</initials><afid>60027272</afid><afid>60027272</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56511083000</author-url><authid>56511083000</authid><authname>Andrews P.</authname><surname>Andrews</surname><given-name>Peter J D</given-name><initials>P.J.D.</initials><afid>60027272</afid><afid>60027272</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35417533500</author-url><authid>35417533500</authid><authname>Wardlaw J.</authname><surname>Wardlaw</surname><given-name>Joanna M.</given-name><initials>J.M.</initials><afid>60027272</afid><afid>60027272</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35417533500</author-url><authid>35417533500</authid><authname>Wardlaw J.</authname><surname>Wardlaw</surname><given-name>Joanna M.</given-name><initials>J.M.</initials><afid>60027272</afid><afid>60027272</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7101906583</author-url><authid>7101906583</authid><authname>Starr J.</authname><surname>Starr</surname><given-name>John M.</given-name><initials>J.M.</initials><afid>60027272</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:36045816000</author-url><authid>36045816000</authid><authname>Deary I.</authname><surname>Deary</surname><given-name>Ian J.</given-name><initials>I.J.</initials><afid>60027272</afid><afid>60027272</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:36045816000</author-url><authid>36045816000</authid><authname>Deary I.</authname><surname>Deary</surname><given-name>Ian J.</given-name><initials>I.J.</initials><afid>60027272</afid><afid>60027272</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55758336800</author-url><authid>55758336800</authid><authname>Marshall I.</authname><surname>Marshall</surname><given-name>Ian</given-name><initials>I.</initials><afid>60027272</afid><afid>60027272</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55758336800</author-url><authid>55758336800</authid><authname>Marshall I.</authname><surname>Marshall</surname><given-name>Ian</given-name><initials>I.</initials><afid>60027272</afid><afid>60027272</afid></author><authkeywords>Ageing | Basal ganglia | Brain metabolites | Healthy volunteers | MR spectroscopy | Older adults</authkeywords><intid>1786087999</intid><source-id>40970</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930198504"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930198504?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930198504&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930198504&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930198504</prism:url><dc:identifier>SCOPUS_ID:84930198504</dc:identifier><eid>2-s2.0-84930198504</eid><dc:title>Network analysis of RE-AIM framework: chronology of the field and the connectivity of its contributors</dc:title><dc:creator>Shoup J.</dc:creator><prism:publicationName>Translational Behavioral Medicine</prism:publicationName><prism:issn>18696716</prism:issn><prism:eIssn>16139860</prism:eIssn><prism:volume>5</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>216-232</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13142-014-0300-1</prism:doi><dc:description>© 2014, Society of Behavioral Medicine. The reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework has been widely used for translational research. We used social network analysis (SNA) to explore how innovative research frameworks, such as RE-AIM, have diffused over time in academic literature. A structured literature review was conducted on RE-AIM between 1999 and 2012. SNA indices of degree score, betweenness, centrality, and authorship ties were used to examine use of RE-AIM. Use of RE-AIM has grown since its inception and spread from a few research centers to use internationally. Investigation of co-authorship revealed many have published on RE-AIM, but a much smaller core of RE-AIM researchers have published together two or more times. SNA revealed how the RE-AIM framework has been used over time and identified areas to further expand use of the framework. SNA can be useful to understand how research frameworks diffuse over time.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105527453</affiliation-url><afid>105527453</afid><affilname>Institute for Health Research</affilname><name-variant>Institute for Health Research</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010307</affiliation-url><afid>60010307</afid><affilname>University of Colorado at Denver</affilname><name-variant>University of Colorado Denver</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112489910</affiliation-url><afid>112489910</afid><affilname>Patient-Centered Outcomes Research Institute</affilname><name-variant>Patient Centered Outcomes Research Institute</name-variant><affiliation-city>Washington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010307</affiliation-url><afid>60010307</afid><affilname>University of Colorado at Denver</affilname><name-variant>University of Colorado Denver</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010307</affiliation-url><afid>60010307</afid><affilname>University of Colorado at Denver</affilname><name-variant>University of Colorado Denver</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028421</affiliation-url><afid>60028421</afid><affilname>University of Colorado School of Medicine</affilname><name-variant>University of Colorado</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23567026300</author-url><authid>23567026300</authid><authname>Shoup J.</authname><surname>Shoup</surname><given-name>Jo Ann</given-name><initials>J.A.</initials><afid>105527453</afid><afid>60010307</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23567026300</author-url><authid>23567026300</authid><authname>Shoup J.</authname><surname>Shoup</surname><given-name>Jo Ann</given-name><initials>J.A.</initials><afid>105527453</afid><afid>60010307</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507760299</author-url><authid>6507760299</authid><authname>Gaglio B.</authname><surname>Gaglio</surname><given-name>Bridget</given-name><initials>B.</initials><afid>112489910</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24469111400</author-url><authid>24469111400</authid><authname>Varda D.</authname><surname>Varda</surname><given-name>Danielle</given-name><initials>D.</initials><afid>60010307</afid><afid>60010307</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24469111400</author-url><authid>24469111400</authid><authname>Varda D.</authname><surname>Varda</surname><given-name>Danielle</given-name><initials>D.</initials><afid>60010307</afid><afid>60010307</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35401386000</author-url><authid>35401386000</authid><authname>Glasgow R.</authname><surname>Glasgow</surname><given-name>Russell E.</given-name><initials>R.E.</initials><afid>60010307</afid><afid>60028421</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35401386000</author-url><authid>35401386000</authid><authname>Glasgow R.</authname><surname>Glasgow</surname><given-name>Russell E.</given-name><initials>R.E.</initials><afid>60010307</afid><afid>60028421</afid></author><authkeywords>Co-authorship analyses | Evaluation | RE-AIM | Social network analyses</authkeywords><intid>1786087892</intid><source-id>21100199546</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930207272"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930207272?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930207272&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930207272&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930207272</prism:url><dc:identifier>SCOPUS_ID:84930207272</dc:identifier><eid>2-s2.0-84930207272</eid><dc:title>Engaging veterans with substance abuse disorders into a research trial: success with study branding, networking, and presence</dc:title><dc:creator>Michalek A.</dc:creator><prism:publicationName>Translational Behavioral Medicine</prism:publicationName><prism:issn>18696716</prism:issn><prism:eIssn>16139860</prism:eIssn><prism:volume>5</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>167-176</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13142-014-0302-z</prism:doi><dc:description>© 2015, Society of Behavioral Medicine. Recruiting and retaining clients in health interventions can be challenging especially when targeting multiple behavior change in high-risk populations. To inform the methods of trials working with similarly complex clinical populations, we describe multi-pronged efforts to recruit and retain a representative sample. In a two-group RCT, veterans were recruited from a Veteran Affairs Medical Center. The goal was to enroll 200 participants over a 25-month period, and to exceed 70 % follow-up for all treatment arms. To meet these goals, a four-pronged strategy was developed: branding, outreach/networking, onsite presence, and incentives. In month 1, 32 % of the proposed sample size was met (n = 64), and by month 2, 45 % (n = 90); the recruitment goal (n = 200) was achieved 13 months ahead of schedule. Retention exceeds 90 % at all time points out to 18 months. The multipronged recruitment and retention plan was efficient, cost effective, and may generalize to other health promotion initiatives.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023691</affiliation-url><afid>60023691</afid><affilname>University of California, San Francisco</affilname><name-variant>University of California, San Francisco</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032838</affiliation-url><afid>60032838</afid><affilname>Stanford University School of Medicine</affilname><name-variant>Stanford University School of Medicine</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662856200</author-url><authid>56662856200</authid><authname>Michalek A.</authname><surname>Michalek</surname><given-name>Anne Kathryn</given-name><initials>A.K.</initials><afid>60023691</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662839500</author-url><authid>56662839500</authid><authname>Kan D.</authname><surname>Kan</surname><given-name>David</given-name><initials>D.</initials><afid>60014232</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102777728</author-url><authid>7102777728</authid><authname>Prochaska J.</authname><surname>Prochaska</surname><given-name>Judith</given-name><initials>J.</initials><afid>60032838</afid></author><authkeywords>Methods research | Multiple-risk behavior change | Recruitment | Retention | Veteran health administration</authkeywords><intid>1786087095</intid><source-id>21100199546</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930202357"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930202357?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930202357&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930202357&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930202357</prism:url><dc:identifier>SCOPUS_ID:84930202357</dc:identifier><eid>2-s2.0-84930202357</eid><dc:title>Decisional outcomes following use of an interactive web-based decision aid for prostate cancer screening</dc:title><dc:creator>Tomko C.</dc:creator><prism:publicationName>Translational Behavioral Medicine</prism:publicationName><prism:issn>18696716</prism:issn><prism:eIssn>16139860</prism:eIssn><prism:volume>5</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>189-197</prism:pageRange><prism:coverDate>2015-06-29</prism:coverDate><prism:coverDisplayDate>29 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13142-014-0301-0</prism:doi><dc:description>© 2014, Society of Behavioral Medicine. Informed decision-making tools are recommended for men considering prostate cancer screening. We evaluated the extent to which use of an interactive, web-based decision aid was associated with decisional and screening outcomes. Participants (N = 253) were 57 (7.0) years old and completed telephone interviews at baseline, 1 month, and 13 months post-baseline. Tracking software captured minutes spent on the website (median = 33.9), sections viewed (median = 4.0/5.0), testimonials viewed (median = 4.0/6.0), and values clarification tool (VCT) use (77.3 %). In multivariable analyses, all four website use variables were positively associated with increased knowledge (p’s &lt; 0.05). Complete VCT use and number of informational sections were positively associated with greater decisional satisfaction (p’s &lt; 0.05). Decisional conflict and screening behavior were not associated with measures of website use. Increased use of informational content and interactive elements were related to improved knowledge and satisfaction. Methods to increase utilization of interactive website components may improve informed decision-making outcomes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020908</affiliation-url><afid>60020908</afid><affilname>Lombardi Comprehensive Cancer Center</affilname><name-variant>Georgetown University Medical Center</name-variant><affiliation-city>Washington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020908</affiliation-url><afid>60020908</afid><affilname>Lombardi Comprehensive Cancer Center</affilname><name-variant>Georgetown University Medical Center</name-variant><affiliation-city>Washington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55891159900</author-url><authid>55891159900</authid><authname>Tomko C.</authname><surname>Tomko</surname><given-name>Catherine</given-name><initials>C.</initials><afid>60020908</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:16030272700</author-url><authid>16030272700</authid><authname>Davis K.</authname><surname>Davis</surname><given-name>Kimberly</given-name><initials>K.</initials><afid>60020908</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663097900</author-url><authid>56663097900</authid><authname>Ludin S.</authname><surname>Ludin</surname><given-name>Samantha</given-name><initials>S.</initials><afid>60020908</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:41761841500</author-url><authid>41761841500</authid><authname>Kelly S.</authname><surname>Kelly</surname><given-name>Scott</given-name><initials>S.</initials><afid>60020908</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662742400</author-url><authid>56662742400</authid><authname>Stern A.</authname><surname>Stern</surname><given-name>Aaron</given-name><initials>A.</initials><afid>60020908</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603202583</author-url><authid>6603202583</authid><authname>Luta G.</authname><surname>Luta</surname><given-name>George</given-name><initials>G.</initials><afid>60020908</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7403523103</author-url><authid>7403523103</authid><authname>Taylor K.</authname><surname>Taylor</surname><given-name>Kathryn L.</given-name><initials>K.L.</initials><afid>60020908</afid></author><authkeywords>Informed decision making | Patient decision aids | Prostate cancer | Prostate cancer screening</authkeywords><intid>36086487</intid><source-id>21100199546</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226092"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226092?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226092&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226092&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226092</prism:url><dc:identifier>SCOPUS_ID:84930226092</dc:identifier><eid>2-s2.0-84930226092</eid><dc:title>Impact of cocoa flavanol intake on age-dependent vascular stiffness in healthy men: a randomized, controlled, double-masked trial</dc:title><dc:creator>Heiss C.</dc:creator><prism:publicationName>Age</prism:publicationName><prism:issn>01619152</prism:issn><prism:eIssn>15744647</prism:eIssn><prism:volume>37</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:coverDate>2015-06-28</prism:coverDate><prism:coverDisplayDate>28 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11357-015-9794-9</prism:doi><dc:description>© 2015, The Author(s). Increased vascular stiffness, endothelial dysfunction, and isolated systolic hypertension are hallmarks of vascular aging. Regular cocoa flavanol (CF) intake can improve vascular function in healthy young and elderly at-risk individuals. However, the mechanisms underlying CF bioactivity remain largely unknown. We investigated the effects of CF intake on cardiovascular function in healthy young and elderly individuals without history, signs, or symptoms of cardiovascular disease by applying particular focus on functional endpoints relevant to cardiovascular aging. In a randomized, controlled, double-masked, parallel-group dietary intervention trial, 22 young (&lt;35 years) and 20 elderly (50–80 year) healthy, male non-smokers consumed either a CF-containing drink (450 mg CF) or nutrient-matched, CF-free control drink bi-daily for 14 days. The primary endpoint was endothelial function as measured by flow-mediated vasodilation (FMD). Secondary endpoints included cardiac output, vascular stiffness, conductance of conduit and resistance arteries, and perfusion in the microcirculation. Following 2 weeks of CF intake, FMD improved in young (6.1 ± 0.7 vs. 7.6 ± 0.7 %, p &lt; 0.001) and elderly (4.9 ± 0.6 vs. 6.3 ± 0.9 %, p &lt; 0.001). Secondary outcomes demonstrated in both groups that CF intake decreased pulse wave velocity and lowered total peripheral resistance, and increased arteriolar and microvascular vasodilator capacity, red cell deformability, and diastolic blood pressure, while cardiac output remained affected. In the elderly, baseline systolic blood pressure was elevated, driven by an arterial-stiffness-related augmentation. CF intake decreased aortic augmentation index (−9 %) and thus systolic blood pressure (−7 mmHg; Clinicaltrials.gov: NCT01639781). CF intake reverses age-related burden of cardiovascular risk in healthy elderly, highlighting the potential of dietary flavanols to maintain cardiovascular health.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025310</affiliation-url><afid>60025310</afid><affilname>Heinrich Heine Universitat</affilname><affiliation-city>Dusseldorf</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012197</affiliation-url><afid>60012197</afid><affilname>University of Reading</affilname><name-variant>University of Reading</name-variant><affiliation-city>Reading</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100563449</affiliation-url><afid>100563449</afid><affilname>Mars, Inc.</affilname><name-variant>Mars, Incorporated</name-variant><affiliation-city>McLean/Washington, D.C.</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025310</affiliation-url><afid>60025310</afid><affilname>Heinrich Heine Universitat</affilname><affiliation-city>Dusseldorf</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35272137800</author-url><authid>35272137800</authid><authname>Heiss C.</authname><surname>Heiss</surname><given-name>Christian</given-name><initials>C.</initials><afid>60025310</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55497459700</author-url><authid>55497459700</authid><authname>Sansone R.</authname><surname>Sansone</surname><given-name>Roberto</given-name><initials>R.</initials><afid>60025310</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662784300</author-url><authid>56662784300</authid><authname>Karimi H.</authname><surname>Karimi</surname><given-name>Hakima</given-name><initials>H.</initials><afid>60025310</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663305100</author-url><authid>56663305100</authid><authname>Krabbe M.</authname><surname>Krabbe</surname><given-name>Moritz</given-name><initials>M.</initials><afid>60025310</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55661102900</author-url><authid>55661102900</authid><authname>Schuler D.</authname><surname>Schuler</surname><given-name>Dominik</given-name><initials>D.</initials><afid>60025310</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:13005658500</author-url><authid>13005658500</authid><authname>Rodriguez-Mateos A.</authname><surname>Rodriguez-Mateos</surname><given-name>Ana</given-name><initials>A.</initials><afid>60025310</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56662860300</author-url><authid>56662860300</authid><authname>Kraemer T.</authname><surname>Kraemer</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60025310</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55463515600</author-url><authid>55463515600</authid><authname>Cortese-Krott M.</authname><surname>Cortese-Krott</surname><given-name>Miriam Margherita</given-name><initials>M.M.</initials><afid>60025310</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7003769113</author-url><authid>7003769113</authid><authname>Kuhnle G.</authname><surname>Kuhnle</surname><given-name>Gunter G C</given-name><initials>G.G.C.</initials><afid>60012197</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:35449673700</author-url><authid>35449673700</authid><authname>Spencer J.</authname><surname>Spencer</surname><given-name>Jeremy P E</given-name><initials>J.P.E.</initials><afid>60012197</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7004322659</author-url><authid>7004322659</authid><authname>Schroeter H.</authname><surname>Schroeter</surname><given-name>Hagen</given-name><initials>H.</initials><afid>100563449</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6602823946</author-url><authid>6602823946</authid><authname>Merx M.</authname><surname>Merx</surname><given-name>Marc W.</given-name><initials>M.W.</initials><afid>60025310</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:24794775000</author-url><authid>24794775000</authid><authname>Kelm M.</authname><surname>Kelm</surname><given-name>Malte</given-name><initials>M.</initials><afid>60025310</afid><afid>60025310</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:24794775000</author-url><authid>24794775000</authid><authname>Kelm M.</authname><surname>Kelm</surname><given-name>Malte</given-name><initials>M.</initials><afid>60025310</afid><afid>60025310</afid></author><authkeywords>Age | Arterial stiffness | Blood pressure | Endothelial function | Nutrition</authkeywords><intid>536087545</intid><article-number>56</article-number><source-id>40283</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929961867"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929961867?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929961867&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929961867&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929961867</prism:url><dc:identifier>SCOPUS_ID:84929961867</dc:identifier><eid>2-s2.0-84929961867</eid><dc:title>Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis</dc:title><dc:creator>Garg N.</dc:creator><prism:publicationName>Clinical Rheumatology</prism:publicationName><prism:issn>07703198</prism:issn><prism:eIssn>14349949</prism:eIssn><prism:volume>34</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1065-1071</prism:pageRange><prism:coverDate>2015-06-28</prism:coverDate><prism:coverDisplayDate>28 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10067-015-2912-3</prism:doi><dc:description>© 2015, International League of Associations for Rheumatology (ILAR). Enhanced cardiovascular risk in ankylosing spondylitis (AS) provides a strong rationale for early therapeutical intervention. In view of the proven benefit of statins in atherosclerotic vascular disease, we aimed to investigate the effect of rosuvastatin on endothelial dysfunction (ED) and inflammatory disease activity in AS. In a single-blind, placebo-controlled, parallel study, 32 AS patients were randomized to receive 24 weeks of treatment with rosuvastatin (10 mg/day, n = 17) and placebo (n = 15) as an adjunct to existing stable antirheumatic drugs. Flow-mediated dilatation (FMD) was assessed by AngioDefender™ (Everest Genomic Ann Arbor, USA). Inflammatory measures (BASDAI, BASFI, CRP and ESR) and pro-inflammatory cytokines (tumour necrosis factor-alpha [TNF-α], interleukin-6 [IL-6] and interleukin-1 [IL-1]) were measured at baseline and after treatment. Lipids and adhesion molecules (intracellular adhesion molecule [ICAM-1] and vascular cell adhesion molecule [VCAM-1]) were estimated at baseline and after treatment. At baseline, inflammatory measures, pro inflammatory cytokines and adhesion molecules were elevated among both groups. After treatment with rosuvastatin, FMD improved significantly (p &lt; 0.01). Levels of inflammatory measures, TNF-α, IL-6 and ICAM-1 decreased significantly (p &lt; 0.01) after treatment with rosuvastatin. Rosuvastatin exerted positive effect on lipid spectrum. No significant change in the placebo group. Significant negative correlation was observed between FMD and IL-6, ICAM-1, CRP after treatment with rosuvastatin. First study to show that rosuvastatin improves inflammatory disease activity and ED in AS. Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-α, which downregulates adhesion molecules and CRP production which in turns improves ED. Improvement in ED in AS occurs through both cholesterol-independent and cholesterol-dependent pathways. Rosuvastatin can mediate modest but clinically apparent anti-inflammatory effects with modification of vascular risk factors in the context of high-grade autoimmune inflammation of AS.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000690</affiliation-url><afid>60000690</afid><affilname>Punjabi University Patiala</affilname><name-variant>Punjabi University</name-variant><affiliation-city>Patiala</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108324475</affiliation-url><afid>108324475</afid><affilname>Fortis Multi Speciality Hospital</affilname><name-variant>Chandigarh and Fortis Multi Speciality Hospital</name-variant><affiliation-city>Mohali</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8725505100</author-url><authid>8725505100</authid><authname>Garg N.</authname><surname>Garg</surname><given-name>Nidhi</given-name><initials>N.</initials><afid>60000690</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6504667438</author-url><authid>6504667438</authid><authname>Krishan P.</authname><surname>Krishan</surname><given-name>Pawan</given-name><initials>P.</initials><afid>60000690</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:26221986600</author-url><authid>26221986600</authid><authname>Syngle A.</authname><surname>Syngle</surname><given-name>Ashit</given-name><initials>A.</initials><afid>108324475</afid></author><authkeywords>Ankylosing spondylitis | Endothelial dysfunction | Flow-mediated dilatation | Inflammation | Rosuvastatin</authkeywords><intid>536043278</intid><source-id>19187</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209334"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209334?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209334&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209334&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209334</prism:url><dc:identifier>SCOPUS_ID:84930209334</dc:identifier><eid>2-s2.0-84930209334</eid><dc:title>Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications</dc:title><dc:creator>Keraliya A.</dc:creator><prism:publicationName>Insights into Imaging</prism:publicationName><prism:eIssn>18694101</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>381-392</prism:pageRange><prism:coverDate>2015-06-28</prism:coverDate><prism:coverDisplayDate>28 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13244-015-0407-z</prism:doi><dc:description>© 2015, The Author(s). Objective: The purpose of this article is to provide a comprehensive review of the role of imaging modalities other than PET/CT in the management of Hodgkin lymphoma (HL). PET/CT is the imaging modality of choice in the management of Hodgkin’s lymphoma (HL). However, imaging modalities other than PET/CT such as plain radiographs, ultrasound, CT, MRI and nuclear imaging can help in various stages of clinical management of HL, including the initial workup and post-treatment surveillance. Both CT and MRI help in detecting recurrences, treatment-related pulmonary, cardiovascular and abdominal complications as well as second malignancies. Familiarity with expected post-treatment changes and complications on surveillance images can help radiologists guide patient management. The purpose of this article is to provide a comprehensive review of the role of imaging modalities other than PET/CT in the management of Hodgkin lymphoma (HL). Main Messages: • Surveillance of HL patients is usually performed with plain radiographs and CT. • Follow-up imaging can depict normal post-treatment changes or treatment-related complications. • Imaging is important for the timely detection of second malignancies in HL patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014334</affiliation-url><afid>60014334</afid><affilname>Dana-Farber Cancer Institute</affilname><name-variant>Dana Farber Cancer Institute</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55917206100</author-url><authid>55917206100</authid><authname>Keraliya A.</authname><surname>Keraliya</surname><given-name>Abhishek R.</given-name><initials>A.R.</initials><afid>60016782</afid><afid>60014334</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55917206100</author-url><authid>55917206100</authid><authname>Keraliya A.</authname><surname>Keraliya</surname><given-name>Abhishek R.</given-name><initials>A.R.</initials><afid>60016782</afid><afid>60014334</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:47561978500</author-url><authid>47561978500</authid><authname>Tirumani S.</authname><surname>Tirumani</surname><given-name>Sree Harsha</given-name><initials>S.H.</initials><afid>60016782</afid><afid>60014334</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:47561978500</author-url><authid>47561978500</authid><authname>Tirumani S.</authname><surname>Tirumani</surname><given-name>Sree Harsha</given-name><initials>S.H.</initials><afid>60016782</afid><afid>60014334</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16025686700</author-url><authid>16025686700</authid><authname>Shinagare A.</authname><surname>Shinagare</surname><given-name>Atul B.</given-name><initials>A.B.</initials><afid>60016782</afid><afid>60014334</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16025686700</author-url><authid>16025686700</authid><authname>Shinagare A.</authname><surname>Shinagare</surname><given-name>Atul B.</given-name><initials>A.B.</initials><afid>60016782</afid><afid>60014334</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8512115300</author-url><authid>8512115300</authid><authname>Ramaiya N.</authname><surname>Ramaiya</surname><given-name>Nikhil H.</given-name><initials>N.H.</initials><afid>60016782</afid><afid>60014334</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8512115300</author-url><authid>8512115300</authid><authname>Ramaiya N.</authname><surname>Ramaiya</surname><given-name>Nikhil H.</given-name><initials>N.H.</initials><afid>60016782</afid><afid>60014334</afid></author><authkeywords>Computed tomography | Hodgkin lymphoma | MRI ultrasound | PET/CT</authkeywords><intid>536087308</intid><source-id>21100212112</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930207707"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930207707?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930207707&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930207707&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930207707</prism:url><dc:identifier>SCOPUS_ID:84930207707</dc:identifier><eid>2-s2.0-84930207707</eid><dc:title>The Nature and Influence of Teacher Beliefs and Knowledge on the Science Teaching Practice of Three Generalist New Zealand Primary Teachers</dc:title><dc:creator>Anderson D.</dc:creator><prism:publicationName>Research in Science Education</prism:publicationName><prism:issn>0157244X</prism:issn><prism:eIssn>15731898</prism:eIssn><prism:volume>45</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>395-423</prism:pageRange><prism:coverDate>2015-06-28</prism:coverDate><prism:coverDisplayDate>28 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11165-014-9428-8</prism:doi><dc:description>© 2014, Springer Science+Business Media Dordrecht. Students’ negative experiences of science in the primary sector have commonly been blamed on poor teacher content knowledge. Yet, teacher beliefs have long been identified as strong influences on classroom practice. Understanding the nature of teacher beliefs and their influence on primary science teaching practice could usefully inform teacher development initiatives. In science education, teacher beliefs about teaching and learning have been proposed as key influences in the development of pedagogical content knowledge for science teaching. This paper uses a multiple qualitative case study design to examine the nature and influence of beliefs on the practice and knowledge development of three generalist primary teachers during the implementation of a unit of work in science. Data for each case study included observations and transcripts of recordings of the lessons forming each science unit, together with multiple interviews with the teacher throughout its implementation. Findings support those of other researchers suggesting that beliefs about purposes of science education, the nature of science, and science teaching and learning strongly influence teacher practice and knowledge. Beliefs about the purposes of science education were found to be a particularly strong influence on practice in the observed cases. However, beliefs about students and the teachers’ aims for education generally, as well as teachers’ notions concerning vertical science curriculum, were also crucially influential on the type of science learning opportunities that were promoted. Beliefs were found to additionally influence the nature of both subject matter knowledge and pedagogical content knowledge for science developed by the teachers.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002316</affiliation-url><afid>60002316</afid><affilname>Victoria University of Wellington</affilname><name-variant>Victoria University of Wellington</name-variant><affiliation-city>Wellington</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26421074500</author-url><authid>26421074500</authid><authname>Anderson D.</authname><surname>Anderson</surname><given-name>Dayle</given-name><initials>D.</initials><afid>60002316</afid></author><authkeywords>Pedagogical content knowledge | Primary science education | Subject matter knowledge | Teacher beliefs | Teacher knowledge</authkeywords><intid>1036081575</intid><source-id>97030</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930195977"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930195977?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930195977&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930195977&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930195977</prism:url><dc:identifier>SCOPUS_ID:84930195977</dc:identifier><eid>2-s2.0-84930195977</eid><dc:title>Imaging of haemodialysis: renal and extrarenal findings</dc:title><dc:creator>Degrassi F.</dc:creator><prism:publicationName>Insights into Imaging</prism:publicationName><prism:eIssn>18694101</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>309-321</prism:pageRange><prism:coverDate>2015-06-28</prism:coverDate><prism:coverDisplayDate>28 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13244-015-0383-3</prism:doi><dc:description>© 2015, The Author(s). Electrolyte alterations and extra-renal disorders are quite frequent in patients undergoing haemodialysis or peritoneal dialysis. The native kidneys may be the site of important pathologies in patients undergoing dialysis, especially in the form of acquired renal cystic disease with frequent malignant transformation. Renal neoplasms represents an important complication of haemodialysis-associated acquired cystic kidney disease and imaging surveillance is suggested. Extra-renal complications include renal osteodistrophy, brown tumours, and thoracic and cardiovascular complications. Other important fields in which imaging techniques may provide important informations are arteriovenous fistula and graft complications. Teaching points • Renal neoplasms represent a dreaded complication of haemodialysis. • In renal osteodystrophy bone resorption typically manifests along the middle phalanges. • Brown tumours are well-defined lytic lesions radiographically, possibly causing bone expansion. • Vascular calcifications are very common in patients undergoing haemodialysis. • Principal complications of the AV fistula consist of thrombosis, aneurysms and pseudoaneurysms.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018363</affiliation-url><afid>60018363</afid><affilname>Universita degli Studi di Trieste</affilname><name-variant>Università di Trieste</name-variant><affiliation-city>Trieste</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55648041600</author-url><authid>55648041600</authid><authname>Degrassi F.</authname><surname>Degrassi</surname><given-name>Ferruccio</given-name><initials>F.</initials><afid>60018363</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004591510</author-url><authid>7004591510</authid><authname>Quaia E.</authname><surname>Quaia</surname><given-name>Emilio</given-name><initials>E.</initials><afid>60018363</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:18437509600</author-url><authid>18437509600</authid><authname>Martingano P.</authname><surname>Martingano</surname><given-name>Paola</given-name><initials>P.</initials><afid>60018363</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54903450700</author-url><authid>54903450700</authid><authname>Cavallaro M.</authname><surname>Cavallaro</surname><given-name>Marco</given-name><initials>M.</initials><afid>60018363</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005357625</author-url><authid>7005357625</authid><authname>Cova M.</authname><surname>Cova</surname><given-name>Maria Assunta</given-name><initials>M.A.</initials><afid>60018363</afid></author><authkeywords>Acquired cystic kidney disease | Dialysis access complications | Haemodialysis | Renal neoplasm | Renal osteodystrophy</authkeywords><intid>536087096</intid><source-id>21100212112</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929958529"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929958529?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929958529&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929958529&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929958529</prism:url><dc:identifier>SCOPUS_ID:84929958529</dc:identifier><eid>2-s2.0-84929958529</eid><dc:title>Erratum to: Psammoma bodies in two types of human ovarian tumours: a mineralogical study</dc:title><dc:creator>Meng F.</dc:creator><prism:publicationName>Mineralogy and Petrology</prism:publicationName><prism:issn>09300708</prism:issn><prism:volume>109</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>367-375</prism:pageRange><prism:coverDate>2015-06-28</prism:coverDate><prism:coverDisplayDate>28 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00710-015-0381-7</prism:doi><dc:description>© 2015, Springer-Verlag Wien. Psammoma body (PB) is a common form of calcification in pathological diagnosis and closely relevant to tumours. This paper focuses on the mineralogical characteristics of PBs in ovarian serous cancer and teratoma by using polarization microscope (POM), environmental scanning electron microscope (ESEM), micro-Fourier transform infrared spectroscopy (micro-FT-IR), transmission electron microscope (TEM), micro-area synchrotron radiation X-ray powder diffraction (μ-SRXRD) and fluorescence (μ-SRXRF). Both the PBs in tissues and separated from eight typical cases were investigated. POM and ESEM observation revealed the inside-out growth pattern of PBs. μ-SRXRD and micro-FT-IR results demonstrated the dominant mineral phase of PBs in ovarian serous cancer and teratoma was AB-type carbonate hydroxyapatite (Ca&lt;inf&gt;10&lt;/inf&gt;[(PO&lt;inf&gt;4&lt;/inf&gt;)&lt;inf&gt;6-x-y&lt;/inf&gt;(CO&lt;inf&gt;3&lt;/inf&gt;)&lt;inf&gt;x&lt;/inf&gt;(HPO&lt;inf&gt;4&lt;/inf&gt;)&lt;inf&gt;y&lt;/inf&gt;][(OH)&lt;inf&gt;2−u&lt;/inf&gt;(CO&lt;inf&gt;3&lt;/inf&gt;)&lt;inf&gt;u&lt;/inf&gt;] with 0 ≤ x,y,u ≤ 2). As observed by ESEM and TEM, the layer-rich PBs in teratoma were up to 70 μm and mainly consisted of 5 nm-wide, 5-12 nm-long columnar crystals; the PBs in ovarian serous cancer with a maximum diameter of 35 μm were composed of slightly longer columnar crystals and granulates with 20-100 nm in diameter. The selected area electron diffraction patterns showed dispersed polycrystalline diffraction rings with arching behavior of (002) diffraction, indicating the aggregated nanocrystals grew in the preferred orientation of (002) face. The EDX and μ-SRXRF results together indicated the existence of Na, Mg, Zn and Sr in PBs. These detailed mineralogical characteristics may help uncover the nature of the pathological PBs in ovary.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014966</affiliation-url><afid>60014966</afid><affilname>Peking University</affilname><name-variant>Peking University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014966</affiliation-url><afid>60014966</afid><affilname>Peking University</affilname><name-variant>Peking University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114557008</affiliation-url><afid>114557008</afid><affilname>Chaihu Health Center of Zhongxiang</affilname><name-variant>Chaihu Health Center of Zhongxiang</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>er</subtype><subtypeDescription>Erratum</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55768537100</author-url><authid>55768537100</authid><authname>Meng F.</authname><surname>Meng</surname><given-name>Fanlu</given-name><initials>F.</initials><afid>60014966</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56651547200</author-url><authid>56651547200</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>Changqiu</given-name><initials>C.</initials><afid>60014966</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55876451200</author-url><authid>55876451200</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yan</given-name><initials>Y.</initials><afid>60014966</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202481288</author-url><authid>7202481288</authid><authname>Lu A.</authname><surname>Lu</surname><given-name>Anhuai</given-name><initials>A.</initials><afid>60014966</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26434808700</author-url><authid>26434808700</authid><authname>Mei F.</authname><surname>Mei</surname><given-name>Fang</given-name><initials>F.</initials><afid>60014966</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56651496000</author-url><authid>56651496000</authid><authname>Liu J.</authname><surname>Liu</surname><given-name>Jianying</given-name><initials>J.</initials><afid>60014966</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56651434700</author-url><authid>56651434700</authid><authname>Du J.</authname><surname>Du</surname><given-name>Jingyun</given-name><initials>J.</initials><afid>114557008</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56651860100</author-url><authid>56651860100</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yan</given-name><initials>Y.</initials><afid>60014966</afid></author><intid>1536042343</intid><source-id>16933</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929961586"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929961586?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929961586&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929961586&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929961586</prism:url><dc:identifier>SCOPUS_ID:84929961586</dc:identifier><eid>2-s2.0-84929961586</eid><dc:title>Low-molecular-weight adiponectin is more closely associated with disease activity of rheumatoid arthritis than other adiponectin multimeric forms</dc:title><dc:creator>Li P.</dc:creator><prism:publicationName>Clinical Rheumatology</prism:publicationName><prism:issn>07703198</prism:issn><prism:eIssn>14349949</prism:eIssn><prism:volume>34</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1025-1030</prism:pageRange><prism:coverDate>2015-06-28</prism:coverDate><prism:coverDisplayDate>28 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10067-015-2899-9</prism:doi><dc:description>© 2015, International League of Associations for Rheumatology (ILAR). Adiponectin is divided into high-molecular-weight (HMW), medium-molecular-weight (MMW), and low-molecular-weight (LMW) forms. These forms differ not only in the number of adiponectin molecules but also in their biological activity. There are conflicting findings regarding the role of adiponectin in rheumatoid arthritis (RA). Moreover, few reports have described the relationships between serum adiponectin multimers levels and RA. Therefore, we examined the association of total adiponectin and its multimers with RA. Two study groups were examined: 180 recently diagnosed untreated RA patients with disease duration less than 1 year (RA group) and 160 age- and sex-matched control subjects (control group). RA-related factors, blood pressure, body mass index, glucose, complete lipid profile, and adiponectin multimers were measured. The levels of total adiponectin and each multimer of adiponectin were significantly lower in the RA than in the control (P &lt; 0.01). Serum levels of total, HMW, MMW, and LMW were positively correlated with triglycerides levels and negatively correlated with the Disease Activity Score for 28 joints (DAS28). Multivariate regression analysis showed that total, HMW, and MMW adiponectin were independently associated with serum triglycerides level. LMW adiponectin was independently correlated with serum triglycerides level and DAS28. The decreased LMW adiponectin levels may be associated with disease activity of RA.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007711</affiliation-url><afid>60007711</afid><affilname>Jilin University</affilname><name-variant>Jilin University</name-variant><affiliation-city>Changchun</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100485709</affiliation-url><afid>100485709</afid><affilname>Daqing Longnan Hospital</affilname><name-variant>Daqing Longnan Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56542013300</author-url><authid>56542013300</authid><authname>Li P.</authname><surname>Li</surname><given-name>Ping</given-name><initials>P.</initials><afid>60007711</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56541949100</author-url><authid>56541949100</authid><authname>Yang L.</authname><surname>Yang</surname><given-name>Li</given-name><initials>L.</initials><afid>60007711</afid><afid>100485709</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56541949100</author-url><authid>56541949100</authid><authname>Yang L.</authname><surname>Yang</surname><given-name>Li</given-name><initials>L.</initials><afid>60007711</afid><afid>100485709</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55839337400</author-url><authid>55839337400</authid><authname>Ma C.</authname><surname>Ma</surname><given-name>Cui li</given-name><initials>C.l.</initials><afid>60007711</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56541930600</author-url><authid>56541930600</authid><authname>Liu B.</authname><surname>Liu</surname><given-name>Bo</given-name><initials>B.</initials><afid>60007711</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56542695000</author-url><authid>56542695000</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xin</given-name><initials>X.</initials><afid>60007711</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56542631800</author-url><authid>56542631800</authid><authname>Ding R.</authname><surname>Ding</surname><given-name>Rui</given-name><initials>R.</initials><afid>60007711</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:8564802700</author-url><authid>8564802700</authid><authname>Bi L.</authname><surname>Bi</surname><given-name>Li qi</given-name><initials>L.q.</initials><afid>60007711</afid></author><authkeywords>Adiponectin | Disease activity | LMW adiponectin | Rheumatoid arthritis</authkeywords><intid>536042883</intid><source-id>19187</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226339"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226339?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226339&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226339&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226339</prism:url><dc:identifier>SCOPUS_ID:84930226339</dc:identifier><eid>2-s2.0-84930226339</eid><dc:title>Naproxen-Enriched Artificial Sediment Induces Oxidative Stress and Genotoxicity in Hyalella azteca</dc:title><dc:creator>Lucero G.</dc:creator><prism:publicationName>Water, Air, and Soil Pollution</prism:publicationName><prism:issn>00496979</prism:issn><prism:eIssn>15732932</prism:eIssn><prism:volume>226</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-27</prism:coverDate><prism:coverDisplayDate>27 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11270-015-2454-y</prism:doi><dc:description>© 2015 Springer International Publishing Switzerland. The nonsteroidal anti-inflammatory naproxen sodium is among the most commonly used pharmaceuticals in Mexico. Nevertheless, there is no adequate regulation to control its sale, use, and disposal. This agent can enter water bodies by diverse pathways, attaining significant concentrations, especially in sediments since they are the final reservoir of many organic contaminants, and may induce damage on hydrobionts. Naproxen sodium is water-soluble, shows stability in aquatic ecosystems, and can form reactive products when oxidized. The aim of this study was to evaluate the oxidative stress and consequent damage to genetic material induced by naproxen sodium in sediments on Hyalella azteca. After 48 h of exposure to artificial sediments enriched with 76.6 and 339.2 mg kg&lt;sup&gt;-1&lt;/sup&gt; (equivalent to 1/10 of the LC&lt;inf&gt;50&lt;/inf&gt; and the NOAEL obtained in an earlier 48-h acute toxicity assay), the following biomarkers were evaluated: lipid peroxidation level, protein carbonyl content, activity of the antioxidant enzymes, and DNA damage. Results show that naproxen sodium induces oxidative stress (increased lipid and protein oxidation, as well as superoxide dismutase and catalase activity and decrease of glutathione peroxidase activity) and genotoxicity (increased oxidative damage of DNA) at sublethal concentrations on H. azteca, being the damage, concentration dependent.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293757</affiliation-url><afid>115293757</afid><affilname>Unidad Profesional Adolfo López Mateos</affilname><name-variant>Unidad Profesional Adolfo López Mateos</name-variant><affiliation-city/><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022869</affiliation-url><afid>60022869</afid><affilname>Universidad Nacional Autonoma de Mexico, Facultad de Medicina</affilname><name-variant>Facultad de Medicina</name-variant><affiliation-city>Mexico City</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115014928</affiliation-url><afid>115014928</afid><affilname>Facultad de Química</affilname><name-variant>Facultad de Química</name-variant><affiliation-city/><affiliation-country>Mexico</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663102600</author-url><authid>56663102600</authid><authname>Lucero G.</authname><surname>Lucero</surname><given-name>García Medina Alba</given-name><initials>G.M.A.</initials><afid>115293757</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663149100</author-url><authid>56663149100</authid><authname>Marcela G.</authname><surname>Marcela</surname><given-name>Galar Martínez</given-name><initials>G.M.</initials><afid>115293757</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56589894600</author-url><authid>56589894600</authid><authname>Sandra G.</authname><surname>Sandra</surname><given-name>García Medina</given-name><initials>G.M.</initials><afid>60022869</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662870300</author-url><authid>56662870300</authid><authname>Manuel G.</authname><surname>Manuel</surname><given-name>Gómez Oliván Leobardo</given-name><initials>G.O.L.</initials><afid>115014928</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56663261600</author-url><authid>56663261600</authid><authname>Celene R.</authname><surname>Celene</surname><given-name>Razo Estrada</given-name><initials>R.E.</initials><afid>115293757</afid></author><authkeywords>Antioxidant enzymes | DNA damage | Hyalella azteca | Lipid peroxidation | Naproxen | Oxidized proteins</authkeywords><intid>1036082941</intid><article-number>195</article-number><source-id>24554</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930208986"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930208986?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930208986&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930208986&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930208986</prism:url><dc:identifier>SCOPUS_ID:84930208986</dc:identifier><eid>2-s2.0-84930208986</eid><dc:title>Evaluation of in vitro and in vivo anti-inflammatory and toxicity studies of methanolic extract of Rumex vesicarius Linn</dc:title><dc:creator>Tukappa NK A.</dc:creator><prism:publicationName>Oriental Pharmacy and Experimental Medicine</prism:publicationName><prism:issn>15982386</prism:issn><prism:eIssn>22111069</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>113-121</prism:pageRange><prism:coverDate>2015-06-27</prism:coverDate><prism:coverDisplayDate>27 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13596-015-0180-z</prism:doi><dc:description>© 2015, Institute of Korean Medicine, Kyung Hee University and Springer Science+Business Media Dordrecht. Rumex vesicarius L. belongs to the family polygonaceae and is popularly known as “bladder dock”. It is a green vegetable traditionally used as an important plant to cure many diseases. In the present study the methanol extract of Rumex vesicarius L. was evaluated for its toxicity and potential in vitro and in vivo anti-inflammatory activity. The extract at different concentration from 100 to 2000 mg/kg bw was used to evaluate the toxicity on albino rat. For evaluating the in vivo anti-inflammatory activity, carrageenan induced edema test in rats were done at the dose 100 mg/kg bw and 200 mg/kg bw. The biochemical, hematological and histopathological studies were also estimated as supportive studies. Effect of methanol extract on protein denaturation and HRBC membrane were estimated to detect invitro anti-inflammatory activity. Acute toxicity and short term toxicity studies revealed that the methanol extract of Rumex vesicarius L. is nontoxic at the studied concentration. The appropriate dose range for preclinical study was found to be 100 mg/kg bw and 200 mg/kg bw. Oral administration of the extract at the dose of 100 and 200 mg/kg bw exhibited dose dependent and significant anti-inflammatory activity in carrageenan induced edema rats. The hematological and biochemical parameters were found normal. Invitro anti-inflammatory studies showed dose dependent activity with the IC50 value of 476.06 μg/ml and 491.355 μg/ml for inhibition of protein denaturation and stabilization of HRBC membrane respectively. Hence present investigation established some pharmacological evidences to support the folklore claim that Rumex vesicarius L. is used as anti-inflammatory agent.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031730</affiliation-url><afid>60031730</afid><affilname>Gulbarga University</affilname><name-variant>Gulbarga University</name-variant><affiliation-city>Gulbarga</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663293000</author-url><authid>56663293000</authid><authname>Tukappa NK A.</authname><surname>Tukappa NK</surname><given-name>Asha</given-name><initials>A.</initials><afid>60031730</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506557437</author-url><authid>6506557437</authid><authname>londonkar R.</authname><surname>londonkar</surname><given-name>Ramesh L.</given-name><initials>R.L.</initials><afid>60031730</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663279000</author-url><authid>56663279000</authid><authname>Kumar CB S.</authname><surname>Kumar CB</surname><given-name>Sanjeev</given-name><initials>S.</initials><afid>60031730</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56500517300</author-url><authid>56500517300</authid><authname>Nayaka H.</authname><surname>Nayaka</surname><given-name>Hanumantappa B.</given-name><initials>H.B.</initials><afid>60031730</afid></author><authkeywords>Acute toxicity | Carrageenan | HRBC | Protein denaturation | Rumex vesicarius L</authkeywords><intid>36085843</intid><source-id>21100206802</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930200106"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930200106?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930200106&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930200106&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930200106</prism:url><dc:identifier>SCOPUS_ID:84930200106</dc:identifier><eid>2-s2.0-84930200106</eid><dc:title>Un Prince dans le miroir de Merlyn: The Sword in the Stone de T.H. White</dc:title><dc:creator>Chelebourg C.</dc:creator><prism:publicationName>Neohelicon</prism:publicationName><prism:issn>03244652</prism:issn><prism:eIssn>15882810</prism:eIssn><prism:volume>42</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>195-207</prism:pageRange><prism:coverDate>2015-06-27</prism:coverDate><prism:coverDisplayDate>27 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11059-014-0264-7</prism:doi><dc:description>© 2014, Akadémiai Kiadó, Budapest, Hungary. First published in 1938, and revised 20 years later, The Sword in the Stone opens T.H. White’s tetralogy of Arthur novels, “The Once and Future King”. In its final version, the novel, conceived in the context of a mounting Nazi threat, takes its cue from an interpretation of Morte Darthur de Malory as an “antidote against war.” Merlin here travels back in time, like the historical novelist, to illuminate the mistakes of the past in the light of the present. His task is an attack against a morally problematic aristocratic imaginary. His burlesque disqualifies chivalrous codes of conduct, which are accused of imposing models of competition that are fatal to peace. Confronted with the bestial brutality of aristocrats, the author confides the task of showing Arthur the road of moral progress to a series of animal fables. By transposing the tragedy he read in Malory in a comic register, White brings his aesthetics in line with an ethics that rejects the ambition of grandeur. His account of Arthur’s childhood uses the genre of the mirror for princes as a model, and tries to regenerate the British monarchy, which finally realizes the objective of the Round Table: to establish and safeguard civilization against the reign of power.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010846</affiliation-url><afid>60010846</afid><affilname>Universite Nancy 2</affilname><name-variant>Université Nancy 2</name-variant><affiliation-city>Nancy</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56338666500</author-url><authid>56338666500</authid><authname>Chelebourg C.</authname><surname>Chelebourg</surname><given-name>Christian</given-name><initials>C.</initials><afid>60010846</afid></author><authkeywords>Aristocratic imaginary | Arthur legend | Merlin | Second World War | T.H. White | The Sword in the Stone</authkeywords><intid>36086101</intid><source-id>5000154506</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929947797"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929947797?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929947797&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929947797&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929947797</prism:url><dc:identifier>SCOPUS_ID:84929947797</dc:identifier><eid>2-s2.0-84929947797</eid><dc:title>Effect of zinc supplements in the attenuated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart</dc:title><dc:creator>Kansal S.</dc:creator><prism:publicationName>Naunyn-Schmiedeberg's Archives of Pharmacology</prism:publicationName><prism:issn>00281298</prism:issn><prism:eIssn>14321912</prism:eIssn><prism:volume>388</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>635-641</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00210-015-1105-6</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg. Hyperlipidemia is regarded as independent risk factor in the development of ischemic heart disease, and it can increase the myocardial susceptibility to ischemia-/reperfusion (I/R)-induced injury. Hyperlipidemia attenuates the cardioprotective response of ischemic preconditioning (IPC). The present study investigated the effect of zinc supplements in the attenuated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat hearts. Hyperlipidemia was induced in rat by feeding high-fat diet (HFD) for 6 weeks then the serum lipid profile was observed. In experiment, the isolated Langendorff rat heart preparation was subjected to 4 cycles of ischemic preconditioning (IPC), then 30 min of ischemia followed by 120 min of reperfusion. Myocardial infarct size was elaborated morphologically by triphenyltetrazolium chloride (TTC) staining and biochemically by lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) release from coronary effluent and left ventricular collagen content. However, the effect of zinc supplement, i.e., zinc pyrithione (10 μM) perfused during reperfusion for 120 min, significantly abrogated the attenuated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart whereas administration of chelator of this zinc ionophore, i.e., N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylene diamine (TPEN; 10 μM), perfused during reperfusion 2 min before the perfusion of zinc pyrithione abrogated the cardioprotective effect of zinc supplement during experiment in hyperlipidemic rat heart. Thus, the administration of zinc supplements limits the infarct size, LDH, and CK-MB and enhanced the collagen level which suggests that the attenuated cardioprotective effect of IPC in hyperlipidemic rat is due to zinc loss during reperfusion caused by ischemia/reperfusion.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012439</affiliation-url><afid>60012439</afid><affilname>Baba Farid University of Health Sciences</affilname><name-variant>Baba Farid University of Health Sciences</name-variant><affiliation-city>Faridkot</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113004171</affiliation-url><afid>113004171</afid><affilname>ISF College of Pharmacy</affilname><name-variant>ISF College of Pharmacy</name-variant><affiliation-city/><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56539563700</author-url><authid>56539563700</authid><authname>Kansal S.</authname><surname>Kansal</surname><given-name>Sunil Kumar</given-name><initials>S.K.</initials><afid>60012439</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56539977300</author-url><authid>56539977300</authid><authname>Jyoti U.</authname><surname>Jyoti</surname><given-name>Uma</given-name><initials>U.</initials><afid>60012439</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56037155100</author-url><authid>56037155100</authid><authname>Sharma S.</authname><surname>Sharma</surname><given-name>Samridhi</given-name><initials>S.</initials><afid>60012439</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55334474300</author-url><authid>55334474300</authid><authname>Kaura A.</authname><surname>Kaura</surname><given-name>Arun</given-name><initials>A.</initials><afid>60012439</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56539485500</author-url><authid>56539485500</authid><authname>Deshmukh R.</authname><surname>Deshmukh</surname><given-name>Rahul</given-name><initials>R.</initials><afid>113004171</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36010542100</author-url><authid>36010542100</authid><authname>Goyal S.</authname><surname>Goyal</surname><given-name>Sandeep</given-name><initials>S.</initials><afid>60012439</afid></author><authkeywords>Collagen | Hyperlipidemia | Ischemic preconditioning | Zinc chelator | Zinc ionophore</authkeywords><intid>2036037199</intid><source-id>20427</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929945972"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929945972?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929945972&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929945972&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929945972</prism:url><dc:identifier>SCOPUS_ID:84929945972</dc:identifier><eid>2-s2.0-84929945972</eid><dc:title>Organ-protective effects on the liver and kidney by minocycline in small piglets undergoing cardiopulonary bypass</dc:title><dc:creator>Dhein S.</dc:creator><prism:publicationName>Naunyn-Schmiedeberg's Archives of Pharmacology</prism:publicationName><prism:issn>00281298</prism:issn><prism:eIssn>14321912</prism:eIssn><prism:volume>388</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>663-676</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00210-015-1115-4</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg. Cardiopulmonary bypass (CPB) often is required for the operative correction of congenital heart defects in small infants. Unfortunately, CPB is associated with injury of inner organs such as the brain, kidney, lung, and liver. Renal failure and increase in liver enzymes are typical side effects observed after CPB. Here, we investigate whether organ protection of the kidney and liver can be achieved with the application of minocycline, which is known - besides its anti-infective effects - to act as a poly-ADP-ribose-polymerase inhibitor. Twenty-nine 4-week-old Angler Sattelschwein-piglets (8-15 kg) were divided into four groups: control group (n = 8), CPB group (n = 9), minocycline-control group (n = 6), and the minocycline-CPB group (n = 6). CPB groups were thoracotomized and underwent CPB for 120 min (cross-clamp, 90 min; reperfusion, 30 min) followed by a 90-min recovery time. The control groups also were thoracotomized but not connected to CPB. The minocycline group received 4 mg/kg minocycline before and 2 mg/kg after CPB. In the kidneys, CPB histologically resulted in widening of Bowman's capsule, and - mainly in tubules - formation of poly-ADP-ribose, nitrosylation of tyrosine-residues, nuclear translocation of hypoxia-induced factor HIF-1α, and of apoptosis-inducing factor (AIF). In addition, we found significantly less ATP in the kidney and significantly increased plasma urea and creatinine. Similar but gradually attenuated changes were found in the liver together with significantly elevated de-Ritis coefficient. These changes in the kidney and liver were significantly diminished by minocycline (except AIF in the liver which was similar in all groups). In conclusion, CPB causes damage in the kidney and - to a lower degree - in the liver, which can be attenuated by minocycline.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008042</affiliation-url><afid>60008042</afid><affilname>Universitat Leipzig</affilname><name-variant>University of Leipzig</name-variant><affiliation-city>Leipzig</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008042</affiliation-url><afid>60008042</afid><affilname>Universitat Leipzig</affilname><name-variant>University of Leipzig</name-variant><affiliation-city>Leipzig</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008042</affiliation-url><afid>60008042</afid><affilname>Universitat Leipzig</affilname><name-variant>University of Leipzig</name-variant><affiliation-city>Leipzig</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56186513900</author-url><authid>56186513900</authid><authname>Dhein S.</authname><surname>Dhein</surname><given-name>Stefan</given-name><initials>S.</initials><afid>60008042</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56417524600</author-url><authid>56417524600</authid><authname>Grassl M.</authname><surname>Grassl</surname><given-name>Maria</given-name><initials>M.</initials><afid>60008042</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56418513500</author-url><authid>56418513500</authid><authname>Gerdom M.</authname><surname>Gerdom</surname><given-name>Maria</given-name><initials>M.</initials><afid>60008042</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:34868728800</author-url><authid>34868728800</authid><authname>Vollroth M.</authname><surname>Vollroth</surname><given-name>Marcel</given-name><initials>M.</initials><afid>60008042</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:12140799500</author-url><authid>12140799500</authid><authname>Bakhtiary F.</authname><surname>Bakhtiary</surname><given-name>Farhad</given-name><initials>F.</initials><afid>60008042</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:48862049100</author-url><authid>48862049100</authid><authname>Von Salisch S.</authname><surname>Von Salisch</surname><given-name>Sandy</given-name><initials>S.</initials><afid>60008042</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:15765601100</author-url><authid>15765601100</authid><authname>Krämer K.</authname><surname>Krämer</surname><given-name>Klaus</given-name><initials>K.</initials><afid>60008042</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7004846677</author-url><authid>7004846677</authid><authname>Sobiraj A.</authname><surname>Sobiraj</surname><given-name>Axel</given-name><initials>A.</initials><afid>60008042</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55995500600</author-url><authid>55995500600</authid><authname>Kostelka M.</authname><surname>Kostelka</surname><given-name>Martin</given-name><initials>M.</initials><afid>60008042</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:35433275800</author-url><authid>35433275800</authid><authname>Mohr F.</authname><surname>Mohr</surname><given-name>Friedrich Wilhelm</given-name><initials>F.W.</initials><afid>60008042</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7003820716</author-url><authid>7003820716</authid><authname>Salameh A.</authname><surname>Salameh</surname><given-name>Aida</given-name><initials>A.</initials><afid>60008042</afid></author><authkeywords>Antiapoptotic | Cardiopulmonary bypass | Extracorporeal circulation | Hepatic damage | Kidney | Liver | Minocycline | Nitrosative stress | Poly-ADP-ribose polymerase PARP | Renal impairment | Renoptrotection</authkeywords><intid>1036037218</intid><source-id>20427</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930210277"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930210277?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930210277&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930210277&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930210277</prism:url><dc:identifier>SCOPUS_ID:84930210277</dc:identifier><eid>2-s2.0-84930210277</eid><dc:title>Hypertrophic cardiomyopathy</dc:title><dc:creator>Varma P.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>153-161</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-015-0364-7</prism:doi><dc:description>© 2015, Indian Association of Cardiovascular-Thoracic Surgeons. Hypertrophic cardiomyopathy is a common genetic cardiovascular disease affecting the general population with an estimated prevalence of 1 in 500 with autosomal dominant pattern of inheritance and is an important cause of intractable heart failure. Up to 70 % of patients present with left ventricular outflow tract obstruction due to asymmetric hypertrophy of the interventricular septum and systolic anterior motion of anterior mitral leaflet. These patients are initially managed with medical treatment. Persistent symptoms (dyspnea and chest pain NYHA class 3 or 4 and syncope) in spite of optimal medical therapy and presence of gradients above 50 mm of Hg at rest or by provocation are usually referred for invasive strategy. Extended surgical myectomy and alcohol septal ablation are current strategies employed for relief of left ventricular outflow tract gradients. There is a higher incidence of residual gradients, more incidences of conduction blocks requiring pacemaker implantation and more risk of life-threatening arrhythmias with alcohol ablation compared to surgery and hence is currently recommended as a treatment option only in elderly patients with poor risk profile for surgery. Early and long-term results after surgery are excellent, making it as the gold standard for management of hypertrophic cardiomyopathy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007898</affiliation-url><afid>60007898</afid><affilname>Amrita Institute of Medical Sciences India</affilname><name-variant>Amrita Institute of Medical Sciences and Research Centre</name-variant><affiliation-city>Kochi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027039</affiliation-url><afid>60027039</afid><affilname>Sree Chitra Tirunal Institute for Medical Sciences and Technology</affilname><name-variant>Sree Chitra Tirunal Institute for Medical Sciences and Technology</name-variant><affiliation-city>Thiruvananthapuram</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113671201</affiliation-url><afid>113671201</afid><affilname>Institute of Medical Sciences</affilname><name-variant>Institute of Medical Sciences</name-variant><affiliation-city>Raipur</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35508231800</author-url><authid>35508231800</authid><authname>Varma P.</authname><surname>Varma</surname><given-name>Praveen Kerala</given-name><initials>P.K.</initials><afid>60007898</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:38961943700</author-url><authid>38961943700</authid><authname>Raman S.</authname><surname>Raman</surname><given-name>Suneel Puthuvassery</given-name><initials>S.P.</initials><afid>60027039</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603902186</author-url><authid>6603902186</authid><authname>Neema P.</authname><surname>Neema</surname><given-name>Praveen Kumar</given-name><initials>P.K.</initials><afid>113671201</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8693834600</author-url><authid>8693834600</authid><authname>Shekar P.</authname><surname>Shekar</surname><given-name>Prem Sadanand</given-name><initials>P.S.</initials><afid>60016782</afid></author><authkeywords>Hypertrophic cardiomyopathy | Myectomy | Surgery</authkeywords><intid>536088130</intid><article-number>364</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930007658"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930007658?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930007658&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930007658&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930007658</prism:url><dc:identifier>SCOPUS_ID:84930007658</dc:identifier><eid>2-s2.0-84930007658</eid><dc:title>A case of rheumatic mitral stenosis with subaortic ventricular septal defect and anomalous right coronary artery from left sinus</dc:title><dc:creator>Abdulsamath M.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>184-186</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-014-0339-0</prism:doi><dc:description>© 2014, Indian Association of Cardiovascular-Thoracic Surgeons. Rheumatic mitral stenosis (MS) is common in India. Ventricular septal defect (VSD) is the commonest congenital heart disease seen clinically. The incidence of right coronary artery (RCA) arising from the left aortic sinus is 0.17 %. The presence of all the three lesions in a patient is likely to be extremely rare. We present a patient who had all the three lesions, and to the best of our knowledge, this is the first such case to be reported.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027039</affiliation-url><afid>60027039</afid><affilname>Sree Chitra Tirunal Institute for Medical Sciences and Technology</affilname><name-variant>Sree Chitra Tirunal Institute for Medical Sciences and Technology</name-variant><affiliation-city>Thiruvananthapuram</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56658760900</author-url><authid>56658760900</authid><authname>Abdulsamath M.</authname><surname>Abdulsamath</surname><given-name>Mohammed Idhrees</given-name><initials>M.I.</initials><afid>60027039</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36136213000</author-url><authid>36136213000</authid><authname>Pillai V.</authname><surname>Pillai</surname><given-name>Vivek</given-name><initials>V.</initials><afid>60027039</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56388509300</author-url><authid>56388509300</authid><authname>Radhakrishnan B.</authname><surname>Radhakrishnan</surname><given-name>Bineesh</given-name><initials>B.</initials><afid>60027039</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56658668800</author-url><authid>56658668800</authid><authname>Paniker V.</authname><surname>Paniker</surname><given-name>Varghese</given-name><initials>V.</initials><afid>60027039</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56388434800</author-url><authid>56388434800</authid><authname>Varma P.</authname><surname>Varma</surname><given-name>Praveen</given-name><initials>P.</initials><afid>60027039</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16233609900</author-url><authid>16233609900</authid><authname>Karunakaran J.</authname><surname>Karunakaran</surname><given-name>Jayakumar</given-name><initials>J.</initials><afid>60027039</afid></author><authkeywords>Rheumatic mitral stenosis | Right coronary artery | Ventricular septal defect</authkeywords><intid>536050421</intid><article-number>339</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930200592"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930200592?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930200592&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930200592&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930200592</prism:url><dc:identifier>SCOPUS_ID:84930200592</dc:identifier><eid>2-s2.0-84930200592</eid><dc:title>Diagnosis and Treatment of Incident Hypertension Among Patients with Diabetes: a U.S. Multi-Disciplinary Group Practice Observational Study</dc:title><dc:creator>Wallace M.</dc:creator><prism:publicationName>Journal of General Internal Medicine</prism:publicationName><prism:issn>08848734</prism:issn><prism:eIssn>15251497</prism:eIssn><prism:volume>30</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>768-776</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11606-015-3202-0</prism:doi><dc:description>© 2015, Society of General Internal Medicine. BACKGROUND: Early hypertension control reduces the risk of cardiovascular complications among patients with diabetes mellitus. There is a need to improve hypertension management among patients with diabetes mellitus. OBJECTiVE: We aimed to evaluate rates and associations of hypertension diagnosis and treatment among patients with diabetes mellitus and incident hypertension. DESIGN: This was a 4-year retrospective analysis of electronic health records. PARTICIPANTS: Adults ≥18 years old (n = 771) with diabetes mellitus, who met criteria for incident hypertension and received primary care at a large, Midwestern academic group practice from 2008 to 2011 were included MAIN MEASURES: Cut-points of 130/80 and 140/90 mmHg were used to identify incident cases of hypertension. Kaplan-Meier analysis estimated the probability of receiving: 1) an initial hypertension diagnosis and 2) antihypertensive medication at specific time points. Cox proportional-hazard frailty models (HR; 95 % CI) were fit to identify associations of time to hypertension diagnosis and treatment. KEY RESULTS: Among patients with diabetes mellitus who met clinical criteria for hypertension, 41 % received a diagnosis and 37 % received medication using the 130/80 mmHg cut-point. At the 140/90 mmHg cut-point, 52 % received a diagnosis and 49 % received medication. Atrial fibrillation (HR 2.18; 1.21–4.67) was associated with faster diagnosis rates; peripheral vascular disease (HR 0.18; 0.04–0.74) and fewer primary care visits (HR 0.93; 0.88–0.98) were associated with slower diagnosis rates. Atrial fibrillation (HR 3.07; 1.39–6.74) and ischemic heart disease/congestive heart failure (HR 2.16; 1.24–3.76) were associated with faster treatment rates; peripheral vascular disease (HR 0.16; 0.04–0.64) and fewer visits (HR 0.93; 0.88–0.98) predicted slower medication initiation. Diagnosis and treatment of incident hypertension were similar using cut-points of 130/80 and 140/90 mmHg. CONCLUSIONS: Among patients with diabetes mellitus, even using a cut-point of 140/90 mmHg, approximately 50 % remained undiagnosed and untreated for hypertension. Future interventions should target patients with multiple comorbidities to improve hypertension and diabetes clinical care.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025553</affiliation-url><afid>60025553</afid><affilname>University of Wisconsin School of Medicine and Public Health</affilname><name-variant>University of Wisconsin</name-variant><affiliation-city>Madison</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015543</affiliation-url><afid>60015543</afid><affilname>University of Pittsburgh</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025553</affiliation-url><afid>60025553</afid><affilname>University of Wisconsin School of Medicine and Public Health</affilname><name-variant>University of Wisconsin</name-variant><affiliation-city>Madison</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025553</affiliation-url><afid>60025553</afid><affilname>University of Wisconsin School of Medicine and Public Health</affilname><name-variant>University of Wisconsin</name-variant><affiliation-city>Madison</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025553</affiliation-url><afid>60025553</afid><affilname>University of Wisconsin School of Medicine and Public Health</affilname><name-variant>University of Wisconsin</name-variant><affiliation-city>Madison</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025553</affiliation-url><afid>60025553</afid><affilname>University of Wisconsin School of Medicine and Public Health</affilname><name-variant>University of Wisconsin</name-variant><affiliation-city>Madison</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56076310200</author-url><authid>56076310200</authid><authname>Wallace M.</authname><surname>Wallace</surname><given-name>Margaret L.</given-name><initials>M.L.</initials><afid>60025553</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56411876400</author-url><authid>56411876400</authid><authname>Magnan E.</authname><surname>Magnan</surname><given-name>Elizabeth M.</given-name><initials>E.M.</initials><afid>60025553</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14219539000</author-url><authid>14219539000</authid><authname>Thorpe C.</authname><surname>Thorpe</surname><given-name>Carolyn T.</given-name><initials>C.T.</initials><afid>60015543</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7201769623</author-url><authid>7201769623</authid><authname>Schumacher J.</authname><surname>Schumacher</surname><given-name>Jessica R.</given-name><initials>J.R.</initials><afid>60025553</afid><afid>60025553</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7201769623</author-url><authid>7201769623</authid><authname>Schumacher J.</authname><surname>Schumacher</surname><given-name>Jessica R.</given-name><initials>J.R.</initials><afid>60025553</afid><afid>60025553</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:10142115300</author-url><authid>10142115300</authid><authname>Smith M.</authname><surname>Smith</surname><given-name>Maureen A.</given-name><initials>M.A.</initials><afid>60025553</afid><afid>60025553</afid><afid>60025553</afid><afid>60025553</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:10142115300</author-url><authid>10142115300</authid><authname>Smith M.</authname><surname>Smith</surname><given-name>Maureen A.</given-name><initials>M.A.</initials><afid>60025553</afid><afid>60025553</afid><afid>60025553</afid><afid>60025553</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:10142115300</author-url><authid>10142115300</authid><authname>Smith M.</authname><surname>Smith</surname><given-name>Maureen A.</given-name><initials>M.A.</initials><afid>60025553</afid><afid>60025553</afid><afid>60025553</afid><afid>60025553</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:10142115300</author-url><authid>10142115300</authid><authname>Smith M.</authname><surname>Smith</surname><given-name>Maureen A.</given-name><initials>M.A.</initials><afid>60025553</afid><afid>60025553</afid><afid>60025553</afid><afid>60025553</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16064087900</author-url><authid>16064087900</authid><authname>Johnson H.</authname><surname>Johnson</surname><given-name>Heather M.</given-name><initials>H.M.</initials><afid>60025553</afid><afid>60025553</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16064087900</author-url><authid>16064087900</authid><authname>Johnson H.</authname><surname>Johnson</surname><given-name>Heather M.</given-name><initials>H.M.</initials><afid>60025553</afid><afid>60025553</afid></author><authkeywords>diabetes mellitus | diagnosis | electronic health records | hypertension</authkeywords><intid>2036082450</intid><source-id>26643</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929948790"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929948790?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929948790&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929948790&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929948790</prism:url><dc:identifier>SCOPUS_ID:84929948790</dc:identifier><eid>2-s2.0-84929948790</eid><dc:title>Experimental colitis in mice is attenuated by topical administration of chlorogenic acid</dc:title><dc:creator>Zatorski H.</dc:creator><prism:publicationName>Naunyn-Schmiedeberg's Archives of Pharmacology</prism:publicationName><prism:issn>00281298</prism:issn><prism:eIssn>14321912</prism:eIssn><prism:volume>388</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>643-651</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00210-015-1110-9</prism:doi><dc:description>© 2015 The Author(s). Epidemiological data suggest that the consumption of polyphenol-rich foods reduces the incidence of cancer, coronary heart disease, and inflammation. Chlorogenic acid (CGA), an ester of caffeic and quinic acids, is one of the most abundant polyphenol compounds in human diet with proven biological effectiveness both in vitro and in vivo. The aim of the study is to investigate the possible anti-inflammatory effect of CGA in the gastrointestinal (GI) tract and its mechanism of action. We used a well-established model of colitis, induced by intracolonic (i.c.) administration of trinitrobenzenesulfonic acid (TNBS) in mice. The anti-inflammatory effect of CGA in the colon was evaluated based on the clinical and macroscopic and microscopic parameters. To investigate the mechanism of protective action of CGA, myeloperoxidase (MPO), H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt;, and NF-κB levels were assessed in the colon tissue. CGA administered i.c. at the dose of 20 mg/kg (two times daily) protected against TNBS-induced colitis more effectively than the same dose administered orally (p.o.), as evidenced by significantly lower macroscopic and ulcer scores. Furthermore, CGA (20 mg/kg, i.c.) reduced neutrophil infiltration, as demonstrated by decreased MPO activity. Moreover, CGA suppressed activation of NF-κB, as evidenced by lower levels of phospho-NF-κB/NF-κB ratio in the tissue. CGA did not affect the oxidative stress pathways. CGA exhibits anti-inflammatory properties through reduction of neutrophil infiltration and inhibition of NF-κB-dependent pathways. Our results suggest that CGA may have the potential to become a valuable supplement in the treatment of GI diseases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006651</affiliation-url><afid>60006651</afid><affilname>Uniwersytet Medyczny w Lodzi</affilname><name-variant>Medical University of Lodz</name-variant><affiliation-city>Lodz</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073652</affiliation-url><afid>60073652</afid><affilname>Tongji University</affilname><name-variant>Tongji University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006651</affiliation-url><afid>60006651</afid><affilname>Uniwersytet Medyczny w Lodzi</affilname><name-variant>Medical University of Lodz</name-variant><affiliation-city>Lodz</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55948636600</author-url><authid>55948636600</authid><authname>Zatorski H.</authname><surname>Zatorski</surname><given-name>Hubert</given-name><initials>H.</initials><afid>60006651</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55577120100</author-url><authid>55577120100</authid><authname>Sałaga M.</authname><surname>Sałaga</surname><given-name>Maciej</given-name><initials>M.</initials><afid>60006651</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56463724500</author-url><authid>56463724500</authid><authname>Zielińska M.</authname><surname>Zielińska</surname><given-name>Marta</given-name><initials>M.</initials><afid>60006651</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55243449700</author-url><authid>55243449700</authid><authname>Piechota-Polańczyk A.</authname><surname>Piechota-Polańczyk</surname><given-name>Aleksandra</given-name><initials>A.</initials><afid>60006651</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55270472700</author-url><authid>55270472700</authid><authname>Owczarek K.</authname><surname>Owczarek</surname><given-name>Katarzyna</given-name><initials>K.</initials><afid>60006651</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55395671900</author-url><authid>55395671900</authid><authname>Kordek R.</authname><surname>Kordek</surname><given-name>Radzisław</given-name><initials>R.</initials><afid>60006651</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6508332006</author-url><authid>6508332006</authid><authname>Lewandowska U.</authname><surname>Lewandowska</surname><given-name>Urszula</given-name><initials>U.</initials><afid>60006651</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56190380400</author-url><authid>56190380400</authid><authname>Chen C.</authname><surname>Chen</surname><given-name>Chunqiu</given-name><initials>C.</initials><afid>60073652</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6603194133</author-url><authid>6603194133</authid><authname>Fichna J.</authname><surname>Fichna</surname><given-name>Jakub</given-name><initials>J.</initials><afid>60006651</afid></author><authkeywords>Chlorogenic acid | Crohn's disease | Experimental colitis | Inflammatory bowel diseases | Trinitrobenzenesulfonic acid | Ulcerative colitis</authkeywords><intid>1786042891</intid><source-id>20427</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930002290"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930002290?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930002290&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930002290&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930002290</prism:url><dc:identifier>SCOPUS_ID:84930002290</dc:identifier><eid>2-s2.0-84930002290</eid><dc:title>A variant of Takotsubo cardiomyopathy—a case report and review of literature</dc:title><dc:creator>Sinha V.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>173-177</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-014-0340-7</prism:doi><dc:description>© 2015, Indian Association of Cardiovascular-Thoracic Surgeons. Takotsubo cardiomyopathy (TCM) is a rare syndrome, and it is even more rare to find it in a premenopausal lady in the immediate postoperative period. Here, we are reporting a case of variant of TCM, along with review of existing literature. A 26-year-old lady who successfully underwent pericardiectomy went into low cardiac output on the first postoperative day. Echocardiography revealed apical ballooning with drastic reduction in left ventricular ejection fraction (LVEF). Her coronary angiography revealed normal coronaries. She was managed conservatively with inotropic support. She made remarkable recovery and her echocardiography on 7th postoperative day showed excellent recovery of apical wall motion abnormality and ejection fraction. Repeat echocardiography after 2 weeks of discharge showed complete normalization of apical ballooning and LV function. She remained well until 1 year after operation with normal LVEF. Regular follow-up is important as it may rarely recur. TCM should be kept in mind as a rare though possible complication after cardiac surgery.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60076420</affiliation-url><afid>60076420</afid><affilname>National Heart Institute, New Delhi</affilname><name-variant>National Heart Institute</name-variant><affiliation-city>New Delhi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60076420</affiliation-url><afid>60076420</afid><affilname>National Heart Institute, New Delhi</affilname><name-variant>National Heart Institute</name-variant><affiliation-city>New Delhi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city>New Delhi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56658352100</author-url><authid>56658352100</authid><authname>Sinha V.</authname><surname>Sinha</surname><given-name>Vijoy Kumar</given-name><initials>V.K.</initials><afid>60076420</afid><afid/></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56658352100</author-url><authid>56658352100</authid><authname>Sinha V.</authname><surname>Sinha</surname><given-name>Vijoy Kumar</given-name><initials>V.K.</initials><afid>60076420</afid><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56390978300</author-url><authid>56390978300</authid><authname>Sharma V.</authname><surname>Sharma</surname><given-name>Vinod</given-name><initials>V.</initials><afid>60076420</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55256839200</author-url><authid>55256839200</authid><authname>Mishra R.</authname><surname>Mishra</surname><given-name>Rekha</given-name><initials>R.</initials><afid>60076420</afid></author><authkeywords>Cardiomyopathies | Takotsubo syndrome | Variant</authkeywords><intid>2036044694</intid><article-number>340</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930193049"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930193049?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930193049&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930193049&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930193049</prism:url><dc:identifier>SCOPUS_ID:84930193049</dc:identifier><eid>2-s2.0-84930193049</eid><dc:title>Transradial Sheathless Approach for PCI</dc:title><dc:creator>Fraser D.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0597-5</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. The lumen of the radial artery in many patients is smaller than the outer diameter of a 6F radial sheath frequently leading to procedural pain, trauma to the radial artery and contributing to radial occlusion. Chronically, neointima formation reduces luminal size further, limiting successful re-intervention in some patients. Sheathless guides are 1–2F sizes smaller than corresponding sheaths and so may potentially reduce radial artery trauma. Although not currently recommended for routine use, the 6.5F Asahi EauCath Sheathless guide has a lower profile than a 5F sheath and the same inner lumen as a 6F guide and has been shown to be especially useful for interventional procedures requiring 6F techniques in patients with small radial arteries. Similarly, the 7.5F Asahi EauCath has a lower profile than a 6F sheath and the same inner lumen as a 7F guide and is useful for procedures requiring a large bore guide catheter. Alternatives include the MediKit Works 5F sheathless system and long dilators designed to allow the sheathless introduction of conventional guides. The recently approved ‘Flip’ dilator is now available outside Japan; however, experience is currently limited.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030886</affiliation-url><afid>60030886</afid><affilname>Manchester Royal Infirmary</affilname><name-variant>Manchester Royal Infirmary</name-variant><affiliation-city>Manchester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003771</affiliation-url><afid>60003771</afid><affilname>University of Manchester</affilname><name-variant>University of Manchester</name-variant><affiliation-city>Manchester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7402646217</author-url><authid>7402646217</authid><authname>Fraser D.</authname><surname>Fraser</surname><given-name>Douglas</given-name><initials>D.</initials><afid>60030886</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56659274400</author-url><authid>56659274400</authid><authname>Mamas M.</authname><surname>Mamas</surname><given-name>Mamas A.</given-name><initials>M.A.</initials><afid>60030886</afid><afid>60003771</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56659274400</author-url><authid>56659274400</authid><authname>Mamas M.</authname><surname>Mamas</surname><given-name>Mamas A.</given-name><initials>M.A.</initials><afid>60030886</afid><afid>60003771</afid></author><authkeywords>Asahi Intecc EauCath | Radial lumen diameter | Sheath outer diameter | Sheathless guide catheter</authkeywords><intid>2036082020</intid><article-number>47</article-number><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929841254"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929841254?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929841254&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929841254&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929841254</prism:url><dc:identifier>SCOPUS_ID:84929841254</dc:identifier><eid>2-s2.0-84929841254</eid><dc:title>Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation</dc:title><dc:creator>Andrade A.</dc:creator><prism:publicationName>Journal of General Internal Medicine</prism:publicationName><prism:issn>08848734</prism:issn><prism:eIssn>15251497</prism:eIssn><prism:volume>30</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>777-782</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11606-015-3201-1</prism:doi><dc:description>© 2015, Society of General Internal Medicine. BACKGROUND: Guidelines for anticoagulant therapy in patients with atrial fibrillation (AF) conflict with each other. The American College of Chest Physicians (ACCP) guidelines suggest no anticoagulant therapy for patients with a CHADS&lt;inf&gt;2&lt;/inf&gt; score of 0. The European Society of Cardiology (ESC) prefer anticoagulant therapy for patients with a CHA&lt;inf&gt;2&lt;/inf&gt;DS&lt;inf&gt;2&lt;/inf&gt;-VASc of 1, which includes 65–74-year-olds with a CHADS&lt;inf&gt;2&lt;/inf&gt; score of 0. Resolving this conflicting advice is important, because these guidelines have potential to change anticoagulant therapy in 10 % of the AF population. METHODS: Using the National Registry of Atrial Fibrillation (NRAF) II data set, we compared these guidelines using stroke equivalents. Based on structured review of 23,657 patient records, we identified 65–74-year-old patients with a CHADS&lt;inf&gt;2&lt;/inf&gt; stroke score of 0 and no contraindication to warfarin. We used Medicare claims data to ascertain rates of ischemic stroke, intracranial hemorrhage, and other hemorrhage. We calculated net stroke equivalents for these (N = 478) patients using a weight of 1.5 for intracranial hemorrhages (ICH) and 1.0 for ischemic stroke. In a multivariate analysis, we used 14,466 records with documented atrial fibrillation and adjusted for CHADS&lt;inf&gt;2&lt;/inf&gt; and HEMORR&lt;inf&gt;2&lt;/inf&gt; HAGES score. RESULTS: In 65–74-year-old patients with a CHADS&lt;inf&gt;2&lt;/inf&gt; stroke score of 0, the stroke equivalents per 100 patient-years was 2.6 with warfarin and 2.9 without warfarin; the difference between these two strategies was not significant (0.3 stroke equivalents, 95 % CI −3.2 to 3.7). However, rates of hemorrhage per 100 patient-years were nearly tripled (hazard ratio 2.9; 95 % CI 1.5–5.4; p = 0.0011) with warfarin (21.1) versus without it (7.4). The most common site for major hemorrhage was gastrointestinal (ICD-9 code 578.9). CONCLUSIONS: By expanding warfarin use to 65-–74-year-olds with a CHADS&lt;inf&gt;2&lt;/inf&gt; score of 0, rates of hemorrhages would rise without a significant reduction in stroke equivalents.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Washington University in St. Louis Medical School Campus</affilname><affiliation-city>St. Louis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010261</affiliation-url><afid>60010261</afid><affilname>Washington University in St. Louis</affilname><name-variant>Washington University in St. Louis</name-variant><affiliation-city>St Louis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107592739</affiliation-url><afid>107592739</afid><affilname>Centers for Medicare &amp; Medicaid Services</affilname><name-variant>National Medicare &amp; Medicaid Center</name-variant><affiliation-city>Dallas</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022756</affiliation-url><afid>60022756</afid><affilname>Washington University in St. Louis, School of Medicine</affilname><name-variant>Washington University, School of Medicine</name-variant><affiliation-city>St Louis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55446644000</author-url><authid>55446644000</authid><authname>Andrade A.</authname><surname>Andrade</surname><given-name>Ambar A.</given-name><initials>A.A.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56512491100</author-url><authid>56512491100</authid><authname>Li J.</authname><surname>Li</surname><given-name>Juan</given-name><initials>J.</initials><afid>60010261</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7101898595</author-url><authid>7101898595</authid><authname>Radford M.</authname><surname>Radford</surname><given-name>Martha J.</given-name><initials>M.J.</initials><afid>107592739</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603315758</author-url><authid>6603315758</authid><authname>Nilasena D.</authname><surname>Nilasena</surname><given-name>David S.</given-name><initials>D.S.</initials><afid>60022756</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005685848</author-url><authid>7005685848</authid><authname>Gage B.</authname><surname>Gage</surname><given-name>Brian F.</given-name><initials>B.F.</initials><afid/><afid>60010261</afid><afid>60022756</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005685848</author-url><authid>7005685848</authid><authname>Gage B.</authname><surname>Gage</surname><given-name>Brian F.</given-name><initials>B.F.</initials><afid/><afid>60010261</afid><afid>60022756</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005685848</author-url><authid>7005685848</authid><authname>Gage B.</authname><surname>Gage</surname><given-name>Brian F.</given-name><initials>B.F.</initials><afid/><afid>60010261</afid><afid>60022756</afid></author><authkeywords>atrial fibrillation | epidemiology | outcomes | stroke | thromboembolism</authkeywords><intid>1536022005</intid><source-id>26643</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930194876"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930194876?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930194876&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930194876&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930194876</prism:url><dc:identifier>SCOPUS_ID:84930194876</dc:identifier><eid>2-s2.0-84930194876</eid><dc:title>Magnesium in CKD: more than a calcification inhibitor?</dc:title><dc:creator>Floege J.</dc:creator><prism:publicationName>Journal of Nephrology</prism:publicationName><prism:issn>11218428</prism:issn><prism:eIssn>17246059</prism:eIssn><prism:volume>28</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>269-277</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40620-014-0140-6</prism:doi><dc:description>© 2014, The Author(s). Magnesium fulfils important roles in multiple physiological processes. Accordingly, a tight regulation of magnesium homeostasis is essential. Dysregulated magnesium serum levels, in particular hypomagnesaemia, are common in patients with chronic kidney disease (CKD) and have been associated with poor clinical outcomes. In cell culture studies as well as in clinical situations magnesium levels were associated with vascular calcification, cardiovascular disease and altered bone-mineral metabolism. Magnesium has also been linked to diseases such as metabolic syndrome, diabetes, hypertension, fatigue and depression, all of which are common in CKD. The present review summarizes and discusses the latest clinical data on the impact of magnesium and possible effects of higher levels on the health status of patients with CKD, including an outlook on the use of magnesium-based phosphate-binding agents in this context.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016653</affiliation-url><afid>60016653</afid><affilname>Rheinisch-Westfalische Technische Hochschule Aachen</affilname><name-variant>RWTH Aachen</name-variant><affiliation-city>Aachen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55961563700</author-url><authid>55961563700</authid><authname>Floege J.</authname><surname>Floege</surname><given-name>Jürgen</given-name><initials>J.</initials><afid>60016653</afid></author><authkeywords>Cardiovascular disease | Chronic kidney disease | Depression | Diabetes | Magnesium</authkeywords><intid>1036081780</intid><article-number>140</article-number><source-id>19950</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929835802"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929835802?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929835802&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929835802&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929835802</prism:url><dc:identifier>SCOPUS_ID:84929835802</dc:identifier><eid>2-s2.0-84929835802</eid><dc:title>Time to Challenge Public Health Guidelines on Physical Activity</dc:title><dc:creator>de Souto Barreto P.</dc:creator><prism:publicationName>Sports Medicine</prism:publicationName><prism:issn>01121642</prism:issn><prism:eIssn>11792035</prism:eIssn><prism:volume>45</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>769-773</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40279-015-0326-7</prism:doi><dc:description>© 2015, Springer International Publishing Switzerland. There is striking evidence in support of physical activity (PA) as a very strong factor in health promotion and disease prevention. Since the mid-1990s, public health guidelines on PA have established PA recommendations to promote health and prevent several non-communicable diseases (NCDs). However, it is not clear that there is universal agreement on the validity of all aspects of these recommendations. Indeed, a growing body of evidence has accumulated over the last 20 years showing that less than 150 min/week of moderate PA, i.e. the minimum PA level currently recommended, promotes health and prevents NCDs. Moreover, when determining whether someone achieves the minimum PA recommendations, the quantities of PA undertaken are added together regardless of what domain of PA they represent, i.e. leisure-time, occupational, transport or housework. However, while convincing evidence exists to show that leisure-time and transport PA are important factors for promoting health, the evidence for occupational PA and housework is mixed. Therefore, the purpose of this article is to discuss two major issues relating to public health guidelines on PA for adults and older adults: the minimum volumes of PA required and the importance of PA domains in health promotion. A proposal on how to tackle these issues and ultimately strengthen PA recommendations is also presented.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024960</affiliation-url><afid>60024960</afid><affilname>CHU de Toulouse</affilname><name-variant>CHU de Toulouse</name-variant><affiliation-city>Toulouse</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027245</affiliation-url><afid>60027245</afid><affilname>Universite Paul Sabatier Toulouse III</affilname><name-variant>Université Paul Sabatier</name-variant><affiliation-city>Toulouse</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102127</affiliation-url><afid>60102127</afid><affilname>Aix Marseille Universite</affilname><name-variant>Aix-Marseille University</name-variant><affiliation-city>Marseille</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36571715600</author-url><authid>36571715600</authid><authname>de Souto Barreto P.</authname><surname>de Souto Barreto</surname><given-name>Philipe</given-name><initials>P.</initials><afid>60024960</afid><afid>60027245</afid><afid>60102127</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36571715600</author-url><authid>36571715600</authid><authname>de Souto Barreto P.</authname><surname>de Souto Barreto</surname><given-name>Philipe</given-name><initials>P.</initials><afid>60024960</afid><afid>60027245</afid><afid>60102127</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36571715600</author-url><authid>36571715600</authid><authname>de Souto Barreto P.</authname><surname>de Souto Barreto</surname><given-name>Philipe</given-name><initials>P.</initials><afid>60024960</afid><afid>60027245</afid><afid>60102127</afid></author><intid>1786022708</intid><source-id>20373</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930207250"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930207250?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930207250&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930207250&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930207250</prism:url><dc:identifier>SCOPUS_ID:84930207250</dc:identifier><eid>2-s2.0-84930207250</eid><dc:title>C reactive protein and long-term risk for chronic kidney disease: a historical prospective study</dc:title><dc:creator>Kugler E.</dc:creator><prism:publicationName>Journal of Nephrology</prism:publicationName><prism:issn>11218428</prism:issn><prism:eIssn>17246059</prism:eIssn><prism:volume>28</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>321-327</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40620-014-0116-6</prism:doi><dc:description>© 2014, SIN-ERGY Srl. Introduction: C reactive protein (CRP) is an acute phase reactant that primarily produced by hepatocytes yet may be locally expressed in renal tubular cells. We assessed the association of CRP and the risk for chronic kidney disease (CKD) development. Methods: Historical prospective cohort study was conducted on subjects attending a screening center in Israel since the year 2000. Subjects with an estimated GFR (eGFR) above 60 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; at baseline were included, and high sensitive (hs) CRP levels as well as eGFR were recorded for each visit. Follow up continued for at least 5 years for each subject until 2013. Risk for CKD at end of follow up was assessed in relation to mean hs-CRP levels of each subject. The confounding effects of other predictors of CKD were examined. A logistic regression model treating CRP as a continuous variable was further applied. Results: Out of 4,345 patients, 42 (1 %) developed CKD in a mean follow up of 7.6 ± 2 years. Elevated levels of CRP were associated with greater risk for CKD (crude OR 4.17, 95 % CI 1.46–11.89). The OR for the association of CRP with CKD when controlling for age and gender was 5.2 (95 % CI 1.7–16.2). When controlling for established renal risk factors, elevated CRP levels remained significantly associated with greater risk for CKD (OR 5.42, 95 % CI 1.76–16.68). When applying logistic regression models treating CRP as a continuous variable, for patients with diabetes mellitus (DM), hypertension (HTN) or eGFR between 60–90 ml\min\1.73 m&lt;sup&gt;2&lt;/sup&gt;, the predictive role of CRP for CKD was highly significant. Conclusion: Elevated CRP level is an independent risk factor for CKD development. In patients with DM, HTN or baseline eGFR between 60–90 ml\min\1.73 m&lt;sup&gt;2&lt;/sup&gt; its predictive role is enhanced.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022119</affiliation-url><afid>60022119</afid><affilname>Rabin Medical Center Israel</affilname><name-variant>Rabin Medical Center</name-variant><affiliation-city>Petah Tiqwa</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005037</affiliation-url><afid>60005037</afid><affilname>Tel Aviv University, Sackler Faculty of Medicine</affilname><name-variant>Tel Aviv University</name-variant><affiliation-city>Ramal Aviv</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022403</affiliation-url><afid>60022403</afid><affilname>Technion - Israel Institute of Technology</affilname><name-variant>Technion</name-variant><affiliation-city>Haifa</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015234</affiliation-url><afid>60015234</afid><affilname>Schneider Childrens Medical Center Israel</affilname><name-variant>Schneider Children's Medical Center</name-variant><affiliation-city>Petah Tiqwa</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022119</affiliation-url><afid>60022119</afid><affilname>Rabin Medical Center Israel</affilname><name-variant>Rabin Medical Center</name-variant><affiliation-city>Petah Tiqwa</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56083278000</author-url><authid>56083278000</authid><authname>Kugler E.</authname><surname>Kugler</surname><given-name>Eitan</given-name><initials>E.</initials><afid>60022119</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7403589091</author-url><authid>7403589091</authid><authname>Cohen E.</authname><surname>Cohen</surname><given-name>Eytan</given-name><initials>E.</initials><afid>60022119</afid><afid>60005037</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7403589091</author-url><authid>7403589091</authid><authname>Cohen E.</authname><surname>Cohen</surname><given-name>Eytan</given-name><initials>E.</initials><afid>60022119</afid><afid>60005037</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202029801</author-url><authid>7202029801</authid><authname>Goldberg E.</authname><surname>Goldberg</surname><given-name>Elad</given-name><initials>E.</initials><afid>60022119</afid><afid>60005037</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202029801</author-url><authid>7202029801</authid><authname>Goldberg E.</authname><surname>Goldberg</surname><given-name>Elad</given-name><initials>E.</initials><afid>60022119</afid><afid>60005037</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24559483400</author-url><authid>24559483400</authid><authname>Nardi Y.</authname><surname>Nardi</surname><given-name>Yuval</given-name><initials>Y.</initials><afid>60022403</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55937071600</author-url><authid>55937071600</authid><authname>Levi A.</authname><surname>Levi</surname><given-name>Amos</given-name><initials>A.</initials><afid>60022119</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8785063700</author-url><authid>8785063700</authid><authname>Krause I.</authname><surname>Krause</surname><given-name>Irit</given-name><initials>I.</initials><afid>60005037</afid><afid>60015234</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8785063700</author-url><authid>8785063700</authid><authname>Krause I.</authname><surname>Krause</surname><given-name>Irit</given-name><initials>I.</initials><afid>60005037</afid><afid>60015234</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56249748000</author-url><authid>56249748000</authid><authname>Garty M.</authname><surname>Garty</surname><given-name>Moshe</given-name><initials>M.</initials><afid>60005037</afid><afid>60022119</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56249748000</author-url><authid>56249748000</authid><authname>Garty M.</authname><surname>Garty</surname><given-name>Moshe</given-name><initials>M.</initials><afid>60005037</afid><afid>60022119</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006011256</author-url><authid>7006011256</authid><authname>Krause I.</authname><surname>Krause</surname><given-name>Ilan</given-name><initials>I.</initials><afid>60022119</afid><afid>60005037</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006011256</author-url><authid>7006011256</authid><authname>Krause I.</authname><surname>Krause</surname><given-name>Ilan</given-name><initials>I.</initials><afid>60022119</afid><afid>60005037</afid></author><authkeywords>Early prevention | Estimated glomerular filtration rate | Inflammatory markers | Nephropathy</authkeywords><intid>536086830</intid><article-number>116</article-number><source-id>19950</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929836215"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929836215?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929836215&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929836215&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929836215</prism:url><dc:identifier>SCOPUS_ID:84929836215</dc:identifier><eid>2-s2.0-84929836215</eid><dc:title>Increased Cardiovascular Disease, Resource Use, and Costs Before the Clinical Diagnosis of Diabetes in Veterans in the Southeastern U.S</dc:title><dc:creator>Olson D.</dc:creator><prism:publicationName>Journal of General Internal Medicine</prism:publicationName><prism:issn>08848734</prism:issn><prism:eIssn>15251497</prism:eIssn><prism:volume>30</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>749-757</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11606-014-3075-7</prism:doi><dc:description>© 2015, Society of General Internal Medicine 2015 (outside the USA). Importance: Screening for diabetes might be more widespread if adverse associations with cardiovascular disease (CVD), resource use, and costs were known to occur earlier than conventional clinical diagnosis. Objective: The purpose of this study was to determine whether adverse effects associated with diabetes begin prior to clinical diagnosis. Design: Veterans with diabetes were matched 1:2 with controls by follow-up, age, race/ethnicity, gender, and VA facility. CVD was obtained from ICD-9 codes, and resource use and costs from VA datasets. Setting: VA facilities in SC, GA, and AL. Participants: Patients with and without diagnosed diabetes. Main Outcome Measures: Diagnosed CVD, resource use, and costs. Results: In this study, the 2,062 diabetic patients and 4,124 controls were 63 years old on average, 99 % male, and 29 % black; BMI was 30.8 in diabetic patients vs. 27.8 in controls (p&lt;0.001). CVD prevalence was higher and there were more outpatient visits in Year −4 before diagnosis through Year +4 after diagnosis among diabetic vs. control patients (all p&lt;0.01); in Year −2, CVD prevalence was 31 % vs. 24 %, and outpatient visits were 22 vs. 19 per year, respectively. Total VA costs/year/veteran were higher in diabetic than control patients from Year −4 ($4,083 vs. $2,754) through Year +5 ($8,347 vs. $5,700) (p&lt;0.003) for each, reflecting underlying increases in outpatient, inpatient, and pharmacy costs (p&lt;0.05 for each). Regression analysis showed that diabetes contributed an average of $1,748/year to costs, independent of CVD (p&lt;0.001). Conclusions and Relevance: VA costs per veteran are higher—over $1,000/year before and $2,000/year after diagnosis of diabetes—due to underlying increases in outpatient, inpatient, and pharmacy costs, greater number of outpatient visits, and increased CVD. Moreover, adverse associations with veterans’ health and the VA healthcare system occur early in the natural history of the disease, several years before diabetes is diagnosed. Since adverse associations begin before diabetes is recognized, greater consideration should be given to systematic screening in order to permit earlier detection and initiation of preventive management. Keeping frequency of CVD and marginal costs in line with those of patients before diabetes is currently diagnosed has the potential to save up to $2 billion a year.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002339</affiliation-url><afid>60002339</afid><affilname>Emory University School of Medicine</affilname><name-variant>Emory University School of Medicine</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000928</affiliation-url><afid>60000928</afid><affilname>Emory University</affilname><name-variant>Emory University</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002339</affiliation-url><afid>60002339</afid><affilname>Emory University School of Medicine</affilname><name-variant>Emory University School of Medicine</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002339</affiliation-url><afid>60002339</afid><affilname>Emory University School of Medicine</affilname><name-variant>Emory University School of Medicine</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000928</affiliation-url><afid>60000928</afid><affilname>Emory University</affilname><name-variant>Emory University</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000928</affiliation-url><afid>60000928</afid><affilname>Emory University</affilname><name-variant>Emory University</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025315</affiliation-url><afid>60025315</afid><affilname>Rollins School of Public Health</affilname><name-variant>Emory University</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001681</affiliation-url><afid>60001681</afid><affilname>Abbott Laboratories</affilname><name-variant>Abbott Laboratories</name-variant><affiliation-city>Abbott Park</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">21</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7402201718</author-url><authid>7402201718</authid><authname>Olson D.</authname><surname>Olson</surname><given-name>Darin E.</given-name><initials>D.E.</initials><afid>60014232</afid><afid>60002339</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7402201718</author-url><authid>7402201718</authid><authname>Olson D.</authname><surname>Olson</surname><given-name>Darin E.</given-name><initials>D.E.</initials><afid>60014232</afid><afid>60002339</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56496001000</author-url><authid>56496001000</authid><authname>Zhu M.</authname><surname>Zhu</surname><given-name>Ming</given-name><initials>M.</initials><afid>60000928</afid><afid>60001681</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56496001000</author-url><authid>56496001000</authid><authname>Zhu M.</authname><surname>Zhu</surname><given-name>Ming</given-name><initials>M.</initials><afid>60000928</afid><afid>60001681</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35240614400</author-url><authid>35240614400</authid><authname>Long Q.</authname><surname>Long</surname><given-name>Qi</given-name><initials>Q.</initials><afid>60000928</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8717461300</author-url><authid>8717461300</authid><authname>Barb D.</authname><surname>Barb</surname><given-name>Diana</given-name><initials>D.</initials><afid>60002339</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56496566100</author-url><authid>56496566100</authid><authname>Haw J.</authname><surname>Haw</surname><given-name>Jeehea S.</given-name><initials>J.S.</initials><afid>60002339</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56496432300</author-url><authid>56496432300</authid><authname>Rhee M.</authname><surname>Rhee</surname><given-name>Mary K.</given-name><initials>M.K.</initials><afid>60014232</afid><afid>60002339</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56496432300</author-url><authid>56496432300</authid><authname>Rhee M.</authname><surname>Rhee</surname><given-name>Mary K.</given-name><initials>M.K.</initials><afid>60014232</afid><afid>60002339</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24466911400</author-url><authid>24466911400</authid><authname>Mohan A.</authname><surname>Mohan</surname><given-name>Arun V.</given-name><initials>A.V.</initials><afid>60002339</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56189634600</author-url><authid>56189634600</authid><authname>Watson-Williams P.</authname><surname>Watson-Williams</surname><given-name>Phyllis I.</given-name><initials>P.I.</initials><afid>60014232</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55893303000</author-url><authid>55893303000</authid><authname>Jackson S.</authname><surname>Jackson</surname><given-name>Sandra L.</given-name><initials>S.L.</initials><afid>60014232</afid><afid>60000928</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55893303000</author-url><authid>55893303000</authid><authname>Jackson S.</authname><surname>Jackson</surname><given-name>Sandra L.</given-name><initials>S.L.</initials><afid>60014232</afid><afid>60000928</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:8544617500</author-url><authid>8544617500</authid><authname>Tomolo A.</authname><surname>Tomolo</surname><given-name>Anne M.</given-name><initials>A.M.</initials><afid>60014232</afid><afid>60002339</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:8544617500</author-url><authid>8544617500</authid><authname>Tomolo A.</authname><surname>Tomolo</surname><given-name>Anne M.</given-name><initials>A.M.</initials><afid>60014232</afid><afid>60002339</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55879182900</author-url><authid>55879182900</authid><authname>Wilson P.</authname><surname>Wilson</surname><given-name>Peter W F</given-name><initials>P.W.F.</initials><afid>60014232</afid><afid>60002339</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55879182900</author-url><authid>55879182900</authid><authname>Wilson P.</authname><surname>Wilson</surname><given-name>Peter W F</given-name><initials>P.W.F.</initials><afid>60014232</afid><afid>60002339</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56491518900</author-url><authid>56491518900</authid><authname>Narayan K.</authname><surname>Narayan</surname><given-name>K. M Venkat</given-name><initials>K.M.V.</initials><afid>60000928</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:55871121050</author-url><authid>55871121050</authid><authname>Lipscomb J.</authname><surname>Lipscomb</surname><given-name>Joseph</given-name><initials>J.</initials><afid>60025315</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7402638005</author-url><authid>7402638005</authid><authname>Phillips L.</authname><surname>Phillips</surname><given-name>Lawrence S.</given-name><initials>L.S.</initials><afid>60014232</afid><afid>60002339</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7402638005</author-url><authid>7402638005</authid><authname>Phillips L.</authname><surname>Phillips</surname><given-name>Lawrence S.</given-name><initials>L.S.</initials><afid>60014232</afid><afid>60002339</afid></author><authkeywords>cardiovascular disease | diabetes | health care cost | prediabetes</authkeywords><intid>1036017330</intid><source-id>26643</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930008663"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930008663?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930008663&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930008663&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930008663</prism:url><dc:identifier>SCOPUS_ID:84930008663</dc:identifier><eid>2-s2.0-84930008663</eid><dc:title>Conversion in off pump coronary artery bypass grafting: a retrospective analysis</dc:title><dc:creator>Salve G.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>141-147</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-014-0356-z</prism:doi><dc:description>© 2015, Indian Association of Cardiovascular-Thoracic Surgeons. Background: Intraoperative conversion of off-pump coronary artery bypass grafting (OPCAB) to on-pump coronary artery bypass grafting (ONCAB) has been associated with adverse outcomes. Inspite of several preoperative risk factors reported in the literature, conversion still remains an unpredictable event. This study aims to determine the incidence and predictors of conversion and attempts to evaluate strategies to prevent the same. Methods: Between June 2011 to May 2012, out of 994 patients who were planned for elective OPCAB by 8 different surgical teams at our institution, 127 patients underwent intraoperative conversion to ONCAB. We conducted a retrospective analysis of these patients under two groups—ONCAB (n = 127) and OPCAB (n = 867). Patients undergoing elective ONCAB and emergency OPCAB were excluded from the study. Results: The incidence of intraoperative conversion was 12.77 %. Those who underwent conversion had a significantly higher rate of postoperative complications including hospital mortality (9.44 versus 2.42 %). Left ventricular dysfunction, history of myocardial infarction, and left main disease emerged as independent predictors of conversion. Conclusion: Association of certain preoperative risk factors can predict the occurrence of intraoperative conversion. Planned and smooth conduct of OPCAB plays a key role to avoid higher mortality and morbidity associated with conversion. If at all unavoidable, a timely conversion can prevent hazards of emergency conversion.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101396814</affiliation-url><afid>101396814</afid><affilname>Sri Jayadeva Institute of Cardiovascular Sciences and Research</affilname><name-variant>Sri Jayadeva Institute of Cardiovascular Sciences and Research</name-variant><affiliation-city>Bangalore</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55855430400</author-url><authid>55855430400</authid><authname>Salve G.</authname><surname>Salve</surname><given-name>Gananjay Gopalrao</given-name><initials>G.G.</initials><afid>101396814</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55855079200</author-url><authid>55855079200</authid><authname>Mavanoor S.</authname><surname>Mavanoor</surname><given-name>Shilpa Suresh</given-name><initials>S.S.</initials><afid>101396814</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56658429000</author-url><authid>56658429000</authid><authname>Kakade S.</authname><surname>Kakade</surname><given-name>Satish Vasantrao</given-name><initials>S.V.</initials><afid>101396814</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56658757400</author-url><authid>56658757400</authid><authname>Dhanyaprakash </authname><surname>Dhanyaprakash</surname><given-name/><initials/><afid>101396814</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55855340700</author-url><authid>55855340700</authid><authname>Sreedhar K.</authname><surname>Sreedhar</surname><given-name>Kumsi</given-name><initials>K.</initials><afid>101396814</afid></author><authkeywords>Conversion | ONCAB | OPCAB</authkeywords><intid>36048395</intid><article-number>356</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930006825"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930006825?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930006825&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930006825&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930006825</prism:url><dc:identifier>SCOPUS_ID:84930006825</dc:identifier><eid>2-s2.0-84930006825</eid><dc:title>A rare aneurysm of the sinus of Valsalva—from the left sinus</dc:title><dc:creator>Philip M.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>193-195</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-014-0353-2</prism:doi><dc:description>© 2015, Indian Association of Cardiovascular-Thoracic Surgeons. Sinus of Valsalva aneurysm (SVA) is a rare anomaly which may be congenital or acquired. We present a rare case of an unruptured calcified SVA arising from the left coronary sinus and extending into the left ventricle. Transesophageal echocardiogram revealed moderate aortic regurgitation. The aneurysm was repaired using a synthetic fabric patch preserving the native valve. Only one case of unruptured left SVA prolapsing into the left ventricle has been reported so far in the English literature. Such lesions are rare since the high pressure of the left ventricle prevents the prolapsing of the aneurysm into it.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000653</affiliation-url><afid>60000653</afid><affilname>Christian Medical College, Vellore</affilname><name-variant>Christian Medical College Hospital</name-variant><affiliation-city>Vellore</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000653</affiliation-url><afid>60000653</afid><affilname>Christian Medical College, Vellore</affilname><name-variant>Christian Medical College Hospital</name-variant><affiliation-city>Vellore</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56592252100</author-url><authid>56592252100</authid><authname>Philip M.</authname><surname>Philip</surname><given-name>Madhu Andrew</given-name><initials>M.A.</initials><afid>60000653</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56591816600</author-url><authid>56591816600</authid><authname>George G.</authname><surname>George</surname><given-name>Gladdy</given-name><initials>G.</initials><afid>60000653</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55573731900</author-url><authid>55573731900</authid><authname>George R.</authname><surname>George</surname><given-name>Ray</given-name><initials>R.</initials><afid>60000653</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6504141356</author-url><authid>6504141356</authid><authname>Gnanamuthu B.</authname><surname>Gnanamuthu</surname><given-name>Birla Roy</given-name><initials>B.R.</initials><afid>60000653</afid></author><authkeywords>Aneurysm | Unruptured | Valsalva</authkeywords><intid>1036045413</intid><article-number>353</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930212713"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930212713?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930212713&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930212713&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930212713</prism:url><dc:identifier>SCOPUS_ID:84930212713</dc:identifier><eid>2-s2.0-84930212713</eid><dc:title>Single-stage repair of aortic arch and associated cardiac defects with antegrade cerebral perfusion using direct innominate artery cannulation in neonates and infants</dc:title><dc:creator>Dharmapuram A.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>127-132</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-015-0367-4</prism:doi><dc:description>© 2015, Indian Association of Cardiovascular-Thoracic Surgeons. Background: Selective cerebral perfusion avoids deep hypothermic circulatory arrest in single-stage repair of the aortic arch and associated cardiac defects in neonates and infants. Direct innominate artery cannulation is accepted as a safe technique to obtain this objective. Methods: From February 2012 to September 2014, 21 patients underwent one-stage repair of aortic arch anomalies associated with intracardiac defects. The age ranged from 16 days to 1 year (median age 2 months). There were six neonates. The weight ranged from 2.4 to 8 kg (median weight 3.5 kg).Two infants had coarctation with diffuse aortic arch hypoplasia, without any associated intracardiac defect. The rest had significant intracardiac defects which were corrected along with arch repair. Cardiopulmonary bypass was initiated with direct arterial return through the base of the innominate artery and routine venous cannulation. All patients were cooled to 24 °C. The arch repair was done using selective cerebral perfusion through the innominate artery with a flow rate of 40 mL/kg/min. After the arch repair, normal bypass was reestablished and intracardiac defects were repaired. Results: There was no mortality. There was no evidence of obvious neurologic injury. All patients had unobstructed flow in the arch repair during intermediate follow-up. Conclusions: Selective cerebral perfusion with direct innominate artery cannulation for arch repair extends the safety of arch repair. The major advantage of this technique is the feasibility to perform a wide end to side anastomosis without space constraint and ability to repair associated cardiac lesions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112608099</affiliation-url><afid>112608099</afid><affilname>Krishna Institute of Medical Sciences (KIMS)</affilname><name-variant>Krishna Institute of Medical Sciences (KIMS)</name-variant><affiliation-city>Secunderabad</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14826439800</author-url><authid>14826439800</authid><authname>Dharmapuram A.</authname><surname>Dharmapuram</surname><given-name>Anil Kumar</given-name><initials>A.K.</initials><afid>112608099</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36178354900</author-url><authid>36178354900</authid><authname>Ramadoss N.</authname><surname>Ramadoss</surname><given-name>Nagarajan</given-name><initials>N.</initials><afid>112608099</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36876164500</author-url><authid>36876164500</authid><authname>Goutami V.</authname><surname>Goutami</surname><given-name>Vejendla</given-name><initials>V.</initials><afid>112608099</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663195600</author-url><authid>56663195600</authid><authname>Mantri N.</authname><surname>Mantri</surname><given-name>Narsimulu</given-name><initials>N.</initials><afid>112608099</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662688800</author-url><authid>56662688800</authid><authname>Turner S.</authname><surname>Turner</surname><given-name>Shishir Pravin</given-name><initials>S.P.</initials><afid>112608099</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56663167300</author-url><authid>56663167300</authid><authname>Vuppali N.</authname><surname>Vuppali</surname><given-name>Nanda Kishor Kumar</given-name><initials>N.K.K.</initials><afid>112608099</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56663261100</author-url><authid>56663261100</authid><authname>Koyalakonda C.</authname><surname>Koyalakonda</surname><given-name>Chandra Shekhar</given-name><initials>C.S.</initials><afid>112608099</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6507567954</author-url><authid>6507567954</authid><authname>Pooboni S.</authname><surname>Pooboni</surname><given-name>Suneel Kumar</given-name><initials>S.K.</initials><afid>112608099</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56662828200</author-url><authid>56662828200</authid><authname>Rao I.</authname><surname>Rao</surname><given-name>Ivatury Mrutunjaya</given-name><initials>I.M.</initials><afid>112608099</afid></author><authkeywords>Arch repair | Innominate artery cannulation | Selective cerebral perfusion</authkeywords><intid>36086123</intid><article-number>367</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929994178"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929994178?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929994178&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929994178&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929994178</prism:url><dc:identifier>SCOPUS_ID:84929994178</dc:identifier><eid>2-s2.0-84929994178</eid><dc:title>Modified Blalock Taussig shunt for management of severe desaturation following bidirectional superior cavopulmonary anastomosis in a 3-month-old child</dc:title><dc:creator>Bhat A.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>165-168</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-014-0355-0</prism:doi><dc:description>© 2015, Indian Association of Cardiovascular-Thoracic Surgeons. Management of desaturation following bidirectional superior cavopulmonary anastomosis can be complex. Causes of desaturation following bidirectional cavopulmonary anastomosis include anastomotic obstruction, presence of a decompressing vein from the cavopulmonary circuit to the inferior vena cava territory or to the atrium, high pulmonary vascular resistance, ventricular dysfunction, and, in rare cases, acute pulmonary arteriovenous malformations. While the cause of desaturation may be obvious in most patients, it may not be conclusive in some. If data suggests acute pulmonary arteriovenous malformations as the cause of desaturation in a 3-month-old baby, it becomes a management challenge because the accepted strategy of performing a completion Fontan operation is very high risk and inadvisable at this age. We present the case of a 3-month-old baby who had severe desaturation following bidirectional superior cavopulmonary anastomosis. Clinical data and angiography were suggestive of pulmonary arteriovenous malformations. We managed the patient successfully with a Blalock-Taussig shunt and he has since had a completion Fontan.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072746</affiliation-url><afid>60072746</afid><affilname>Hamad General Hospital</affilname><name-variant>Hamad General Hospital</name-variant><affiliation-city>Doha</affiliation-city><affiliation-country>Qatar</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072746</affiliation-url><afid>60072746</afid><affilname>Hamad General Hospital</affilname><name-variant>Hamad General Hospital</name-variant><affiliation-city>Doha</affiliation-city><affiliation-country>Qatar</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7102056821</author-url><authid>7102056821</authid><authname>Bhat A.</authname><surname>Bhat</surname><given-name>Akhlaque Nabi</given-name><initials>A.N.</initials><afid>60072746</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56126238300</author-url><authid>56126238300</authid><authname>Rahmath M.</authname><surname>Rahmath</surname><given-name>Muhammed Riyas</given-name><initials>M.R.</initials><afid>60072746</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55669356500</author-url><authid>55669356500</authid><authname>John J.</authname><surname>John</surname><given-name>Jiju</given-name><initials>J.</initials><afid>60072746</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55915028500</author-url><authid>55915028500</authid><authname>Bhaskar P.</authname><surname>Bhaskar</surname><given-name>Pradeep</given-name><initials>P.</initials><afid>60072746</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56627709700</author-url><authid>56627709700</authid><authname>Dilawar M.</authname><surname>Dilawar</surname><given-name>Muhammad</given-name><initials>M.</initials><afid>60072746</afid></author><authkeywords>Blalock-Taussig shunt | Pulmonary arteriovenous malformation | Superior cavopulmonary anastomosis</authkeywords><intid>1536049677</intid><article-number>355</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930199940"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930199940?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930199940&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930199940&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930199940</prism:url><dc:identifier>SCOPUS_ID:84930199940</dc:identifier><eid>2-s2.0-84930199940</eid><dc:title>Nitric oxide in the normal kidney and in patients with diabetic nephropathy</dc:title><dc:creator>Tessari P.</dc:creator><prism:publicationName>Journal of Nephrology</prism:publicationName><prism:issn>11218428</prism:issn><prism:eIssn>17246059</prism:eIssn><prism:volume>28</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>257-268</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40620-014-0136-2</prism:doi><dc:description>© 2014, Italian Society of Nephrology. Nitric oxide (NO) is a gas with biological and regulatory properties, produced from arginine by the way of nitric oxide synthases (NOS), and with a very short half-life (few seconds). A “coupled” NOS activity leads to NO generation, whereas its uncoupling produces the reactive oxygen species peroxynitrite (ONOO&lt;sup&gt;−&lt;/sup&gt;). Uncoupling is usually due to inflammation, oxidative stress, decreased cofactor availability, or excessive NO production. Competitive inhibitors of NO production are post-translationally methylated arginine residues in proteins, which are constantly released into the circulation. NO availability is altered in many clinical conditions associated with vascular dysfunction, such as diabetes mellitus. The kidney plays an important role in body NO homeostasis. This article provides an overview of current literature, on NO production/availability, with a focus on diabetic nephropathy. In diabetes, NO availability is usually decreased (with exception of the early, hyper filtration phase of nephropathy in Type 1 diabetes), and it could constitute a factor of the generalized vasculopathy present in diabetic nephropathy. NO generation in Type 2 diabetes with nephropathy is inversely associated with the dimethyl-arginine concentrations, which are therefore important modulators of NO synthesis independently from the classic stimulatory pathways (such as the insulin effect). A disturbed NO metabolism is present in diabetes associated with nephropathy. Although modulation of NO production is not yet a common therapeutical strategy, a number of yet experimental compounds need to be tested as potential interventions to treat the vascular dysfunction and nephropathy in diabetes, as well as in other diseased states. Finally, in diabetic nephropathy NO deficiency may be associated to that of hydrogen sulfide, another interesting gaseous mediator which is increasingly investigated.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000481</affiliation-url><afid>60000481</afid><affilname>Universita degli Studi di Padova</affilname><name-variant>University of Padova</name-variant><affiliation-city>Padua</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005911521</author-url><authid>7005911521</authid><authname>Tessari P.</authname><surname>Tessari</surname><given-name>Paolo</given-name><initials>P.</initials><afid>60000481</afid></author><authkeywords>Arginine | Diabetes mellitus | Nephropathy | Nitric oxide | Stable isotopes | Vascular disease</authkeywords><intid>536087046</intid><article-number>136</article-number><source-id>19950</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929996346"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929996346?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929996346&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929996346&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929996346</prism:url><dc:identifier>SCOPUS_ID:84929996346</dc:identifier><eid>2-s2.0-84929996346</eid><dc:title>Our experience of intraoperative autologous blood donation in patients undergoing elective valve surgery</dc:title><dc:creator>Ghosh K.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>133-140</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-015-0359-4</prism:doi><dc:description>© 2015, Indian Association of Cardiovascular-Thoracic Surgeons. Background: Allogenic blood transfusions are associated with risks, costs, intermittent shortages, and questionable efficacy. Multiple alternatives have been advocated, and intraoperative autologous blood donation (IAD) or acute normovolemic hemodilution is one of these options. Methods: Ninety-nine patients were allocated into two groups, group A (n = 50) where intraoperative blood donation was done and group B (n = 49) where standard care was provided without autologous blood donation. Autologous blood was removed and was replaced simultaneously with an equal volume of hydroxyl-ethyl starch solution in group A. Banked blood was transfused in both the groups when the hemoglobin (Hb) was less than 6g/dl on cardiopulmonary bypass (CPB) and less than 9g/dl after CPB. Results: The two groups were comparable as regard to demographic data, type of surgical procedures, duration of CPB, duration of aortic cross clamp, duration of postoperative ventilation, re-exploration for excessive bleeding, postoperative coagulation profile, chest tube drainage, liver function, and renal function. However, the lowest Hb recorded on CPB was significantly lower in group A (6.7 ± 0.38 vs. 8.1 ± 0.62, p &lt; 0.0001). The postoperative platelet count was higher in group A (1.95 ± 0.21 vs. 1.79 ± 0.18, p value &lt;0.001). Total allogenic blood requirement measured in units (bags) was significantly lower in group A both intraoperatively (0.73 ± 0.52 vs. 1.7 ± 0.44, p &lt; 0.000) and postoperatively (1.58 ± 0.6 vs. 2.3 ± 0.8, p value &lt; 0.0001). Postoperative FFP requirement was also significantly lower in group A—340 ± 102.51 ml vs. 522.65 ± 60.71 ml, p &lt; 0.0001. The intraoperative crystalloid requirement was significantly lower in group A—438.8 ± 116.78 ml vs. 1334.89 ± 362.56 with p value &lt;0.0001. Conclusion: Autologous intraoperative blood donation is a useful modality to provide better outcome after valve surgery.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100682639</affiliation-url><afid>100682639</afid><affilname>IPGME</affilname><name-variant>I.P.G.M.E &amp;R</name-variant><affiliation-city>Kolkata</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37012472000</author-url><authid>37012472000</authid><authname>Ghosh K.</authname><surname>Ghosh</surname><given-name>Kakali</given-name><initials>K.</initials><afid>100682639</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24336324700</author-url><authid>24336324700</authid><authname>SenDasgupta C.</authname><surname>SenDasgupta</surname><given-name>Chaitali</given-name><initials>C.</initials><afid>100682639</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37037917400</author-url><authid>37037917400</authid><authname>Mahapatra S.</authname><surname>Mahapatra</surname><given-name>Subhendu</given-name><initials>S.</initials><afid>100682639</afid></author><authkeywords>Autologous predonation | Cardiac surgery | CPB</authkeywords><intid>36048777</intid><article-number>359</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930195486"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930195486?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930195486&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930195486&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930195486</prism:url><dc:identifier>SCOPUS_ID:84930195486</dc:identifier><eid>2-s2.0-84930195486</eid><dc:title>Prevalence and correlates of depersonalization in students aged 12–18 years in Germany</dc:title><dc:creator>Michal M.</dc:creator><prism:publicationName>Social Psychiatry and Psychiatric Epidemiology</prism:publicationName><prism:issn>09337954</prism:issn><prism:volume>50</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>995-1003</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00127-014-0957-2</prism:doi><dc:description>© 2014, Springer-Verlag Berlin Heidelberg. Background: Depersonalization (DP) involves unpleasant experiences of detachment from one’s sense of self or unreality in the environment. DP may occur in a broad range of conditions, among healthy persons due to sleep loss, drug induced, secondary to anxiety disorders or primary in depersonalization disorder. Although DP has an early age of onset, little is known about the prevalence and correlates of DP among adolescents. Methods: Between January and June 2011, we conducted a questionnaire-based representative survey of pupils aged 12–18 years in the federal state Rhineland-Palatinate of Germany. The final sample comprised 3,809 pupils. We analyzed the prevalence of depersonalization and its correlates regarding sociodemographic characteristics, substance abuse, global mental distress and resilience factors. Results: One-third of the sample showed severe global mental distress, and 11.9 % were in the range of clinically significant depersonalization. Depersonalized students were less often living with both parents (67.3 vs. 75.7 %), came more often from an disadvantaged socioeconomic background, had a very severe level of global mental distress (comparable to psychiatric inpatients), were more often smoking and abusing cannabis and they suffered from specific impairments regarding social insecurity, global self-efficacy and active coping abilities. Conclusions: Experiences of depersonalization were very common among adolescents and may indicate an increased risk for poor academic achievement and mental health in the long term. Prospective studies are needed to investigate the course and clinical relevance of depersonalization for the development of the adolescents.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031216</affiliation-url><afid>60031216</afid><affilname>Johannes Gutenberg Universitat Mainz</affilname><name-variant>University of Mainz</name-variant><affiliation-city>Mainz</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031216</affiliation-url><afid>60031216</afid><affilname>Johannes Gutenberg Universitat Mainz</affilname><name-variant>University of Mainz</name-variant><affiliation-city>Mainz</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7102740772</author-url><authid>7102740772</authid><authname>Michal M.</authname><surname>Michal</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60031216</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37076938300</author-url><authid>37076938300</authid><authname>Duven E.</authname><surname>Duven</surname><given-name>Eva</given-name><initials>E.</initials><afid>60031216</afid><afid>60031216</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37076938300</author-url><authid>37076938300</authid><authname>Duven E.</authname><surname>Duven</surname><given-name>Eva</given-name><initials>E.</initials><afid>60031216</afid><afid>60031216</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37067152300</author-url><authid>37067152300</authid><authname>Giralt S.</authname><surname>Giralt</surname><given-name>Sebastian</given-name><initials>S.</initials><afid>60031216</afid><afid>60031216</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37067152300</author-url><authid>37067152300</authid><authname>Giralt S.</authname><surname>Giralt</surname><given-name>Sebastian</given-name><initials>S.</initials><afid>60031216</afid><afid>60031216</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56076315500</author-url><authid>56076315500</authid><authname>Dreier M.</authname><surname>Dreier</surname><given-name>Michael</given-name><initials>M.</initials><afid>60031216</afid><afid>60031216</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56076315500</author-url><authid>56076315500</authid><authname>Dreier M.</authname><surname>Dreier</surname><given-name>Michael</given-name><initials>M.</initials><afid>60031216</afid><afid>60031216</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35604010200</author-url><authid>35604010200</authid><authname>Müller K.</authname><surname>Müller</surname><given-name>Kai W.</given-name><initials>K.W.</initials><afid>60031216</afid><afid>60031216</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35604010200</author-url><authid>35604010200</authid><authname>Müller K.</authname><surname>Müller</surname><given-name>Kai W.</given-name><initials>K.W.</initials><afid>60031216</afid><afid>60031216</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7202828314</author-url><authid>7202828314</authid><authname>Adler J.</authname><surname>Adler</surname><given-name>Julia</given-name><initials>J.</initials><afid>60031216</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005494922</author-url><authid>7005494922</authid><authname>Beutel M.</authname><surname>Beutel</surname><given-name>Manfred E.</given-name><initials>M.E.</initials><afid>60031216</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23973806500</author-url><authid>23973806500</authid><authname>Wölfling K.</authname><surname>Wölfling</surname><given-name>Klaus</given-name><initials>K.</initials><afid>60031216</afid><afid>60031216</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23973806500</author-url><authid>23973806500</authid><authname>Wölfling K.</authname><surname>Wölfling</surname><given-name>Klaus</given-name><initials>K.</initials><afid>60031216</afid><afid>60031216</afid></author><authkeywords>Cannabis | Coping | Depersonalization | General self-efficacy | Resilience | School | Smoking</authkeywords><intid>1536087569</intid><source-id>19841</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225049"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225049?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225049&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225049&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225049</prism:url><dc:identifier>SCOPUS_ID:84930225049</dc:identifier><eid>2-s2.0-84930225049</eid><dc:title>Optical measurements of gas bubbles in oil behind a cavitating micro-orifice flow</dc:title><dc:creator>Iben U.</dc:creator><prism:publicationName>Experiments in Fluids</prism:publicationName><prism:issn>07234864</prism:issn><prism:volume>56</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00348-015-1979-6</prism:doi><dc:description>© 2015, Springer-Verlag Berlin Heidelberg. In hydraulic systems, it is common for air release to occur behind valves or throttles in the form of bubbles. These air bubbles can affect the behavior and the performance of these systems to a substantial extent. In the paper, gas release in a liquid flow behind an orifice is analyzed by optical methods for various operation points. The bubbles are observed with a digital camera, and a detection algorithm based on the Hough transformation is used to determine their number and size. The appearance of gas bubbles is very sensitive to the inlet and outlet pressure of the orifice. Gas bubbles are only observed if choking cavitation occurs. An empirical relationship between an adjusted cavitation number and the appearance of gas release is presented. It is assumed that the observed bubbles contain mostly air. With the applied pressure differences, up to 30 % of the dissolved air was degassed in the form of bubbles.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015776</affiliation-url><afid>60015776</afid><affilname>Robert Bosch GmbH</affilname><name-variant>Robert Bosch GmbH</name-variant><affiliation-city>Gerlingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018353</affiliation-url><afid>60018353</afid><affilname>Technische Universitat Dresden</affilname><name-variant>Technische Universität Dresden</name-variant><affiliation-city>Dresden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105785620</affiliation-url><afid>105785620</afid><affilname>Hochschule für Technik und Wirtschaft Dresden</affilname><name-variant>Hochschule für Technik und Wirtschaft Dresden</name-variant><affiliation-city>Dresden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015776</affiliation-url><afid>60015776</afid><affilname>Robert Bosch GmbH</affilname><name-variant>Robert Bosch GmbH</name-variant><affiliation-city>Gerlingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56236771800</author-url><authid>56236771800</authid><authname>Iben U.</authname><surname>Iben</surname><given-name>Uwe</given-name><initials>U.</initials><afid>60015776</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55432134400</author-url><authid>55432134400</authid><authname>Wolf F.</authname><surname>Wolf</surname><given-name>Fabian</given-name><initials>F.</initials><afid>60015776</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663247300</author-url><authid>56663247300</authid><authname>Freudigmann H.</authname><surname>Freudigmann</surname><given-name>Hans Arndt</given-name><initials>H.A.</initials><afid>60015776</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7101928988</author-url><authid>7101928988</authid><authname>Fröhlich J.</authname><surname>Fröhlich</surname><given-name>Jochen</given-name><initials>J.</initials><afid>60018353</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8123520300</author-url><authid>8123520300</authid><authname>Heller W.</authname><surname>Heller</surname><given-name>Winfried</given-name><initials>W.</initials><afid>105785620</afid></author><intid>1036081979</intid><source-id>20327</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929840774"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929840774?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929840774&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929840774&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929840774</prism:url><dc:identifier>SCOPUS_ID:84929840774</dc:identifier><eid>2-s2.0-84929840774</eid><dc:title>Use of Interpreters by Physicians for Hospitalized Limited English Proficient Patients and Its Impact on Patient Outcomes</dc:title><dc:creator>López L.</dc:creator><prism:publicationName>Journal of General Internal Medicine</prism:publicationName><prism:issn>08848734</prism:issn><prism:eIssn>15251497</prism:eIssn><prism:volume>30</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>783-789</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11606-015-3213-x</prism:doi><dc:description>© 2015, Society of General Internal Medicine. BACKGROUND: Few studies have examined the impact of inpatient interpreter use for limited English proficient (LEP) patients on length of stay (LOS), 30-day post discharge emergency department (ED) visits and 30-day hospital readmission rates for LEP patients. METHODS: A retrospective cohort analysis was conducted of all hospitalized patients admitted to the general medicine service at a large academic center. For patients self-reported as LEP, use of interpreters during each episode of hospitalization was categorized as: 1) interpreter used by non-MD (i.e., nurse); 2) interpreter used by a non-Hospitalist MD; 3) interpreter used by Hospitalist; and 4) no interpreter used during hospitalization. We examined the association of English proficiency and interpreter use on outcomes utilizing Poisson and logistic regression models. RESULTS: Of 4,224 patients, 564 (13 %) were LEP. Of these LEP patients, 65.8 % never had a documented interpreter visit, 16.8 % utilized an interpreter with a non-MD, 12.6 % utilized an interpreter with a non-Hospitalist MD and 4.8 % utilized an interpreter with a hospitalist present. In adjusted models, compared to English speakers, LEP patients with no interpreters had significantly shorter LOS. There were no differences in readmission rates and ED utilization between LEP and English-speaking patients. Compared to LEP patients with no interpreter use, those who had a physician use an interpreter had odds for a longer LOS, but there was no difference in odds of readmission or ED utilization. CONCLUSION: Academic hospital clinician use of interpreters remains highly variable and physicians may selectively be using interpreters for the sickest patients.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000650</affiliation-url><afid>60000650</afid><affilname>Harvard College</affilname><name-variant>Harvard College Library</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019029</affiliation-url><afid>60019029</afid><affilname>Christiana Care Health System</affilname><name-variant>Christiana Care Health System</name-variant><affiliation-city>Wilmington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24825053300</author-url><authid>24825053300</authid><authname>López L.</authname><surname>López</surname><given-name>Lenny</given-name><initials>L.</initials><afid>60029929</afid><afid>60016782</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24825053300</author-url><authid>24825053300</authid><authname>López L.</authname><surname>López</surname><given-name>Lenny</given-name><initials>L.</initials><afid>60029929</afid><afid>60016782</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:42262624800</author-url><authid>42262624800</authid><authname>Rodriguez F.</authname><surname>Rodriguez</surname><given-name>Fátima</given-name><initials>F.</initials><afid>60016782</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56511758700</author-url><authid>56511758700</authid><authname>Huerta D.</authname><surname>Huerta</surname><given-name>Diego</given-name><initials>D.</initials><afid>60000650</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005981704</author-url><authid>7005981704</authid><authname>Soukup J.</authname><surname>Soukup</surname><given-name>Jane</given-name><initials>J.</initials><afid>60016782</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7007076722</author-url><authid>7007076722</authid><authname>Hicks L.</authname><surname>Hicks</surname><given-name>Leroi</given-name><initials>L.</initials><afid>60019029</afid></author><authkeywords>interpreter use | length of stay | limited English proficiency | thirty-day readmissions</authkeywords><intid>2036017040</intid><source-id>26643</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930224771"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930224771?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930224771&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930224771&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930224771</prism:url><dc:identifier>SCOPUS_ID:84930224771</dc:identifier><eid>2-s2.0-84930224771</eid><dc:title>Dermal toxicity study of rice bran supercritical CO&lt;inf&gt;2&lt;/inf&gt; extract in Sprague-Dawley rats</dc:title><dc:creator>Choi J.</dc:creator><prism:publicationName>Food Science and Biotechnology</prism:publicationName><prism:issn>12267708</prism:issn><prism:volume>24</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>1167-1176</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10068-015-0149-1</prism:doi><dc:description>© 2015, The Korean Society of Food Science and Technology and Springer Science+Business Media Dordrecht. The present study was carried out to evaluate the dermal toxicity of topically administered rice bran supercritical CO&lt;inf&gt;2&lt;/inf&gt; extract (RB-SCE; 500, 1,000, and 2,000 mg/kg) in male and female rats when given as a single dose and a 4-week repeated dose. In all rats that underwent the single-dose toxicity test, there were no abnormal changes in clinical signs or body weight and no deaths or abnormal gross necropsy findings related to RB-SCE. Based on the above results, the LD&lt;inf&gt;50&lt;/inf&gt; is &gt;2,000 mg/kg in both sexes. In all rats that underwent the 4-week repeated dermal toxicity test, there were no abnormal RB-SCEassociated changes with respect to external signs, urine and blood, or organs. The no-observed-adverse-effect level (NOAEL) of RB-SCE was thus considered to be 2,000 mg/kg/day for both sexes and the target organ. RB-SCE can be regarded as a very safe agent for topical dermal administration at a moderate dose.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002296</affiliation-url><afid>60002296</afid><affilname>Silla University</affilname><name-variant>Silla University</name-variant><affiliation-city>Busan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113846113</affiliation-url><afid>113846113</afid><affilname>ECOMINE Co., Ltd</affilname><name-variant>ECOMINE Co., Ltd</name-variant><affiliation-city>Busan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012704</affiliation-url><afid>60012704</afid><affilname>Kyungpook National University</affilname><name-variant>Kyungpook National University</name-variant><affiliation-city>Daegu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35104615200</author-url><authid>35104615200</authid><authname>Choi J.</authname><surname>Choi</surname><given-name>Jae Suk</given-name><initials>J.S.</initials><afid>60002296</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56338490500</author-url><authid>56338490500</authid><authname>Cheon E.</authname><surname>Cheon</surname><given-name>Eun Jin</given-name><initials>E.J.</initials><afid>60002296</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56459209300</author-url><authid>56459209300</authid><authname>Kim T.</authname><surname>Kim</surname><given-name>Tae Uk</given-name><initials>T.U.</initials><afid>60002296</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55815465000</author-url><authid>55815465000</authid><authname>Moon W.</authname><surname>Moon</surname><given-name>Woi Sook</given-name><initials>W.S.</initials><afid>113846113</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56007021900</author-url><authid>56007021900</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Joo Wan</given-name><initials>J.W.</initials><afid>60012704</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7406090824</author-url><authid>7406090824</authid><authname>Kim M.</authname><surname>Kim</surname><given-name>Mi Ryung</given-name><initials>M.R.</initials><afid>60002296</afid></author><authkeywords>dermal toxicity | noobserve-adverse-effect level | rat | rice bran | supercritical CO&lt;inf&gt;2&lt;/inf&gt; extract</authkeywords><intid>36085508</intid><source-id>12100154903</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930009058"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930009058?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930009058&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930009058&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930009058</prism:url><dc:identifier>SCOPUS_ID:84930009058</dc:identifier><eid>2-s2.0-84930009058</eid><dc:title>An algorithm to identify the development of lymphedema after breast cancer treatment</dc:title><dc:creator>Yen T.</dc:creator><prism:publicationName>Journal of Cancer Survivorship</prism:publicationName><prism:issn>19322259</prism:issn><prism:eIssn>19322267</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>161-171</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11764-014-0393-z</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. Purpose: Large, population-based studies are needed to better understand lymphedema, a major source of morbidity among breast cancer survivors. One challenge is identifying lymphedema in a consistent fashion. We sought to develop and validate an algorithm using Medicare claims to identify lymphedema after breast cancer surgery. Methods: From a population-based cohort of 2,597 elderly (65+) women who underwent incident breast cancer surgery in 2003 and completed annual telephone surveys through 2008, two algorithms were developed using Medicare claims from half of the cohort and validated in the remaining half. A lymphedema-positive case was defined by patient report. Results: A simple two ICD-9 code algorithm had 69 % sensitivity, 96 % specificity, positive predictive value &gt;75 % if prevalence of lymphedema is &gt;16 %, negative predictive value &gt;90 %, and area under receiver operating characteristic curve (AUC) of 0.82 (95 % CI 0.80–0.85). A more sophisticated, multi-step algorithm utilizing diagnostic and treatment codes, logistic regression methods, and a reclassification step performed similarly to the two-code algorithm. Conclusions: Given the similar performance of the two validated algorithms, the ease of implementing the simple algorithm and the fact that the simple algorithm does not include treatment codes, we recommend that this two-code algorithm be validated in and applied to other population-based breast cancer cohorts. Implications for Cancer Survivors: This validated lymphedema algorithm will facilitate the conduct of large, population-based studies in key areas (incidence rates, risk factors, prevention measures, treatment, and cost/economic analyses) that are critical to advancing our understanding and management of this challenging and debilitating chronic disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012553</affiliation-url><afid>60012553</afid><affilname>Medical College of Wisconsin</affilname><name-variant>Medical College of Wisconsin</name-variant><affiliation-city>Milwaukee</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012553</affiliation-url><afid>60012553</afid><affilname>Medical College of Wisconsin</affilname><name-variant>Medical College of Wisconsin</name-variant><affiliation-city>Milwaukee</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012553</affiliation-url><afid>60012553</afid><affilname>Medical College of Wisconsin</affilname><name-variant>Medical College of Wisconsin</name-variant><affiliation-city>Milwaukee</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56055286600</author-url><authid>56055286600</authid><authname>Yen T.</authname><surname>Yen</surname><given-name>Tina W F</given-name><initials>T.W.F.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56055286600</author-url><authid>56055286600</authid><authname>Yen T.</authname><surname>Yen</surname><given-name>Tina W F</given-name><initials>T.W.F.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56658429600</author-url><authid>56658429600</authid><authname>Laud P.</authname><surname>Laud</surname><given-name>Purushuttom W.</given-name><initials>P.W.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56658429600</author-url><authid>56658429600</authid><authname>Laud P.</authname><surname>Laud</surname><given-name>Purushuttom W.</given-name><initials>P.W.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602627148</author-url><authid>6602627148</authid><authname>Sparapani R.</authname><surname>Sparapani</surname><given-name>Rodney A.</given-name><initials>R.A.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602627148</author-url><authid>6602627148</authid><authname>Sparapani R.</authname><surname>Sparapani</surname><given-name>Rodney A.</given-name><initials>R.A.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56235893900</author-url><authid>56235893900</authid><authname>Li J.</authname><surname>Li</surname><given-name>Jianing</given-name><initials>J.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56235893900</author-url><authid>56235893900</authid><authname>Li J.</authname><surname>Li</surname><given-name>Jianing</given-name><initials>J.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004461800</author-url><authid>7004461800</authid><authname>Nattinger A.</authname><surname>Nattinger</surname><given-name>Ann B.</given-name><initials>A.B.</initials><afid>60012553</afid></author><authkeywords>Algorithm | Breast cancer | Lymphedema | Medicare | Survivorship</authkeywords><intid>2036044341</intid><article-number>393</article-number><source-id>5400152645</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929710115"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929710115?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929710115&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929710115&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929710115</prism:url><dc:identifier>SCOPUS_ID:84929710115</dc:identifier><eid>2-s2.0-84929710115</eid><dc:title>Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility</dc:title><dc:creator>Noreen M.</dc:creator><prism:publicationName>Immunologic Research</prism:publicationName><prism:issn>0257277X</prism:issn><prism:eIssn>15590755</prism:eIssn><prism:volume>62</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>234-252</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12026-015-8640-6</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Toll like receptors (TLRs) play a crucial role in regulation of innate as well as adaptive immunity. TLRs recognize a distinct but limited repertoire of conserved microbial products. Ligand binding to TLRs activates the signaling cascade and results in activation of multiple inflammatory genes. Variation in this immune response is under genetic control. Polymorphisms in genes associated with inflammatory pathway especially influence the outcome of diseases. TLR2 makes heterodimer with TLR1 or TLR6 and recognizes a wide variety of microbial ligands. In this review, we summarize studies of polymorphisms in genes encoding TLR1, TLR2, TLR4, TLR6, and most polymorphic adaptor protein, Mal/TIRAP, revealing their effect on susceptibility to diseases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60059937</affiliation-url><afid>60059937</afid><affilname>National University of Sciences and Technology Pakistan</affilname><name-variant>National University of Sciences and Technology</name-variant><affiliation-city>Rawalpindi</affiliation-city><affiliation-country>Pakistan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60038659</affiliation-url><afid>60038659</afid><affilname>University of Sargodha</affilname><name-variant>University of Sargodha</name-variant><affiliation-city>Sargodha</affiliation-city><affiliation-country>Pakistan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54909237500</author-url><authid>54909237500</authid><authname>Noreen M.</authname><surname>Noreen</surname><given-name>Mamoona</given-name><initials>M.</initials><afid>60059937</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56559468100</author-url><authid>56559468100</authid><authname>Arshad M.</authname><surname>Arshad</surname><given-name>Muhammad</given-name><initials>M.</initials><afid>60038659</afid></author><authkeywords>Disease | Mal/TIRAP | Polymorphism | Susceptibility | Toll like receptors</authkeywords><intid>1035995178</intid><article-number>8640</article-number><source-id>20808</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930009437"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930009437?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930009437&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930009437&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930009437</prism:url><dc:identifier>SCOPUS_ID:84930009437</dc:identifier><eid>2-s2.0-84930009437</eid><dc:title>Late revascularization of brachial artery injury: two cases</dc:title><dc:creator>Demir D.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>181-183</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-014-0343-4</prism:doi><dc:description>© 2014, Indian Association of Cardiovascular-Thoracic Surgeons. Traumatic brachial artery injuries are important peripheral vascular injuries. Vascular lacerations of the upper extremity can result in severe dysfunction, loss of limbs, and/or death. Emergency surgery has almost always been needed immediately after arterial injuries. In our practice, however, we have encountered Syrian refugees presenting with symptoms and signs of ischemia 2 months following brachial artery sustained in war. A lot of reports on brachial artery injury are found in literature, but revascularization after 2 months for completely transected arteries was the most unique aspect of our cases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115004394</affiliation-url><afid>115004394</afid><affilname>Sanliurfa Mehmet Akif Inan Education and Research Hospital</affilname><name-variant>Şanlıurfa Mehmet Akif İnan Education and Research Hospital</name-variant><affiliation-city>Sanliurfa</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115004394</affiliation-url><afid>115004394</afid><affilname>Sanliurfa Mehmet Akif Inan Education and Research Hospital</affilname><name-variant>Şanlıurfa Mehmet Akif İnan Education and Research Hospital</name-variant><affiliation-city>Sanliurfa</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56599060300</author-url><authid>56599060300</authid><authname>Demir D.</authname><surname>Demir</surname><given-name>Deniz</given-name><initials>D.</initials><afid>115004394</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506393211</author-url><authid>6506393211</authid><authname>Tulay C.</authname><surname>Tulay</surname><given-name>Cumhur Murat</given-name><initials>C.M.</initials><afid>115004394</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:13404028300</author-url><authid>13404028300</authid><authname>Abanoz M.</authname><surname>Abanoz</surname><given-name>Mustafa</given-name><initials>M.</initials><afid>115004394</afid></author><authkeywords>Brachial artery injury | Peripheral artery | Vascular surgery</authkeywords><intid>1536049569</intid><article-number>343</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929709531"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929709531?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929709531&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929709531&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929709531</prism:url><dc:identifier>SCOPUS_ID:84929709531</dc:identifier><eid>2-s2.0-84929709531</eid><dc:title>Periodontal bone loss and risk of epithelial ovarian cancer</dc:title><dc:creator>Babic A.</dc:creator><prism:publicationName>Cancer Causes and Control</prism:publicationName><prism:issn>09575243</prism:issn><prism:eIssn>15737225</prism:eIssn><prism:volume>26</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>941-947</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10552-015-0575-7</prism:doi><dc:description>© 2015, Springer International Publishing Switzerland. Purpose: Periodontitis, a chronic inflammatory response to pathogenic bacteria in the oral microbiome, is common among adults. It is associated with several medical conditions, including cardiovascular diseases, and potentially with esophageal, lung, oral, and pancreatic cancer. One of the proposed mechanisms behind these associations is systemic inflammation, which has also been implicated in ovarian cancer etiology. The aim of this study was to evaluate association between ovarian cancer and periodontal bone loss. Methods: The association between periodontal bone loss, a marker of periodontitis, and risk of epithelial ovarian cancer was estimated among 60,560 participants of the prospective Nurses’ Health Study using Cox proportional hazards analysis. Competing risks analysis was used to estimate association by histologic subtype. Results: We did not observe an increased risk of ovarian cancer among participants with periodontal bone loss (HR 0.86, 95 % CI 0.64–1.15). Among women younger than 69 years, periodontal bone loss was associated with a 40 % (HR 0.60, 95 % CI 0.36–0.98) decreased ovarian cancer risk, while there was no association in women older than 69 (HR 1.09, 95 % CI 0.75–1.58), although this difference did not reach statistical significance (p-heterogeneity = 0.06). We observed a suggestive decreased risk for serous tumors (HR 0.76, 95 % CI 0.53–1.09). The number of natural teeth and root canals, other metrics of oral health, were not associated with ovarian cancer risk. Conclusion: Our results do not support an increased ovarian cancer risk in women with periodontal bone loss; however, there was a significant decrease in risk in women younger than 69. Given the unexpected association between periodontal bone loss and ovarian cancer risk in younger women, further research is warranted.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115038872</affiliation-url><afid>115038872</afid><affilname>Harvard T.H. Chan School of Public Health</affilname><name-variant>Harvard T. H. Chan School of Public Health</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013450</affiliation-url><afid>60013450</afid><affilname>University of North Carolina School of Dentistry</affilname><name-variant>UNC School of Dentistry</name-variant><affiliation-city>Chapel Hill</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56421890600</author-url><authid>56421890600</authid><authname>Babic A.</authname><surname>Babic</surname><given-name>Ana</given-name><initials>A.</initials><afid>115038872</afid><afid>60016782</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56421890600</author-url><authid>56421890600</authid><authname>Babic A.</authname><surname>Babic</surname><given-name>Ana</given-name><initials>A.</initials><afid>115038872</afid><afid>60016782</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35321499000</author-url><authid>35321499000</authid><authname>Poole E.</authname><surname>Poole</surname><given-name>Elizabeth M.</given-name><initials>E.M.</initials><afid>60016782</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8319868700</author-url><authid>8319868700</authid><authname>Terry K.</authname><surname>Terry</surname><given-name>Kathryn L.</given-name><initials>K.L.</initials><afid>115038872</afid><afid>60016782</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8319868700</author-url><authid>8319868700</authid><authname>Terry K.</authname><surname>Terry</surname><given-name>Kathryn L.</given-name><initials>K.L.</initials><afid>115038872</afid><afid>60016782</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202751360</author-url><authid>7202751360</authid><authname>Cramer D.</authname><surname>Cramer</surname><given-name>Daniel W.</given-name><initials>D.W.</initials><afid>115038872</afid><afid>60016782</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202751360</author-url><authid>7202751360</authid><authname>Cramer D.</authname><surname>Cramer</surname><given-name>Daniel W.</given-name><initials>D.W.</initials><afid>115038872</afid><afid>60016782</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701468166</author-url><authid>6701468166</authid><authname>Teles R.</authname><surname>Teles</surname><given-name>Ricardo P.</given-name><initials>R.P.</initials><afid>60013450</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603804318</author-url><authid>6603804318</authid><authname>Tworoger S.</authname><surname>Tworoger</surname><given-name>Shelley S.</given-name><initials>S.S.</initials><afid>115038872</afid><afid>60016782</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603804318</author-url><authid>6603804318</authid><authname>Tworoger S.</authname><surname>Tworoger</surname><given-name>Shelley S.</given-name><initials>S.S.</initials><afid>115038872</afid><afid>60016782</afid></author><authkeywords>Cohort study | Oral microbiome | Ovarian cancer | Periodontitis</authkeywords><intid>536000903</intid><article-number>575</article-number><source-id>28796</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929998261"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929998261?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929998261&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929998261&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929998261</prism:url><dc:identifier>SCOPUS_ID:84929998261</dc:identifier><eid>2-s2.0-84929998261</eid><dc:title>Relative sweetness, sweetness quality, and temporal profile of xylooligosaccharides and luo han guo (Siraitia grosvenorii) extract</dc:title><dc:creator>Kim M.</dc:creator><prism:publicationName>Food Science and Biotechnology</prism:publicationName><prism:issn>12267708</prism:issn><prism:volume>24</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>965-973</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10068-015-0124-x</prism:doi><dc:description>© 2015, The Korean Society of Food Science and Technology and Springer Science+Business Media Dordrecht. This study was conducted to elucidate comprehensive sensory profiles of potential natural alternative sweeteners, xylooligosaccharides (XOS), and luo han guo extract (LHGE). Relative sweetness to 5% sucrose was obtained using the two-alternative forced-choice method. Sensory and temporal profiles were identified using descriptive analysis and time-intensity analysis, respectively. XOS and LHGE were 0.25- and 75.76-fold sweeter than 5% sucrose solution, respectively. At equi-sweetness concentrations to 5% sucrose, XOS was characterized by sourish and corn silk flavor. LHGE was distinguished from other sweeteners by its yellowness, honey-like flavor, and licorice flavor. Bitterness and acridness of these sweeteners were not significantly different from those of sucrose. Both sweeteners exhibited a delayed time to peak intensity and persistent sweet aftertaste. Further studies are required to enhance the sweetness profile of XOS and LHGE toward achieving more sucrose-like sweetness impression.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006245</affiliation-url><afid>60006245</afid><affilname>Kookmin University</affilname><name-variant>Kookmin University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027884</affiliation-url><afid>60027884</afid><affilname>Sejong University</affilname><name-variant>Sejong University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106661381</affiliation-url><afid>106661381</afid><affilname>TS Corporation</affilname><name-variant>TS Corporation</name-variant><affiliation-city>Incheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012704</affiliation-url><afid>60012704</afid><affilname>Kyungpook National University</affilname><name-variant>Kyungpook National University</name-variant><affiliation-city>Daegu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56403513800</author-url><authid>56403513800</authid><authname>Kim M.</authname><surname>Kim</surname><given-name>Min Ji</given-name><initials>M.J.</initials><afid>60006245</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56658198400</author-url><authid>56658198400</authid><authname>Yoo S.</authname><surname>Yoo</surname><given-name>Sang Ho</given-name><initials>S.H.</initials><afid>60027884</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56658154300</author-url><authid>56658154300</authid><authname>Jung S.</authname><surname>Jung</surname><given-name>Sangwon</given-name><initials>S.</initials><afid>106661381</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56477757000</author-url><authid>56477757000</authid><authname>Park M.</authname><surname>Park</surname><given-name>Mi Kyung</given-name><initials>M.K.</initials><afid>60012704</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24764545900</author-url><authid>24764545900</authid><authname>Hong J.</authname><surname>Hong</surname><given-name>Jae Hee</given-name><initials>J.H.</initials><afid>60006245</afid></author><authkeywords>descriptive analysis | luo han guo | relative sweetness | time-intensity analysis | xylooligosaccharides</authkeywords><intid>536050410</intid><source-id>12100154903</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930008550"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930008550?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930008550&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930008550&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930008550</prism:url><dc:identifier>SCOPUS_ID:84930008550</dc:identifier><eid>2-s2.0-84930008550</eid><dc:title>Anomalous origin of left pulmonary artery from aorta with tetralogy of Fallot in an adult: what is protecting the lung?</dc:title><dc:creator>Mathur A.</dc:creator><prism:publicationName>Indian Journal of Thoracic and Cardiovascular Surgery</prism:publicationName><prism:issn>09709134</prism:issn><prism:eIssn>09737723</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>187-189</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12055-014-0341-6</prism:doi><dc:description>© 2014, Indian Association of Cardiovascular-Thoracic Surgeons. Anomalous origin of one-branch pulmonary artery from aorta (AOPA) is a rare congenital anomaly. Uncorrected, it leads to rapid and frequently irreversible pulmonary hypertension. Association with tetralogy of Fallot is very rare and poses a problem of variable pulmonary vascular resistance. Surgical correction involves closure of ventricular septal defect, relief of right ventricular outflow obstruction, and reconstruction of the pulmonary confluence. The AOPA lung appears to be protected from irreversible vascular changes even in adulthood by unknown mechanisms.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115280910</affiliation-url><afid>115280910</afid><affilname>Narayana Multispeciality Hospital</affilname><name-variant>Narayana Multispeciality Hospital</name-variant><affiliation-city>Jaipur</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115280910</affiliation-url><afid>115280910</afid><affilname>Narayana Multispeciality Hospital</affilname><name-variant>Narayana Multispeciality Hospital</name-variant><affiliation-city>Jaipur</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7201657341</author-url><authid>7201657341</authid><authname>Mathur A.</authname><surname>Mathur</surname><given-name>Alok</given-name><initials>A.</initials><afid>115280910</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56658286000</author-url><authid>56658286000</authid><authname>Mathur A.</authname><surname>Mathur</surname><given-name>Ankit</given-name><initials>A.</initials><afid>115280910</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56658312300</author-url><authid>56658312300</authid><authname>Garg P.</authname><surname>Garg</surname><given-name>Pradeep</given-name><initials>P.</initials><afid>115280910</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56658226900</author-url><authid>56658226900</authid><authname>Sharma N.</authname><surname>Sharma</surname><given-name>Neeraj</given-name><initials>N.</initials><afid>115280910</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56658374400</author-url><authid>56658374400</authid><authname>Mittal P.</authname><surname>Mittal</surname><given-name>Piyush</given-name><initials>P.</initials><afid>115280910</afid></author><authkeywords>Pulmonary vascular resistance | Tetralogy of Fallot | Ventricular septal defect</authkeywords><intid>1036044920</intid><article-number>341</article-number><source-id>12100155625</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929843674"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929843674?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929843674&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929843674&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929843674</prism:url><dc:identifier>SCOPUS_ID:84929843674</dc:identifier><eid>2-s2.0-84929843674</eid><dc:title>Predicting Non-Adherence with Outpatient Colonoscopy Using a Novel Electronic Tool that Measures Prior Non-Adherence</dc:title><dc:creator>Blumenthal D.</dc:creator><prism:publicationName>Journal of General Internal Medicine</prism:publicationName><prism:issn>08848734</prism:issn><prism:eIssn>15251497</prism:eIssn><prism:volume>30</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>724-731</prism:pageRange><prism:coverDate>2015-06-26</prism:coverDate><prism:coverDisplayDate>26 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11606-014-3165-6</prism:doi><dc:description>© 2015, Society of General Internal Medicine. BACKGROUND: Accurately predicting the risk of no-show for a scheduled colonoscopy can help target interventions to improve compliance with colonoscopy, and thereby reduce the disease burden of colorectal cancer and enhance the utilization of resources within endoscopy units. OBJECTIVES: We aimed to utilize information available in an electronic medical record (EMR) and endoscopy scheduling system to create a predictive model for no-show risk, and to simultaneously evaluate the role for natural language processing (NLP) in developing such a model. DESIGN: This was a retrospective observational study using discovery and validation phases to design a colonoscopy non-adherence prediction model. An NLP-derived variable called the Non-Adherence Ratio (“NAR”) was developed, validated, and included in the model. PARTICIPANTS: Patients scheduled for outpatient colonoscopy at an Academic Medical Center (AMC) that is part of a multi-hospital health system, 2009 to 2011, were included in the study. MAIN MEASURES: Odds ratios for non-adherence were calculated for all variables in the discovery cohort, and an Area Under the Receiver Operating Curve (AUC) was calculated for the final non-adherence prediction model. KEY RESULTS: The non-adherence model included six variables: 1) gender; 2) history of psychiatric illness, 3) NAR; 4) wait time in months; 5) number of prior missed endoscopies; and 6) education level. The model achieved discrimination in the validation cohort (AUC= =70.2 %). At a threshold non-adherence score of 0.46, the model’s sensitivity and specificity were 33 % and 92 %, respectively. Removing the NAR from the model significantly reduced its predictive power (AUC = 64.3 %, difference = 5.9 %, p &lt; 0.001). CONCLUSIONS: A six-variable model using readily available clinical and demographic information demonstrated accuracy for predicting colonoscopy non-adherence. The NAR, a novel variable developed using NLP technology, significantly strengthened this model’s predictive power.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55013369200</author-url><authid>55013369200</authid><authname>Blumenthal D.</authname><surname>Blumenthal</surname><given-name>Daniel M.</given-name><initials>D.M.</initials><afid>60029929</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507019259</author-url><authid>6507019259</authid><authname>Singal G.</authname><surname>Singal</surname><given-name>Gaurav</given-name><initials>G.</initials><afid>60029929</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56487419900</author-url><authid>56487419900</authid><authname>Mangla S.</authname><surname>Mangla</surname><given-name>Shikha S.</given-name><initials>S.S.</initials><afid>60016782</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603040905</author-url><authid>6603040905</authid><authname>Macklin E.</authname><surname>Macklin</surname><given-name>Eric A.</given-name><initials>E.A.</initials><afid>60029929</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7401719142</author-url><authid>7401719142</authid><authname>Chung D.</authname><surname>Chung</surname><given-name>Daniel C.</given-name><initials>D.C.</initials><afid>60029929</afid><afid>60029929</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7401719142</author-url><authid>7401719142</authid><authname>Chung D.</authname><surname>Chung</surname><given-name>Daniel C.</given-name><initials>D.C.</initials><afid>60029929</afid><afid>60029929</afid></author><authkeywords>adherence | cancer screening | colorectal cancer | prediction rules | quality improvement</authkeywords><intid>2036016990</intid><source-id>26643</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924085586"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924085586?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924085586&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924085586&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0144861715001344"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924085586</prism:url><dc:identifier>SCOPUS_ID:84924085586</dc:identifier><eid>2-s2.0-84924085586</eid><dc:title>Carbohydrate composition of peach palm (Bactris gasipaes Kunth) by-products flours</dc:title><dc:creator>Bolanho B.</dc:creator><prism:publicationName>Carbohydrate Polymers</prism:publicationName><prism:issn>01448617</prism:issn><prism:volume>124</prism:volume><prism:pageRange>196-200</prism:pageRange><prism:coverDate>2015-06-25</prism:coverDate><prism:coverDisplayDate>25 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.carbpol.2015.02.021</prism:doi><pii>S0144861715001344</pii><dc:description>© 2015 Elsevier Ltd. The flours obtained from peach palm by-products are rich in dietary fiber (62-71%) and they can be used as food ingredients. The aim of this work was to investigate the carbohydrate composition of the flours processed from the residual parts (stem and median sheath) of a hearts-of-palm industry. The flours were fractionated, based on their solubility, whose monomeric compounds were determined. The fraction containing mostly cellulose (S5) was the most abundant (26-28%), followed by the sum of fractions (S2, 53, S4) extracted with alkaline solutions (21-22%). The S1 fraction contained the highest percentage of uronic acids, which characterizes the presence of pectin. Xylose and arabinose were found in high proportion in S2 and S3 fractions. The S4 and S5 fractions, rich in glucose, were the main portion of the cell wall material and correspond to the insoluble fraction of the dietary fiber.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029498</affiliation-url><afid>60029498</afid><affilname>Universidade Estadual de Maringa</affilname><name-variant>State University of Maringá</name-variant><affiliation-city>Maringa</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018034</affiliation-url><afid>60018034</afid><affilname>Universidade Estadual de Ponta Grossa</affilname><name-variant>State University of Ponta Grossa</name-variant><affiliation-city>Ponta Grossa</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027866</affiliation-url><afid>60027866</afid><affilname>Universidade Estadual de Londrina</affilname><name-variant>Universidade Estadual de Londrina</name-variant><affiliation-city>Londrina</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56039146800</author-url><authid>56039146800</authid><authname>Bolanho B.</authname><surname>Bolanho</surname><given-name>Beatriz Cervejeira</given-name><initials>B.C.</initials><afid>60029498</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507858608</author-url><authid>6507858608</authid><authname>Danesi E.</authname><surname>Danesi</surname><given-name>Eliane Dalva Godoy</given-name><initials>E.D.G.</initials><afid>60018034</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602333582</author-url><authid>6602333582</authid><authname>Beléia A.</authname><surname>Beléia</surname><given-name>Adelaide Del Pino</given-name><initials>A.D.P.</initials><afid>60027866</afid></author><authkeywords>Cellulose | Fractionation | Hemicelluloses | Monosaccharides | Pectin</authkeywords><intid>35081121</intid><source-id>25801</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928574576"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928574576?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928574576&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928574576&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009279715001507"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928574576</prism:url><dc:identifier>SCOPUS_ID:84928574576</dc:identifier><eid>2-s2.0-84928574576</eid><dc:title>Ameliorative efficacy of tetrahydrocurcumin against arsenic induced oxidative damage, dyslipidemia and hepatic mitochondrial toxicity in rats</dc:title><dc:creator>Muthumani M.</dc:creator><prism:publicationName>Chemico-Biological Interactions</prism:publicationName><prism:issn>00092797</prism:issn><prism:eIssn>18727786</prism:eIssn><prism:volume>235</prism:volume><prism:pageRange>95-105</prism:pageRange><prism:coverDate>2015-06-25</prism:coverDate><prism:coverDisplayDate>25 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbi.2015.04.006</prism:doi><pii>S0009279715001507</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Arsenic (As) is a well-known human carcinogen and a potent hepatotoxin. Environmental exposure to arsenic imposes a serious health hazard to humans and other animals worldwide. Tetrahydrocurcumin (THC), one of the major metabolites of curcumin, exhibits many of the same physiological and pharmacological activities as curcumin and in some systems may exert greater antioxidant activity than the curcumin. It has been reported that THC has antioxidant efficacy attributable to the presence of identical β-diketone of 3rd and 5th substitution in heptane moiety. In the present study, rats were orally treated with arsenic alone (5 mg kg&lt;sup&gt;-1&lt;/sup&gt; bw/day) with THC (80 mg kg&lt;sup&gt;-1&lt;/sup&gt; bw/day) for 28 days. Hepatotoxicity was measured by the increased activities of serum hepatospecific enzymes, namely aspartate transaminase, alanine transaminase, alkaline phosphatase and bilirubin along with increased elevation of lipid peroxidative markers, thiobarbituric acid reactive substances. And also elevated levels of serum cholesterol, triglycerides, free fatty acids and phospholipids were observed in arsenic intoxicated rats. These effects of arsenic were coupled with enhanced mitochondrial swelling, inhibition of cytochrome c oxidase, Ca&lt;sup&gt;2+&lt;/sup&gt;ATPase and a decrease in mitochondrial calcium content. The toxic effect of arsenic was also indicated by significantly decreased activities of enzymatic antioxidants such as superoxide dismutase, catalase, and glutathione peroxidase along with non-enzymatic antioxidant such as reduced glutathione. Administration of THC exhibited significant reversal of arsenic induced toxicity in hepatic tissue. All these changes were supported by the reduction of arsenic concentration and histopathological observations of the liver. These results suggest that THC has a protective effect over arsenic induced toxicity in rat.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027171</affiliation-url><afid>60027171</afid><affilname>Annamalai University</affilname><name-variant>Annamalai University</name-variant><affiliation-city>Annamalai Nagar</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54399006400</author-url><authid>54399006400</authid><authname>Muthumani M.</authname><surname>Muthumani</surname><given-name>M.</given-name><initials>M.</initials><afid>60027171</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:27067862200</author-url><authid>27067862200</authid><authname>Miltonprabu S.</authname><surname>Miltonprabu</surname><given-name>S.</given-name><initials>S.</initials><afid>60027171</afid></author><authkeywords>Arsenic | Liver | Mitochondria | Rat | Tetrahydrocurcumin</authkeywords><intid>1785803646</intid><source-id>24652</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928128964"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928128964?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928128964&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928128964&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009279715001519"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928128964</prism:url><dc:identifier>SCOPUS_ID:84928128964</dc:identifier><eid>2-s2.0-84928128964</eid><dc:title>Mild hypothyroidism improves glucose tolerance in experimental type 2 diabetes</dc:title><dc:creator>Ashwini S.</dc:creator><prism:publicationName>Chemico-Biological Interactions</prism:publicationName><prism:issn>00092797</prism:issn><prism:eIssn>18727786</prism:eIssn><prism:volume>235</prism:volume><prism:pageRange>47-55</prism:pageRange><prism:coverDate>2015-06-25</prism:coverDate><prism:coverDisplayDate>25 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbi.2015.04.007</prism:doi><pii>S0009279715001519</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Background: Co-existence of type 2 diabetes and hypothyroidism is an emerging trend observed in clinical practice. Although the effects of isolated type 2 diabetes and hypothyroidism are well known, there are limited studies addressing the metabolic complications when these two conditions co-exist. The aim of the present study was to assess the interaction between type 2 diabetes and hypothyroidism with respect to glucose tolerance, dyslipidemia and redox balance in a state were these two diseases coexist. Methods: Sixty male Wistar Albino rats were randomised into six groups. Group 1: control, Group 2: overt hypothyroidism, Group 3: mild hypothyroidism, Group 4: type 2 diabetes, Group 5: mild hypothyroidism + type 2 diabetes, Group 6: overt hypothyroidism + type 2 diabetes. Experimental hypothyroidism was created by the administration of propyl-2-thiouracil and type 2 diabetes by feeding rats with 60% fructose (w/w). The duration of the study was 6 weeks. All the parameters were estimated at the start (basal) and the end of the study. Intraperitoneal glucose tolerance test was carried out and area under curve (AUC) calculated to assess the glucose tolerance. Thyroid profile, lipid profile and oxidative stress parameters were also measured. Results: Plasma TSH level was elevated 3-fold in the mild hypothyroid group and 15.2-fold in the overt hypothyroid group in comparison to the control group. Thyroid profile was found to be normal in type 2 diabetic group. There was no significant difference between hypothyroidism and hypothyroidism + diabetes groups with respect to thyroid profile. Among the six groups the degree of glucose intolerance was found to be maximum for overt hypothyroidism + diabetes group, followed by diabetes group and overt hypothyroidism group. An interesting finding was that glucose intolerance was significantly reduced in mild hypothyroidism + diabetes group (increase in AUC: 48.04%) in comparison with isolated diabetes group (increase in AUC: 71.63%). Similar results were obtained with parameters of oxidative stress. Oxidative stress was observed in overt hypothyroidism + diabetes, diabetes, overt hypothyroidism groups with severity decreasing in that order. Coexistence of mild hypothyroidism with diabetes decreased oxidative stress in comparison with isolated diabetes group. There was no statistical difference in lipid profile between mild hypothyroidism + diabetes and isolated diabetes group. Conclusion: Presence of mild hypothyroidism in type 2 diabetes confers a protective effect with respect to glucose tolerance and redox balance whereas presence of overt hypothyroidism in type 2 diabetes has a deleterious effect. The increased incidence of hypothyroidism in diabetes, especially subclinical hypothyroidism, could be a reflection of a physiological attempt by the body to mitigate damage wrought by diabetes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006000</affiliation-url><afid>60006000</afid><affilname>Jawaharlal Institute of Postgraduate Medical Education and Research India</affilname><name-variant>Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)</name-variant><affiliation-city>Pondicherry</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26032516000</author-url><authid>26032516000</authid><authname>Ashwini S.</authname><surname>Ashwini</surname><given-name>S.</given-name><initials>S.</initials><afid>60006000</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603413344</author-url><authid>6603413344</authid><authname>Bobby Z.</authname><surname>Bobby</surname><given-name>Zachariah</given-name><initials>Z.</initials><afid>60006000</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56599840100</author-url><authid>56599840100</authid><authname>Joseph M.</authname><surname>Joseph</surname><given-name>Manoj</given-name><initials>M.</initials><afid>60006000</afid></author><authkeywords>Glucose tolerance | Mild hypothyroidism | Overt hypothyroidism | Oxidative stress | Type 2 diabetes</authkeywords><intid>535732975</intid><source-id>24652</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929455540"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929455540?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929455540&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929455540&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929455540</prism:url><dc:identifier>SCOPUS_ID:84929455540</dc:identifier><eid>2-s2.0-84929455540</eid><dc:title>SKF-96365 strongly inhibits voltage-gated sodium current in rat ventricular myocytes</dc:title><dc:creator>Chen K.</dc:creator><prism:publicationName>Pflugers Archiv European Journal of Physiology</prism:publicationName><prism:issn>00316768</prism:issn><prism:eIssn>14322013</prism:eIssn><prism:volume>467</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1227-1236</prism:pageRange><prism:coverDate>2015-06-23</prism:coverDate><prism:coverDisplayDate>23 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00424-014-1565-4</prism:doi><dc:description>© 2014, Springer-Verlag Berlin Heidelberg. SKF-96365 (1-(beta-[3-(4-methoxy-phenyl) propoxy]-4-methoxyphenethyl)-1H-imidazole hydrochloride) is a general TRPC channel antagonist commonly used to characterize the potential functions of TRPC channels in cardiovascular system. Recent reports showed that SKF-96365 induced a reduction in cardiac conduction. The present study investigates whether the reduced cardiac conduction caused by SKF-96365 is related to the blockade of voltage-gated sodium current (I&lt;inf&gt;Na&lt;/inf&gt;) in rat ventricular myocytes using the whole-cell patch voltage-clamp technique. It was found that SKF-96365 inhibited I&lt;inf&gt;Na&lt;/inf&gt; in rat ventricular myocytes in a concentration-dependent manner. The compound (1 μM) negatively shifted the potential of I&lt;inf&gt;Na&lt;/inf&gt; availability by 9.5 mV, increased the closed-state inactivation of I&lt;inf&gt;Na&lt;/inf&gt;, and slowed the recovery of I&lt;inf&gt;Na&lt;/inf&gt; from inactivation. The inhibition of cardiac I&lt;inf&gt;Na&lt;/inf&gt; by SKF-96365 was use-dependent and frequency-dependent, and the IC&lt;inf&gt;50&lt;/inf&gt; was decreased from 1.36 μM at 0.5 Hz to 1.03, 0.81, 0.61, 0.56 μM at 1, 2, 5, 10 Hz, respectively. However, the selective TRPC3 antagonist Pyr3 decreased cardiac I&lt;inf&gt;Na&lt;/inf&gt; by 8.5 % at 10 μM with a weak use and frequency dependence. These results demonstrate that the TRPC channel antagonist SKF-96365 strongly blocks cardiac I&lt;inf&gt;Na&lt;/inf&gt; in use-dependent and frequency-dependent manners. Caution should be taken for interpreting the alteration of cardiac electrical activity when SKF-96365 is used in native cells as a TRPC antagonist.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025761</affiliation-url><afid>60025761</afid><affilname>Huazhong University of Science and Technology</affilname><name-variant>Huazhong Univ. of Sci. and Technol.</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025761</affiliation-url><afid>60025761</afid><affilname>Huazhong University of Science and Technology</affilname><name-variant>Huazhong Univ. of Sci. and Technol.</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56160361700</author-url><authid>56160361700</authid><authname>Chen K.</authname><surname>Chen</surname><given-name>Kui Hao</given-name><initials>K.H.</initials><afid>60006541</afid><afid>60006541</afid><afid>60025761</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56160361700</author-url><authid>56160361700</authid><authname>Chen K.</authname><surname>Chen</surname><given-name>Kui Hao</given-name><initials>K.H.</initials><afid>60006541</afid><afid>60006541</afid><afid>60025761</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56160361700</author-url><authid>56160361700</authid><authname>Chen K.</authname><surname>Chen</surname><given-name>Kui Hao</given-name><initials>K.H.</initials><afid>60006541</afid><afid>60006541</afid><afid>60025761</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55719442200</author-url><authid>55719442200</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hui</given-name><initials>H.</initials><afid>60006541</afid><afid>60006541</afid><afid>60025761</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55719442200</author-url><authid>55719442200</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hui</given-name><initials>H.</initials><afid>60006541</afid><afid>60006541</afid><afid>60025761</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55719442200</author-url><authid>55719442200</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hui</given-name><initials>H.</initials><afid>60006541</afid><afid>60006541</afid><afid>60025761</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56442845000</author-url><authid>56442845000</authid><authname>Yang L.</authname><surname>Yang</surname><given-name>Lei</given-name><initials>L.</initials><afid>60006541</afid><afid>60025761</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56442845000</author-url><authid>56442845000</authid><authname>Yang L.</authname><surname>Yang</surname><given-name>Lei</given-name><initials>L.</initials><afid>60006541</afid><afid>60025761</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35932258500</author-url><authid>35932258500</authid><authname>Jin M.</authname><surname>Jin</surname><given-name>Man Wen</given-name><initials>M.W.</initials><afid>60025761</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8224611300</author-url><authid>8224611300</authid><authname>Li G.</authname><surname>Li</surname><given-name>Gui Rong</given-name><initials>G.R.</initials><afid>60006541</afid><afid>60006541</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8224611300</author-url><authid>8224611300</authid><authname>Li G.</authname><surname>Li</surname><given-name>Gui Rong</given-name><initials>G.R.</initials><afid>60006541</afid><afid>60006541</afid></author><authkeywords>Cardiac myocytes | Pyr3 | SKF-96365 | Voltage-gated sodium current</authkeywords><intid>2035959522</intid><article-number>7</article-number><source-id>17025</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929414429"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929414429?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929414429&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929414429&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929414429</prism:url><dc:identifier>SCOPUS_ID:84929414429</dc:identifier><eid>2-s2.0-84929414429</eid><dc:title>Effect of growth rate on wood quality of teak (Tectona grandis L. f.): a comparative study of teak grown under differing site quality conditions</dc:title><dc:creator>Anish M.</dc:creator><prism:publicationName>Journal of the Indian Academy of Wood Science</prism:publicationName><prism:issn>0972172X</prism:issn><prism:eIssn>09768432</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>81-88</prism:pageRange><prism:coverDate>2015-06-22</prism:coverDate><prism:coverDisplayDate>22 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13196-015-0147-1</prism:doi><dc:description>© 2015, Indian Academy of Wood Science. The present study was carried out to analyse the effect of rate of growth on the wood quality of teak from samples collected from trees which were grown within India as well as from outside. Teak samples (basal discs) from 14 different locations viz. Nilambur, Malayattoor, Konni, Ranni, Vadavar (TN) and Betul (MP) within India and Myanmar, Thailand, Ghana, Benin, Cameroon, Sudan, Tanzania and Trinidad outside India were included in the study. To study the effect of growth rate on wood quality, the collected samples were classified as fast grown and slow grown based on their average ring width. Those samples having an average ring width ≥5 mm and those having an average ring width &lt;5 mm were categorised into fast grown and slow grown respectively. The analysis on variation in wood physical, anatomical and biochemical properties between the two categories revealed that, fast grown samples were characterized with higher specific gravity, moisture content (air dry) and shrinkage compared to the slow grown, but properties like vessel diameter, vessel area, ray height, ray width and extractive content (%) was found to be significantly higher for slow grown samples. However, fast and slow grown teak showed similarity with respect to other properties such as heartwood content (%), heartwood colour and bark thickness.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013109</affiliation-url><afid>60013109</afid><affilname>Kerala Agricultural University</affilname><name-variant>Kerala Agricultural University</name-variant><affiliation-city>Thrissur</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013109</affiliation-url><afid>60013109</afid><affilname>Kerala Agricultural University</affilname><name-variant>Kerala Agricultural University</name-variant><affiliation-city>Thrissur</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646365300</author-url><authid>56646365300</authid><authname>Anish M.</authname><surname>Anish</surname><given-name>M. C.</given-name><initials>M.C.</initials><afid>60013109</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55329790000</author-url><authid>55329790000</authid><authname>Anoop E.</authname><surname>Anoop</surname><given-name>E. V.</given-name><initials>E.V.</initials><afid>60013109</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56646430100</author-url><authid>56646430100</authid><authname>Vishnu R.</authname><surname>Vishnu</surname><given-name>R.</given-name><initials>R.</initials><afid>60013109</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56646383400</author-url><authid>56646383400</authid><authname>Sreejith B.</authname><surname>Sreejith</surname><given-name>B.</given-name><initials>B.</initials><afid>60013109</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35078484100</author-url><authid>35078484100</authid><authname>Jijeesh C.</authname><surname>Jijeesh</surname><given-name>C. M.</given-name><initials>C.M.</initials><afid>60013109</afid></author><authkeywords>Anatomical properties | Extractive content | Fast grown | Heart wood colour | Slow grown | Teak | Wood quality</authkeywords><intid>1785956119</intid><article-number>11</article-number><source-id>19700182259</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929458258"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929458258?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929458258&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929458258&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929458258</prism:url><dc:identifier>SCOPUS_ID:84929458258</dc:identifier><eid>2-s2.0-84929458258</eid><dc:title>Dietary Sodium and Cardiovascular Disease</dc:title><dc:creator>Smyth A.</dc:creator><prism:publicationName>Current Hypertension Reports</prism:publicationName><prism:issn>15226417</prism:issn><prism:eIssn>15343111</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-22</prism:coverDate><prism:coverDisplayDate>22 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11906-015-0559-8</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Although an essential nutrient, higher sodium intake is associated with increasing blood pressure (BP), forming the basis for current population-wide sodium restriction guidelines. While short-term clinical trials have achieved low intake (&lt;2.0 g/day), this has not been reproduced in long-term trials (&gt;6 months). Guidelines assume that low sodium intake will reduce BP and reduce cardiovascular disease (CVD), compared to moderate intake. However, current observational evidence suggests a J-shaped association between sodium intake and CVD; the lowest risks observed with 3–5 g/day but higher risk with &lt;3 g/day. Importantly, these observational data also confirm the association between higher intake (&gt;5 g/day) and increased risk of CVD. Although lower intake may reduce BP, this may be offset by marked increases in neurohormones and other adverse effects which may paradoxically be adverse. Large randomised clinical trials with sufficient follow-up are required to provide robust data on the long-term effects of sodium reduction on CVD incidence. Until such trials are completed, current evidence suggests that moderate sodium intake for the general population (3–5 g/day) is likely the optimum range for CVD prevention.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031828</affiliation-url><afid>60031828</afid><affilname>McMaster University</affilname><name-variant>McMaster University</name-variant><affiliation-city>Hamilton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008539</affiliation-url><afid>60008539</afid><affilname>National University of Ireland Galway</affilname><name-variant>National University of Ireland</name-variant><affiliation-city>Galway</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26022572600</author-url><authid>26022572600</authid><authname>Smyth A.</authname><surname>Smyth</surname><given-name>Andrew</given-name><initials>A.</initials><afid>60031828</afid><afid>60008539</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26022572600</author-url><authid>26022572600</authid><authname>Smyth A.</authname><surname>Smyth</surname><given-name>Andrew</given-name><initials>A.</initials><afid>60031828</afid><afid>60008539</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56418679100</author-url><authid>56418679100</authid><authname>O’Donnell M.</authname><surname>O’Donnell</surname><given-name>Martin</given-name><initials>M.</initials><afid>60031828</afid><afid>60008539</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56418679100</author-url><authid>56418679100</authid><authname>O’Donnell M.</authname><surname>O’Donnell</surname><given-name>Martin</given-name><initials>M.</initials><afid>60031828</afid><afid>60008539</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14321895500</author-url><authid>14321895500</authid><authname>Mente A.</authname><surname>Mente</surname><given-name>Andrew</given-name><initials>A.</initials><afid>60031828</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202749318</author-url><authid>7202749318</authid><authname>Yusuf S.</authname><surname>Yusuf</surname><given-name>Salim</given-name><initials>S.</initials><afid>60031828</afid></author><authkeywords>Cardiovascular disease | Guidelines | Hypertension | Salt intake | Sodium</authkeywords><intid>1535963577</intid><article-number>8</article-number><source-id>23135</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929456804"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929456804?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929456804&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929456804&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929456804</prism:url><dc:identifier>SCOPUS_ID:84929456804</dc:identifier><eid>2-s2.0-84929456804</eid><dc:title>“The Most Supportive Environment in the World”? Tracing the Development of an Institutional ‘Ecosystem’ for Social Enterprise</dc:title><dc:creator>Roy M.</dc:creator><prism:publicationName>Voluntas</prism:publicationName><prism:issn>09578765</prism:issn><prism:volume>26</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>777-800</prism:pageRange><prism:coverDate>2015-06-22</prism:coverDate><prism:coverDisplayDate>22 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11266-014-9459-9</prism:doi><dc:description>© 2014, International Society for Third-Sector Research and The Johns Hopkins University. While numerous accounts of policy frameworks associated with country-level support for social enterprise activity exist, explanations for when, why and how policy interventions in support of social enterprise have been adopted have been, to date, much more thin on the ground. This paper aims to contribute to addressing this perceived gap by presenting the case of Scotland, recently hailed by First Minister Alex Salmond as “the most supportive environment in the world for social enterprise”. Historical Institutionalism is used to explain how such a ‘supportive environment’ might have come about and, looking at, in turn, when, why and how the conditions for social enterprise in Scotland have developed, we attempt to contribute to the ongoing international debate concerning the importance of the policy environment to fostering the conditions for social enterprise activity not only to emerge, but also to thrive.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007573</affiliation-url><afid>60007573</afid><affilname>Glasgow Caledonian University</affilname><name-variant>Glasgow Caledonian University</name-variant><affiliation-city>Glasgow</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007573</affiliation-url><afid>60007573</afid><affilname>Glasgow Caledonian University</affilname><name-variant>Glasgow Caledonian University</name-variant><affiliation-city>Glasgow</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115249983</affiliation-url><afid>115249983</afid><affilname>SENSCOT</affilname><name-variant>SENSCOT</name-variant><affiliation-city>Edinburgh</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115249575</affiliation-url><afid>115249575</afid><affilname>Social Enterprise Academy/Community Business Network for Scotland</affilname><name-variant>Social Enterprise Academy/Community Business Network for Scotland</name-variant><affiliation-city>Edinburgh</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55599310700</author-url><authid>55599310700</authid><authname>Roy M.</authname><surname>Roy</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60007573</afid><afid>60007573</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55599310700</author-url><authid>55599310700</authid><authname>Roy M.</authname><surname>Roy</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60007573</afid><afid>60007573</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55985042900</author-url><authid>55985042900</authid><authname>McHugh N.</authname><surname>McHugh</surname><given-name>Neil</given-name><initials>N.</initials><afid>60007573</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55984371400</author-url><authid>55984371400</authid><authname>Huckfield L.</authname><surname>Huckfield</surname><given-name>Leslie</given-name><initials>L.</initials><afid>60007573</afid><afid>115249983</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55984371400</author-url><authid>55984371400</authid><authname>Huckfield L.</authname><surname>Huckfield</surname><given-name>Leslie</given-name><initials>L.</initials><afid>60007573</afid><afid>115249983</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55598664000</author-url><authid>55598664000</authid><authname>Kay A.</authname><surname>Kay</surname><given-name>Alan</given-name><initials>A.</initials><afid>60007573</afid><afid>115249575</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55598664000</author-url><authid>55598664000</authid><authname>Kay A.</authname><surname>Kay</surname><given-name>Alan</given-name><initials>A.</initials><afid>60007573</afid><afid>115249575</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56464790100</author-url><authid>56464790100</authid><authname>Donaldson C.</authname><surname>Donaldson</surname><given-name>Cam</given-name><initials>C.</initials><afid>60007573</afid></author><authkeywords>Historical institutionalism | Political devolution | Scotland | Social enterprise | UK</authkeywords><intid>1535964658</intid><article-number>3</article-number><source-id>15725</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929459147"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929459147?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929459147&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929459147&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929459147</prism:url><dc:identifier>SCOPUS_ID:84929459147</dc:identifier><eid>2-s2.0-84929459147</eid><dc:title>The Future of Elderly Care in Nigeria: Borrowing a Leaf from a Foreign Land</dc:title><dc:creator>Dokpesi A.</dc:creator><prism:publicationName>Ageing International</prism:publicationName><prism:issn>01635158</prism:issn><prism:eIssn>1936606X</prism:eIssn><prism:volume>40</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>81-97</prism:pageRange><prism:coverDate>2015-06-22</prism:coverDate><prism:coverDisplayDate>22 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12126-014-9205-z</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. In Nigeria, government attitude towards elderly care has been quite indifferent since independence. This is informed by the notion that, the population aging in Nigeria is minimal in terms of the total composition; and that traditionally, the children would always take care of their aged parents. However the family and community base informal social supports, upon which this notion is partly based, have waned in recent years under the yoke of excruciating socioeconomic conditions. More so, recent survey reports and demographic projections point to an unprepared reality, of the increasing nature of both the absolute and proportional numbers of the elderly population in Nigeria. This article therefore discusses the challenges of the elderly Nigerians, under such conditions, and the need for a change in government policy attitude to aging issues in Nigeria. It suggests that government should be proactive in addressing the potential upsurge in population aging now, through the borrowing of ideas which are relevant to our peculiar circumstances; and the blending of the formal and informal mechanisms for assisting the senior citizens in the attainment of graceful aging.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017980</affiliation-url><afid>60017980</afid><affilname>University of Benin</affilname><name-variant>University of Benin Teaching Hospital</name-variant><affiliation-city>Benin</affiliation-city><affiliation-country>Nigeria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56451676000</author-url><authid>56451676000</authid><authname>Dokpesi A.</authname><surname>Dokpesi</surname><given-name>Augustine Okhobo</given-name><initials>A.O.</initials><afid>60017980</afid></author><authkeywords>Elderly care | Globalization | Government policy attitude | Graceful aging | Nigeria | Socio economic conditions</authkeywords><intid>535965234</intid><article-number>1</article-number><source-id>28473</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929409334"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929409334?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929409334&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929409334&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929409334</prism:url><dc:identifier>SCOPUS_ID:84929409334</dc:identifier><eid>2-s2.0-84929409334</eid><dc:title>Predictors of Presenteeism and Activity Impairment Outside Work in Patients with Spondyloarthritis</dc:title><dc:creator>Haglund E.</dc:creator><prism:publicationName>Journal of Occupational Rehabilitation</prism:publicationName><prism:issn>10530487</prism:issn><prism:volume>25</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>288-295</prism:pageRange><prism:coverDate>2015-06-22</prism:coverDate><prism:coverDisplayDate>22 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10926-014-9537-2</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. Purposes To assess predictors of presenteeism (reduced productivity at work) and activity impairment outside work in patients with spondyloarthritis (SpA). Methods Multivariate logistic regression analysis was used to study predictors of presenteeism and activity impairment in 1,253 patients with SpA based on a 2.5 year follow-up questionnaire. The Work Productivity and Activity Impairment (WPAI) questionnaire was used as main outcome. Age, gender, lifestyle factors, subgroups, disease duration, and different patient reported outcome measures (PROMs) were studied as possible predictors. The association between presenteeism and WPAI activity impairment outside work was assessed. Results Out of 1,253 patients, 757 reported being in work and of these 720 responded to the WPAI questionnaire. The mean (confidence interval, CI) reported presenteeism was 25 % (23–27 %) and mean activity impairment 33 % (31–35 %) (0–100 %, 0 = no reduction). Significant predictors of presenteeism and activity impairment at follow-up (controlled for gender, age, spondyloarthritis subgroups and presenteeism at baseline) were presenteeism at baseline, poor quality of life, worse disease activity, decreased physical function, lower self-efficacy pain and symptom, higher scores of anxiety, depression, smoking and low education level, and for activity impairment also female sex. There was a strong association between presenteeism and activity impairment outside work (OR 16.7; 95 % CI 11.6–24.3; p &lt; 0.001). Conclusions Presenteeism and activity impairment were not only predicted by presenteeism at baseline, but also by several PROMs commonly used in clinical rheumatology practice. Impaired activity outside work could indicate problems also at work suggesting why both areas need to be addressed in the clinical situation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113831969</affiliation-url><afid>113831969</afid><affilname>Spenshult Research and Development Center</affilname><name-variant>Spenshult Research and Development Center</name-variant><affiliation-city>Halmstad</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029170</affiliation-url><afid>60029170</afid><affilname>Lunds Universitet</affilname><name-variant>University of Lund</name-variant><affiliation-city>Lund</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029170</affiliation-url><afid>60029170</afid><affilname>Lunds Universitet</affilname><name-variant>University of Lund</name-variant><affiliation-city>Lund</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022085</affiliation-url><afid>60022085</afid><affilname>Hogskolan i Halmstad</affilname><name-variant>Halmstad University</name-variant><affiliation-city>Halmstad</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23978032200</author-url><authid>23978032200</authid><authname>Haglund E.</authname><surname>Haglund</surname><given-name>Emma</given-name><initials>E.</initials><afid>113831969</afid><afid>60029170</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23978032200</author-url><authid>23978032200</authid><authname>Haglund E.</authname><surname>Haglund</surname><given-name>Emma</given-name><initials>E.</initials><afid>113831969</afid><afid>60029170</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003466910</author-url><authid>7003466910</authid><authname>Petersson I.</authname><surname>Petersson</surname><given-name>Ingemar F.</given-name><initials>I.F.</initials><afid>60029170</afid><afid>60029170</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003466910</author-url><authid>7003466910</authid><authname>Petersson I.</authname><surname>Petersson</surname><given-name>Ingemar F.</given-name><initials>I.F.</initials><afid>60029170</afid><afid>60029170</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507704605</author-url><authid>6507704605</authid><authname>Bremander A.</authname><surname>Bremander</surname><given-name>Ann</given-name><initials>A.</initials><afid>113831969</afid><afid>60029170</afid><afid>60022085</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507704605</author-url><authid>6507704605</authid><authname>Bremander A.</authname><surname>Bremander</surname><given-name>Ann</given-name><initials>A.</initials><afid>113831969</afid><afid>60029170</afid><afid>60022085</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507704605</author-url><authid>6507704605</authid><authname>Bremander A.</authname><surname>Bremander</surname><given-name>Ann</given-name><initials>A.</initials><afid>113831969</afid><afid>60029170</afid><afid>60022085</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:9742225200</author-url><authid>9742225200</authid><authname>Bergman S.</authname><surname>Bergman</surname><given-name>Stefan</given-name><initials>S.</initials><afid>113831969</afid><afid>60029170</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:9742225200</author-url><authid>9742225200</authid><authname>Bergman S.</authname><surname>Bergman</surname><given-name>Stefan</given-name><initials>S.</initials><afid>113831969</afid><afid>60029170</afid></author><authkeywords>Activity impairment | Ankylosing spondylitis | Predictors | Presenteeism | Spondyloarthritis | Work productivity</authkeywords><intid>1785957105</intid><article-number>4</article-number><source-id>29283</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928577905"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928577905?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928577905&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928577905&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115002457"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928577905</prism:url><dc:identifier>SCOPUS_ID:84928577905</dc:identifier><eid>2-s2.0-84928577905</eid><dc:title>Identifying panaxynol, a natural activator of nuclear factor erythroid-2 related factor 2 (Nrf2) from American ginseng as a suppressor of inflamed macrophage-induced cardiomyocyte hypertrophy</dc:title><dc:creator>Qu C.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>326-336</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.04.004</prism:doi><pii>S0378874115002457</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Ethnopharmacological relevance American ginseng is capable of ameliorating cardiac dysfunction and activating Nrf2, a master regulator of antioxidant defense, in the heart. This study was designed to isolate compounds from American ginseng and to determine those responsible for the Nrf2-mediated resolution of inflamed macrophage-induced cardiomyocyte hypertrophy. Materials and methods A standardized crude extract of American ginseng was supplied by the National Research Council of Canada, Institute for National Measurement Standards. A bioassay-based fractionization of American ginseng was performed to identify the putative substances which could activate Nrf2-mediated suppression of pro-inflammatory cytokine expression in macrophages and macrophage-mediated pro-hypertrophic growth in cardiomyocytes. Results A hexane fraction of an anti-inflammatory crude extract of American ginseng was found to be most effective in suppressing the inflammatory responses in macrophages. Preparative, reverse-phase HPLC and a comparative analysis by analytical scale LC-UV/MS revealed the hexane fraction contains predominantly C&lt;inf&gt;17&lt;/inf&gt; polyacetylenes and linolenic acid. Panaxynol, one of the major polyacetylenes, was found to be a potent Nrf2 activator. Panaxynol posttranscriptionally activated Nrf2 by inhibiting Kelch-like ECH-associated protein (Keap) 1-mediated degradation without affecting the binding of Keap1 and Nrf2. Moreover, panaxynol suppressed a selected set of cytokine expression via the activation of Nrf2 while minimally regulating nuclear factor-kappa B (NF-κB)-mediated cytokine expression in macrophages. It also dramatically inhibited the inflamed macrophage-mediated cardiomyocyte death and hypertrophy by activating Nrf2 in macrophages. Conclusions These results demonstrate that American ginseng-derived panaxynol is a specific Nrf2 activator and panaxynol-activated Nrf2 signaling is at least partly responsible for American ginseng-induced health benefit in the heart.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031031</affiliation-url><afid>60031031</afid><affilname>Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006281</affiliation-url><afid>60006281</afid><affilname>University of South Carolina School of Medicine</affilname><name-variant>University of South Carolina</name-variant><affiliation-city>Columbia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092862</affiliation-url><afid>60092862</afid><affilname>Qilu Hospital of Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60089935</affiliation-url><afid>60089935</afid><affilname>Linyi People's Hospital</affilname><name-variant>Linyi People's Hospital</name-variant><affiliation-city>Linyi</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009839</affiliation-url><afid>60009839</afid><affilname>Conseil national de recherches Canada</affilname><name-variant>National Research Council Canada</name-variant><affiliation-city>Ottawa</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024279</affiliation-url><afid>60024279</afid><affilname>South Carolina College of Pharmacy</affilname><name-variant>South Carolina College of Pharmacy</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006281</affiliation-url><afid>60006281</afid><affilname>University of South Carolina School of Medicine</affilname><name-variant>University of South Carolina</name-variant><affiliation-city>Columbia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56606729400</author-url><authid>56606729400</authid><authname>Qu C.</authname><surname>Qu</surname><given-name>Chen</given-name><initials>C.</initials><afid>60031031</afid><afid>60006281</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56606729400</author-url><authid>56606729400</authid><authname>Qu C.</authname><surname>Qu</surname><given-name>Chen</given-name><initials>C.</initials><afid>60031031</afid><afid>60006281</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55859024200</author-url><authid>55859024200</authid><authname>Li B.</authname><surname>Li</surname><given-name>Bin</given-name><initials>B.</initials><afid>60092862</afid><afid>60089935</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55859024200</author-url><authid>55859024200</authid><authname>Li B.</authname><surname>Li</surname><given-name>Bin</given-name><initials>B.</initials><afid>60092862</afid><afid>60089935</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56020445200</author-url><authid>56020445200</authid><authname>Lai Y.</authname><surname>Lai</surname><given-name>Yimu</given-name><initials>Y.</initials><afid>60006281</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56606545200</author-url><authid>56606545200</authid><authname>Li H.</authname><surname>Li</surname><given-name>Hechu</given-name><initials>H.</initials><afid>60006281</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603275337</author-url><authid>6603275337</authid><authname>Windust A.</authname><surname>Windust</surname><given-name>Anthony</given-name><initials>A.</initials><afid>60009839</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602522204</author-url><authid>6602522204</authid><authname>Hofseth L.</authname><surname>Hofseth</surname><given-name>Lorne J.</given-name><initials>L.J.</initials><afid>60024279</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005891809</author-url><authid>7005891809</authid><authname>Nagarkatti M.</authname><surname>Nagarkatti</surname><given-name>Mitzi</given-name><initials>M.</initials><afid>60006281</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005792287</author-url><authid>7005792287</authid><authname>Nagarkatti P.</authname><surname>Nagarkatti</surname><given-name>Prakash</given-name><initials>P.</initials><afid>60006281</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35249532600</author-url><authid>35249532600</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xing Li</given-name><initials>X.L.</initials><afid>60092862</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7401987219</author-url><authid>7401987219</authid><authname>Tang D.</authname><surname>Tang</surname><given-name>Dongqi</given-name><initials>D.</initials><afid>60092862</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7005910491</author-url><authid>7005910491</authid><authname>Janicki J.</authname><surname>Janicki</surname><given-name>Joseph S.</given-name><initials>J.S.</initials><afid>60006281</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:24279087600</author-url><authid>24279087600</authid><authname>Tian X.</authname><surname>Tian</surname><given-name>Xingsong</given-name><initials>X.</initials><afid>60031031</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56637153200</author-url><authid>56637153200</authid><authname>Cui T.</authname><surname>Cui</surname><given-name>Taixing</given-name><initials>T.</initials><afid>60006281</afid><afid>60092862</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56637153200</author-url><authid>56637153200</authid><authname>Cui T.</authname><surname>Cui</surname><given-name>Taixing</given-name><initials>T.</initials><afid>60006281</afid><afid>60092862</afid></author><authkeywords>American ginseng | Cardiomyocytes | Inflammation | Macrophages | Nrf2 | Panaxynol</authkeywords><intid>35802824</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929658695"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929658695?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929658695&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929658695&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115001531"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929658695</prism:url><dc:identifier>SCOPUS_ID:84929658695</dc:identifier><eid>2-s2.0-84929658695</eid><dc:title>Embelia ribes ameliorates lipopolysaccharide-induced acute respiratory distress syndrome</dc:title><dc:creator>Shirole R.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>356-363</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.03.009</prism:doi><pii>S0378874115001531</pii><dc:description>© 2015 Elsevier Ireland Ltd. Ethnopharmacological relevance Embelia ribes Burm. f. (Fam. Myrsinaceae) locally known as Vidanga have been used for treating tumors, ascites, bronchitis, jaundice, diseases of the heart and brain in traditional Indian medicine. However, no scientific studies providing new insights in its pharmacological properties with respect to acute respiratory distress syndrome have been investigated. Aim The present investigation aimed to elucidate the effectiveness of Embelin isolated from Embelia ribes seeds on attenuation of LPS-induced acute respiratory distress syndrome in murine models. Methods Embelin (5, 10 and 20 mg/kg/day, i.p.) and Roflumilast (1 mg/kg/day, p.o.) were administered for four days and prior to LPS in rats (i.t.). Four hour after LPS challenge animals were anesthesized and bronchoalveolar lavage was done with ice-cold phosphate buffer. Assessment of BAL fluid was done for albumin, total protein, total cell and neutrophil count, TNF-α levels, nitrosoative stress. Superior lobe of right lung was used for histopathologic evaluation. Inferior lobe of right lung was used to obtain lung edema. Left lung was used for myeloperoxidase estimation. Arterial blood was collected immediately and analyzed for pH, pO&lt;inf&gt;2&lt;/inf&gt; and pCO&lt;inf&gt;2&lt;/inf&gt; were estimated. Results Pretreatment with embelin (5, 10 and 20 mg/kg, i.p.) decreased lung edema, mononucleated cellular infiltration, nitrate/nitrite, total protein, albumin concentrations, TNF-α in the bronchoalveolar lavage fluid and myeloperoxidase activity in lung homogenate. Embelin markedly prevented pO&lt;inf&gt;2&lt;/inf&gt; down-regulation and pCO&lt;inf&gt;2&lt;/inf&gt; augmentation. Additionally, it attenuated lung histopathological changes in acute respiratory distress syndrome model. Conclusion The study demonstrates the effectiveness of Embelia ribes Burm. f. (Fam. Myrsinaceae) seeds in acute respiratory distress syndrome possibly related to its anti-inflammatory and protective effect against LPS induced airway inflammation by reducing nitrosative stress, reducing physiological parameters of blood gas change, TNF-α and mononucleated cellular infiltration indicating it as a potential therapeutic agent for acute respiratory distress syndrome.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60075916</affiliation-url><afid>60075916</afid><affilname>A. R. A. College of Pharmacy, Dhule</affilname><name-variant>A.R.A. College of Pharmacy</name-variant><affiliation-city>Dhule</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015597</affiliation-url><afid>60015597</afid><affilname>Bombay College of Pharmacy</affilname><name-variant>Bombay College of Pharmacy</name-variant><affiliation-city>Mumbai</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60075916</affiliation-url><afid>60075916</afid><affilname>A. R. A. College of Pharmacy, Dhule</affilname><name-variant>A.R.A. College of Pharmacy</name-variant><affiliation-city>Dhule</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56089201900</author-url><authid>56089201900</authid><authname>Shirole R.</authname><surname>Shirole</surname><given-name>R. L.</given-name><initials>R.L.</initials><afid>60075916</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14066725700</author-url><authid>14066725700</authid><authname>Shirole N.</authname><surname>Shirole</surname><given-name>N. L.</given-name><initials>N.L.</initials><afid>60075916</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004015371</author-url><authid>7004015371</authid><authname>Saraf M.</authname><surname>Saraf</surname><given-name>M. N.</given-name><initials>M.N.</initials><afid>60015597</afid></author><authkeywords>Acute respiratory distress syndrome | Embelia ribes | Embelin | Lipopolysaccharide</authkeywords><intid>1535991439</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928478024"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928478024?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928478024&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928478024&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115001270"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928478024</prism:url><dc:identifier>SCOPUS_ID:84928478024</dc:identifier><eid>2-s2.0-84928478024</eid><dc:title>Ethnopharmacological importance of medicinal flora from the district of Vehari, Punjab province, Pakistan</dc:title><dc:creator>Ahmed N.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>66-78</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.02.048</prism:doi><pii>S0378874115001270</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Ethnopharmacological relevance Ethnopharmacological studies are important for the discovery of new drugs from reported indigenous flora. The current study was aimed to document medicinal flora and its therapeutic actions along with the relative importance in local health care system of the district of Vehari, Punjab province, Pakistan. Materials and method Rapid appraisal approach (RAA) and semi structured interviews were used along with the group meetings with herbalists, local inhabitants and landowners to collect the relevant data. Results and discussions A total 77 medicinal plants belonging to 41 families disseminated among 71 genera were reported. Fabaceae was the predominant family over others with 9 reported medicinal plant species. Use frequency of leaves was at peak with 30.12% followed by stem 24.62%, fruit 14.22%, flower 12.97%, seeds 12.13%, bark 4.6% and pod 1.25%, in herbal preparations. Allium cepa exhibited the highest use value (0.90) while lowest use value (UV) was reflected by Aerva javanica (0.10). Documentation of various medicinal plants for the treatment of cancer, hepatitis and cardiac disorders is evidence in favor to highlight the value of medicinal flora. Conclusions Unfortunately, no attention has been paid to this treasure in term of conservation and utilization in modern healthcare system, where these plants can be a best replacement of chemically synthesized drugs. It is also recommended that plants exhibiting high UV should be screened for detailed bio-active phytochemicals.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108069031</affiliation-url><afid>108069031</afid><affilname>Quiad-I-Azam University</affilname><name-variant>Quiad-i-Azam University</name-variant><affiliation-city/><affiliation-country>Pakistan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60089631</affiliation-url><afid>60089631</afid><affilname>COMSATS Institute of Information Technology</affilname><name-variant>COMSATS Institute of Information Technology</name-variant><affiliation-city>Islamabad</affiliation-city><affiliation-country>Pakistan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60038659</affiliation-url><afid>60038659</afid><affilname>University of Sargodha</affilname><name-variant>University of Sargodha</name-variant><affiliation-city>Sargodha</affiliation-city><affiliation-country>Pakistan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114249212</affiliation-url><afid>114249212</afid><affilname>Faculty of Agricultural and Natural Resources</affilname><name-variant>Faculty of Agricultural and Natural Resources</name-variant><affiliation-city/><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108069031</affiliation-url><afid>108069031</afid><affilname>Quiad-I-Azam University</affilname><name-variant>Quiad-i-Azam University</name-variant><affiliation-city/><affiliation-country>Pakistan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15076634100</author-url><authid>15076634100</authid><authname>Ahmed N.</authname><surname>Ahmed</surname><given-name>Nadeem</given-name><initials>N.</initials><afid>108069031</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:42061858800</author-url><authid>42061858800</authid><authname>Mahmood A.</authname><surname>Mahmood</surname><given-name>Adeel</given-name><initials>A.</initials><afid>60089631</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:46062158900</author-url><authid>46062158900</authid><authname>Mahmood A.</authname><surname>Mahmood</surname><given-name>Aqeel</given-name><initials>A.</initials><afid>60038659</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56541348600</author-url><authid>56541348600</authid><authname>Sadeghi Z.</authname><surname>Sadeghi</surname><given-name>Zahra</given-name><initials>Z.</initials><afid>114249212</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701716992</author-url><authid>6701716992</authid><authname>Farman M.</authname><surname>Farman</surname><given-name>Muhammad</given-name><initials>M.</initials><afid>108069031</afid></author><authkeywords>Cancer | Hepatitis | Medicinal flora | Pakistan | Use value</authkeywords><intid>1535793463</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927517593"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927517593?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927517593&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927517593&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115001932"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927517593</prism:url><dc:identifier>SCOPUS_ID:84927517593</dc:identifier><eid>2-s2.0-84927517593</eid><dc:title>Pharmacokinetics, safety, and tolerability of single and multiple-doses of pinocembrin injection administered intravenously in healthy subjects</dc:title><dc:creator>Cao G.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>31-36</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.03.041</prism:doi><pii>S0378874115001932</pii><dc:description>© 2015 Elsevier Ireland Ltd. Ethnopharmacological relevance Pinocembrin is the most abundant flavonoid in propolis. Preclinical studies have suggested that pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both in vivo and in vitro. To investigate the safety, tolerability and pharmacokinetics of a new neuroprotective agent, pinocembrin. Materials and method A double-blind, placebo-controlled, randomized study was carried out in 58 healthy subjects. Single ascending doses of pinocembrin (20-150 mg) were evaluated in 5 cohorts. Multi-dose was studied at pinocembrin 60 mg. Results Pinocembrin was well tolerated. No serious adverse events occurred. No subjects were discontinued because of a treatment emergent AE. Treatment related adverse event was acute urticaria. Two subjects in 150 mg cohort developed grade II urticaria during the study. One subject discontinued after 3 days at 60 mg bid because of diarrhea. In the single-dose study, the mean peak plasma pinocembrin concentration was obtained at the end of the 30-min infusion. The C&lt;inf&gt;max&lt;/inf&gt; ranged from 0.28 μg mL&lt;sup&gt;-1&lt;/sup&gt; to 2.46 μg mL&lt;sup&gt;-1&lt;/sup&gt;. AUC &lt;inf&gt;(0,∞)&lt;/inf&gt; ranged from 10.34 μg mL&lt;sup&gt;-1&lt;/sup&gt; min to 89.34 μg mL&lt;sup&gt;-1&lt;/sup&gt; min. The T&lt;inf&gt;1/2&lt;/inf&gt; was similar across 5 dose groups, ranging from 40 to 55 min. Both urinary and feces excretion levels of pinocembrin were extremely low and similar among each dose groups, with mean values ranging from 0.07% to 0.17% and 0.94% to 1.94% of the administered dose, respectively. Linear increases in C&lt;inf&gt;max&lt;/inf&gt; and AUC&lt;inf&gt;(0,∞)&lt;/inf&gt; were observed. The pharmacokinetics of pinocembrin in multiple-dose was similar to those observed in the single-dose study, with no evidence of accumulation. Both urinary and feces excretion levels of pinocembrin were extremely low. Conclusions Pinocembrin displayed linear plasma pharmacokinetics over the dose range, 20-150 mg and was well tolerated up to 120 mg day&lt;sup&gt;-1&lt;/sup&gt; when administered intravenously to healthy adults. No major safety concerns were identified that would preclude further clinical development of pinocembrin injection.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106442346</affiliation-url><afid>106442346</afid><affilname>Beijing Hospital</affilname><name-variant>Beijing Hospital</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031031</affiliation-url><afid>60031031</afid><affilname>Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100625629</affiliation-url><afid>100625629</afid><affilname>Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.</affilname><name-variant>ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.</name-variant><affiliation-city>Shijiazhuang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54683570000</author-url><authid>54683570000</authid><authname>Cao G.</authname><surname>Cao</surname><given-name>Guoying</given-name><initials>G.</initials><afid>106442346</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56589629900</author-url><authid>56589629900</authid><authname>Ying P.</authname><surname>Ying</surname><given-name>Pengyue</given-name><initials>P.</initials><afid>100625629</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56124102700</author-url><authid>56124102700</authid><authname>Yan B.</authname><surname>Yan</surname><given-name>Bei</given-name><initials>B.</initials><afid>106442346</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55178166700</author-url><authid>55178166700</authid><authname>Xue W.</authname><surname>Xue</surname><given-name>Wei</given-name><initials>W.</initials><afid>106442346</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:18037547800</author-url><authid>18037547800</authid><authname>Li K.</authname><surname>Li</surname><given-name>Kexin</given-name><initials>K.</initials><afid>106442346</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004526107</author-url><authid>7004526107</authid><authname>Shi A.</authname><surname>Shi</surname><given-name>Aixin</given-name><initials>A.</initials><afid>106442346</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55286373200</author-url><authid>55286373200</authid><authname>Sun T.</authname><surname>Sun</surname><given-name>Taohua</given-name><initials>T.</initials><afid>60031031</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56123849900</author-url><authid>56123849900</authid><authname>Yan J.</authname><surname>Yan</surname><given-name>Jiling</given-name><initials>J.</initials><afid>100625629</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56374121500</author-url><authid>56374121500</authid><authname>Hu X.</authname><surname>Hu</surname><given-name>Xin</given-name><initials>X.</initials><afid>106442346</afid></author><authkeywords>Pharmacokinetics | Phase I | Pinocembrin | Safety | Tolerability</authkeywords><intid>1035630375</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927725620"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927725620?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927725620&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927725620&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115001993"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927725620</prism:url><dc:identifier>SCOPUS_ID:84927725620</dc:identifier><eid>2-s2.0-84927725620</eid><dc:title>Use of traditional Chinese medicine in patients with hyperlipidemia: A population-based study in Taiwan</dc:title><dc:creator>Chu S.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>129-135</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.03.047</prism:doi><pii>S0378874115001993</pii><dc:description>Ethno-pharmacological relevance Chinese herbal products (CHPs) are commonly used in patients with hyperlipidemia in traditional Chinese medicine (TCM). Because hyperlipidemia and related disease are common issues worldwide, this study analyzed the prescription patterns and frequencies of CHPs for treating patients with hyperlipidemia in Taiwan. Background Traditional Chinese medicine (TCM) has become popular as a therapy for controlling symptoms in patients with hyperlipidemia. This study aimed to analyze the prescription patterns of TCM for patients with hyperlipidemia in Taiwan. Methods The study population was recruited from a random-sampled cohort of 1,000,000 people from the National Health Insurance Research Database between 2003 and 2009. We identified 30,784 outpatient visits related with hyperlipidemia diagnosis and collected these medical records. Association rules of data mining were conducted to explore the co-prescription patterns for Chinese herbal products (CHPs). Results The most commonly prescribed herbal formula for hyperlipidemia treatment was Xue-Fu-Zhu-Yu-Tang (16.1%), and Shan Zha (Crataegi fructus; 25.0%) was the most commonly prescribed single herb. The most commonly prescribed combination of an herbal formula and a single herb was Xue-Fu-Zhu-Yu-Tang and Dan Shen (Radix Salviae Miltiorrhizae), and the most commonly prescribed combination of couplet herbs was Dan Shen and Shan Zha. Conclusion Xue-Fu-Zhu-Yu-Tang is the most frequently prescribed formula and is typically prescribed with Shan Zha, Dan Shen, and He Shou Wu for patients with hyperlipidemia. Clinical trials are warranted in future research to investigate the effects of the CHPs in terms of safety and efficacy and in particular to evaluate potential interactions with conventional treatments.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031913</affiliation-url><afid>60031913</afid><affilname>Chang Gung Memorial Hospital</affilname><name-variant>Chang Gung Memorial Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005429</affiliation-url><afid>60005429</afid><affilname>National Taiwan University</affilname><name-variant>National Taiwan University</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031913</affiliation-url><afid>60031913</afid><affilname>Chang Gung Memorial Hospital</affilname><name-variant>Chang Gung Memorial Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005429</affiliation-url><afid>60005429</afid><affilname>National Taiwan University</affilname><name-variant>National Taiwan University</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073385</affiliation-url><afid>60073385</afid><affilname>National Taiwan University Hospital</affilname><name-variant>National Taiwan University Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56594162200</author-url><authid>56594162200</authid><authname>Chu S.</authname><surname>Chu</surname><given-name>Shih Meng</given-name><initials>S.M.</initials><afid>60031913</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55471909200</author-url><authid>55471909200</authid><authname>Shih W.</authname><surname>Shih</surname><given-name>Wei Tai</given-name><initials>W.T.</initials><afid>60031913</afid><afid>60005429</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55471909200</author-url><authid>55471909200</authid><authname>Shih W.</authname><surname>Shih</surname><given-name>Wei Tai</given-name><initials>W.T.</initials><afid>60031913</afid><afid>60005429</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56593908500</author-url><authid>56593908500</authid><authname>Yang Y.</authname><surname>Yang</surname><given-name>Yao Hsu</given-name><initials>Y.H.</initials><afid>60031913</afid><afid>60005429</afid><afid>60031913</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56593908500</author-url><authid>56593908500</authid><authname>Yang Y.</authname><surname>Yang</surname><given-name>Yao Hsu</given-name><initials>Y.H.</initials><afid>60031913</afid><afid>60005429</afid><afid>60031913</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56593908500</author-url><authid>56593908500</authid><authname>Yang Y.</authname><surname>Yang</surname><given-name>Yao Hsu</given-name><initials>Y.H.</initials><afid>60031913</afid><afid>60005429</afid><afid>60031913</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56593899700</author-url><authid>56593899700</authid><authname>Chen P.</authname><surname>Chen</surname><given-name>Pau Chung</given-name><initials>P.C.</initials><afid>60005429</afid><afid>60005429</afid><afid>60073385</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56593899700</author-url><authid>56593899700</authid><authname>Chen P.</authname><surname>Chen</surname><given-name>Pau Chung</given-name><initials>P.C.</initials><afid>60005429</afid><afid>60005429</afid><afid>60073385</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56593899700</author-url><authid>56593899700</authid><authname>Chen P.</authname><surname>Chen</surname><given-name>Pau Chung</given-name><initials>P.C.</initials><afid>60005429</afid><afid>60005429</afid><afid>60073385</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56594147500</author-url><authid>56594147500</authid><authname>Chu Y.</authname><surname>Chu</surname><given-name>Yen Hua</given-name><initials>Y.H.</initials><afid>60031913</afid></author><authkeywords>Chinese herbal products | Hyperlipidemia | NHIRD | Prescription pattern | Traditional chinese medicine</authkeywords><intid>35665975</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928496504"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928496504?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928496504&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928496504&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115002421"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928496504</prism:url><dc:identifier>SCOPUS_ID:84928496504</dc:identifier><eid>2-s2.0-84928496504</eid><dc:title>The traditional drug Gongjin-Dan ameliorates chronic fatigue in a forced-stress mouse exercise model</dc:title><dc:creator>Hong S.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>268-278</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.04.001</prism:doi><pii>S0378874115002421</pii><dc:description>© 2015 Elsevier Ireland Ltd. Ethnopharmacological relevance Gongjin-Dan is a representative traditional Oriental medicine herbal drug that has been used to treat chronic fatigue symptoms for several hundred years. We evaluated the anti-fatigue effects of Gongjin-Dan and the underlying mechanisms in a chronic forced exercise mouse model. Methods and materials Balb/C male mice underwent an extreme treadmill-based running stress (1-h, 5 days/week), and daily oral administration of distilled water, Gongjin-Dan (100, 200, or 400 mg/kg), or ascorbic acid (100 mg/kg) for 28 days. The anti-fatigue effects of Gongjin-Dan were evaluated with behavioral tests (exercise tolerance and swimming tests), and the corresponding mechanisms were investigated based on oxidative stress and inflammatory cytokine and stress hormone levels in skeletal muscle, sera, and brain tissue. Results Gongjin-Dan significantly increased exercise tolerance and latency times but reduced the number of electric shocks and immobilization time on the treadmill running and swimming tests, compared with the control group. Gongjin-Dan also significantly ameliorated alterations in oxidative stress-related biomarkers (reactive oxygen species and malondialdehyde), inflammatory cytokines (tumor necrosis factor-α, interleukin-1 beta, interleukin-6, and interferon-γ) and glycogen and l-lactate levels in skeletal muscle, compared with those in the control group. Moreover, Gongjin-Dan considerably normalized the forced running stress-induced changes in serum corticosterone and adrenaline levels, as well as brain serotonin level. These antioxidant and anti-stress effects of Gongjin-Dan were supported by the results of Western blotting (4-hydroxynonenal and heme oxygenase-1) and the gene expression levels (serotonin receptor and serotonin transporter). Conclusion These results support the clinical relevance of Gongjin-Dan regarding anti-chronic fatigue properties. The underlying mechanisms involve attenuation of oxidative and inflammatory reactions in muscle and regulation of the stress response through the hypothalmo-pituitary-adrenal axis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023742</affiliation-url><afid>60023742</afid><affilname>Daejeon University</affilname><name-variant>Daejeon University</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023742</affiliation-url><afid>60023742</afid><affilname>Daejeon University</affilname><name-variant>Daejeon University</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60081221</affiliation-url><afid>60081221</afid><affilname>Korea Institute of Oriental Medicine</affilname><name-variant>Korea Institute of Oriental Medicine</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023742</affiliation-url><afid>60023742</afid><affilname>Daejeon University</affilname><name-variant>Daejeon University</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60081221</affiliation-url><afid>60081221</afid><affilname>Korea Institute of Oriental Medicine</affilname><name-variant>Korea Institute of Oriental Medicine</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56605646200</author-url><authid>56605646200</authid><authname>Hong S.</authname><surname>Hong</surname><given-name>Sung Shin</given-name><initials>S.S.</initials><afid>60023742</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56605693100</author-url><authid>56605693100</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>Ji Young</given-name><initials>J.Y.</initials><afid>60023742</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55206521700</author-url><authid>55206521700</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>Jin Seok</given-name><initials>J.S.</initials><afid>60023742</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56605609500</author-url><authid>56605609500</authid><authname>Lee H.</authname><surname>Lee</surname><given-name>Hye Won</given-name><initials>H.W.</initials><afid>60081221</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36522994700</author-url><authid>36522994700</authid><authname>Kim H.</authname><surname>Kim</surname><given-name>Hyeong Geug</given-name><initials>H.G.</initials><afid>60023742</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56605916700</author-url><authid>56605916700</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>Sam Keun</given-name><initials>S.K.</initials><afid>60023742</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55348761600</author-url><authid>55348761600</authid><authname>Park B.</authname><surname>Park</surname><given-name>Bong Ki</given-name><initials>B.K.</initials><afid>60081221</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:9243903000</author-url><authid>9243903000</authid><authname>Son C.</authname><surname>Son</surname><given-name>Chang Gue</given-name><initials>C.G.</initials><afid>60023742</afid></author><authkeywords>Antioxidant | Chronic fatigue | Gongjin-Dan | HPA | Oxidative stress</authkeywords><intid>1785794523</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927513291"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927513291?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927513291&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927513291&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115001798"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927513291</prism:url><dc:identifier>SCOPUS_ID:84927513291</dc:identifier><eid>2-s2.0-84927513291</eid><dc:title>A network pharmacology approach to determine active ingredients and rationality of herb combinations of Modified-Simiaowan for treatment of gout</dc:title><dc:creator>Zhao F.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>1-16</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.03.035</prism:doi><pii>S0378874115001798</pii><dc:description>© 2015 The Authors. Abstract Ethnopharmacological relevance Modified Simiaowan (MSW) is a traditional Chinese medicine (TCM) formula and is widely used as a clinically medication formula for its efficiency in treating gouty diseases.To predict the active ingredients in MSW and uncover the rationality of herb combinations of MSW. Materials and methods Three drug-target networks including the "candidate ingredient-target network" (cI-cT) that links the candidate ingredients and targets, the "core ingredient-target-pathway network" connecting core potential ingredients and targets through related pathways, and the "rationality of herb combinations of MSW network", which was derived from the cI-cT network, were developed to dissect the active ingredients in MSW and relationship between ingredients in herb combinations and their targets for gouty diseases. On the other hand, herbal ingredients comparisons were also conducted based on six physicochemical properties to investigate whether the herbs in MSW are similar in chemicals. Moreover, HUVEC viability and expression levels of ICAM-1 induced by monosodium urate (MSU) crystals were assessed to determine the activities of potential ingredients in MSW. Results Predicted by the core ingredient-target-pathway network, we collected 30 core ingredients in MSW and 25 inflammatory cytokines and uric acid synthetase or transporters, which are effective for gouty treatment through some related pathways. Experimental results also confirmed that those core ingredients could significantly increase HUVEC viability and attenuate the expression of ICAM-1, which supported the effectiveness of MSW in treating gouty diseases. Moreover, heat-clearing and dampness-eliminating herbs in MSW have similar physicochemical properties, which stimulate all the inflammatory and uric acid-lowing targets respectively, while the core drug and basic prescription in MSW stimulate the major and almost all the core targets, respectively. Conclusion Our work successfully predicts the active ingredients in MSW and explains the cooperation between these ingredients and corresponding targets through related pathways for gouty diseases, and provides basis for an alternative approach to investigate the rationality of herb combinations of MSW on the network pharmacology level, which might be beneficial to drug development and applications.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005189</affiliation-url><afid>60005189</afid><affilname>Nanjing University of Traditional Chinese Medicine</affilname><name-variant>Nanjing University of Traditional Chinese Medicine</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005189</affiliation-url><afid>60005189</afid><affilname>Nanjing University of Traditional Chinese Medicine</affilname><name-variant>Nanjing University of Traditional Chinese Medicine</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113978717</affiliation-url><afid>113978717</afid><affilname>Changzhou Seventh People's Hospital</affilname><name-variant>Changzhou Seventh People's Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56534480400</author-url><authid>56534480400</authid><authname>Zhao F.</authname><surname>Zhao</surname><given-name>Fangli</given-name><initials>F.</initials><afid>60005189</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56590085500</author-url><authid>56590085500</authid><authname>Guochun L.</authname><surname>Guochun</surname><given-name>Li</given-name><initials>L.</initials><afid>60005189</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55919533000</author-url><authid>55919533000</authid><authname>Yang Y.</authname><surname>Yang</surname><given-name>Yanhua</given-name><initials>Y.</initials><afid>113978717</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7401640551</author-url><authid>7401640551</authid><authname>Shi L.</authname><surname>Shi</surname><given-name>Le</given-name><initials>L.</initials><afid>60005189</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55547112186</author-url><authid>55547112186</authid><authname>Xu L.</authname><surname>Xu</surname><given-name>Li</given-name><initials>L.</initials><afid>60005189</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:15027804800</author-url><authid>15027804800</authid><authname>Yin L.</authname><surname>Yin</surname><given-name>Lian</given-name><initials>L.</initials><afid>60005189</afid></author><authkeywords>Active ingredients | Gout | Herb combinations | Modified Simiaowan | Network pharmacology</authkeywords><intid>35632690</intid><article-number>9395</article-number><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927633941"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927633941?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927633941&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927633941&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115000720"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927633941</prism:url><dc:identifier>SCOPUS_ID:84927633941</dc:identifier><eid>2-s2.0-84927633941</eid><dc:title>In vitro relaxant and spasmolytic effects of essential oil of Pistacia integerrima Stewart ex Brandis Galls</dc:title><dc:creator>Shirole R.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>61-65</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.02.001</prism:doi><pii>S0378874115000720</pii><dc:description>© 2015 Published by Elsevier Ireland Ltd. Ethnopharmacological relevance Pistacia integerrima J.L. Stewart ex Brandis (Family: Anacardiaceae) galls are used in Indian ethnomedicine for its anti-asthmatic, sedative and spasmolytic properties, however, there are no scientific studies demonstrating its spasmolytic activity. The present investigation deals with the evaluation of relaxant and spasmolytic activities of the essential oil isolated from the galls of Pistacia integerrima J.L. Stewart ex Brandis (EOPI). Materials and methods In vitro pharmacological assays were carried out on rabbit jejunum spontaneous contractions, guinea pig ileum. The present investigation studied the relaxation of basal tone of isolated guinea pig ileum by possible involvement of NO, prostaglandins, membrane Na&lt;sup&gt;+&lt;/sup&gt; channels, potassium channel, enteric nervous system, adrenoceptors, Ca&lt;sup&gt;2+&lt;/sup&gt; channels. Additional studies were conducted for comparison of the relaxant effects of EOPI on CaCl&lt;inf&gt;2&lt;/inf&gt; induced contraction in calcium free tyrode solution, effect on nifedipine insensitive component of ACh-induced contraction and on the contractile machinery to intracellular [Ca&lt;sup&gt;2+&lt;/sup&gt;] on isolated guinea pig ileum. Results EOPI at non-relaxing dose potentiated the isoprenaline induced relaxation of rabbit jejunum. EOPI (50 μg/mL) exhibited 28% relaxation of basal tone of 60 mM K&lt;sup&gt;+&lt;/sup&gt; induced contraction which is unaltered by preincubation with 0.5 mM hexamethonium, 0.5 μM Tetrodotoxin, 1 μM indomethacin, and 100 μM L-NG-Nitroarginine Methyl Ester (L-NAME). EOPI inhibited Ca&lt;sup&gt;2+&lt;/sup&gt; induced contraction of isolated guinea pig ileum in Ca&lt;sup&gt;2+&lt;/sup&gt; free medium. EOPI (10 μg/ml) potentiated the reversal of a KCl-induced tonic contraction has been observed in Ca&lt;sup&gt;2+&lt;/sup&gt; free medium. Conclusion The present investigation reinforces the use of Pistacia integerrima Stewart ex Brandis as antispasmodic in folk medicine. Moreover, it is demonstrated the involvement of β- adrenoceptors and calcium channels in this activity, but not the participation of nicotinic receptors, Na&lt;sup&gt;+&lt;/sup&gt; channels, prostaglandins or nitric oxide.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60075916</affiliation-url><afid>60075916</afid><affilname>A. R. A. College of Pharmacy, Dhule</affilname><name-variant>A.R.A. College of Pharmacy</name-variant><affiliation-city>Dhule</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60075916</affiliation-url><afid>60075916</afid><affilname>A. R. A. College of Pharmacy, Dhule</affilname><name-variant>A.R.A. College of Pharmacy</name-variant><affiliation-city>Dhule</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015597</affiliation-url><afid>60015597</afid><affilname>Bombay College of Pharmacy</affilname><name-variant>Bombay College of Pharmacy</name-variant><affiliation-city>Mumbai</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56089201900</author-url><authid>56089201900</authid><authname>Shirole R.</authname><surname>Shirole</surname><given-name>R. L.</given-name><initials>R.L.</initials><afid>60075916</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14066725700</author-url><authid>14066725700</authid><authname>Shirole N.</authname><surname>Shirole</surname><given-name>N. L.</given-name><initials>N.L.</initials><afid>60075916</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004015371</author-url><authid>7004015371</authid><authname>Saraf M.</authname><surname>Saraf</surname><given-name>M. N.</given-name><initials>M.N.</initials><afid>60015597</afid></author><authkeywords>Essential oil | Pistacia integerrima | Smooth muscle and ileum</authkeywords><intid>35647176</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927701210"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927701210?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927701210&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927701210&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115002019"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927701210</prism:url><dc:identifier>SCOPUS_ID:84927701210</dc:identifier><eid>2-s2.0-84927701210</eid><dc:title>In vivo estrogenic-like activities of Gouania longipetala Hemsl. (Rhamnaceae) bark extracts in a post-menopause-like model of ovariectomized Wistar rats</dc:title><dc:creator>Paul Désiré D.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>122-128</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.03.049</prism:doi><pii>S0378874115002019</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Ethnopharmacological relevance Gouania longipetala is commonly used in Cameroonian traditional medicine to manage women fertility and menopausal complaints. However, despite this use, the estrogenic properties of G. longipetala have not been studied until now. Aim of study The present study was aimed to assess estrogenic activities of the stem bark aqueous (GLA) and ethanolic (GLE) extracts of G. longipetala in post-menopause-like model of ovariectomized (Ovx) Wistar rats. Material and methods Animals were either sham-operated or Ovx. 84 days after ovariectomy, animals were divided into seven groups of five animals and were daily treated for 28 days with distilled water (10 mL/kg) for group 1, 2% solution of Tween 80 (10 mL/kg) for group 2, estradiol valerate (1 mg/kg) for group 3, GLA (45 or 180 mg/kg) and GLE (40 or 160 mg/kg) for groups 4 to 7 respectively. Sham-operated animals daily received distilled water (10 mL/kg). During the experimental period, the body weight was registered every week. At the day 29, blood pressure was registered by invasive method while uterine and vagina morphometry as well as body, uterine and abdominal fat weights changes were analyzed. Serum levels of total cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol were determined. Moreover, oxidative stress markers such as nitrites, reduced glutathione (GSH) and malondialdehyde (MDA) were measured in homogenized liver and aorta. Results Compared with the sham control, vagina and uterine dystrophy and elevated blood pressure were observed in Ovx rats treated with vehicles. Biochemical parameters showed a significant increase of total cholesterol, triglycerides, LDL-cholesterol and MDA as well as a significant decrease of nitrites and GSH in Ovx animals treated with vehicle as compared to sham group. GLA and GLE displayed estrogen-like effects on vagina and did not affect uterine wet weight and epithelial height compared with vehicle groups. Both extracts displayed anti-atherogenic properties by reducing AI, AIP and LDL-cholesterol level as compared to vehicles groups. GLA and GLE significantly prevented the increase of MDA induced by ovariectomy as compared to rats treated with vehicles. Conclusion This study showed that GLA and GLE exhibited estrogenic effects by providing vaginal lubrication, by modulating blood pressure and improving lipid profile, oxidative status and endothelial function and may not have an undesirable influence on the endometrium in ovariectomized rats.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070928</affiliation-url><afid>60070928</afid><affilname>Universite de Yaounde I</affilname><name-variant>University of Yaoundé I</name-variant><affiliation-city>Yaounde</affiliation-city><affiliation-country>Cameroon</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55751850400</author-url><authid>55751850400</authid><authname>Paul Désiré D.</authname><surname>Paul Désiré</surname><given-name>Dzeufiet Djomeni</given-name><initials>D.D.</initials><afid>60070928</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56595235400</author-url><authid>56595235400</authid><authname>Yolande Sandrine M.</authname><surname>Yolande Sandrine</surname><given-name>Mengue Ngadena</given-name><initials>M.N.</initials><afid>60070928</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55751751100</author-url><authid>55751751100</authid><authname>Danielle Claude B.</authname><surname>Danielle Claude</surname><given-name>Bilanda</given-name><initials>B.</initials><afid>60070928</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56595272900</author-url><authid>56595272900</authid><authname>Mireille K.</authname><surname>Mireille</surname><given-name>Kameni</given-name><initials>K.</initials><afid>60070928</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56595259100</author-url><authid>56595259100</authid><authname>Oumarou Bibi-Farouck A.</authname><surname>Oumarou Bibi-Farouck</surname><given-name>Aboubakar</given-name><initials>A.</initials><afid>60070928</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:23968295700</author-url><authid>23968295700</authid><authname>Théophile D.</authname><surname>Théophile</surname><given-name>Dimo</given-name><initials>D.</initials><afid>60070928</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:16307840800</author-url><authid>16307840800</authid><authname>Pierre K.</authname><surname>Pierre</surname><given-name>Kamtchouing</given-name><initials>K.</initials><afid>60070928</afid></author><authkeywords>Anti-atherogenic | Estrogen-like | Gouania longipetala | Oxidative status | Post-menopause</authkeywords><intid>1035662295</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927546029"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927546029?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927546029&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927546029&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115001737"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927546029</prism:url><dc:identifier>SCOPUS_ID:84927546029</dc:identifier><eid>2-s2.0-84927546029</eid><dc:title>Thuja occidentalis L. and its active compound, α-thujone: Promising effects in the treatment of polycystic ovary syndrome without inducing osteoporosis</dc:title><dc:creator>Küpeli Akkol E.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>168</prism:volume><prism:pageRange>25-30</prism:pageRange><prism:coverDate>2015-06-20</prism:coverDate><prism:coverDisplayDate>20 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.03.029</prism:doi><pii>S0378874115001737</pii><dc:description>© 2015 Elsevier Ireland Ltd. Ethnopharmacological relevance Thuja occidentalis L. (Cupressaceae) has been used in folk medicine for the treatment of rheumatism, amenorrhea, cystitis, and uterine carcinomas, and as an abortifacient and contraceptive. Aim of the study The present study aimed to determine whether T. occidentalis oil and α-thujone could be beneficial in the treatment of polycystic ovary syndrome (PCOS). Materials and methods T. occidentalis oil and α-thujone were administered to rats with letrozole-induced PCOS for 21 days. At the end of 21 days, the rats were sacrificed and blood samples were taken by cardiac puncture. The levels of serum gonadotropins, steroids, blood lipid, leptin, and glucose and the values of antioxidant parameters were measured. Results The results demonstrated that estradiol and progesterone levels significantly increased, while luteinizing hormone (LH) and testosterone levels decreased in the T. occidentalis- and α-thujone-administered groups. The plasma low-density lipoprotein-cholesterol (LDL-C), leptin, and glucose concentrations were also significantly decreased in the T. occidentalis and α-thujone groups when compared to the control group. Histopathological findings demonstrated that the T. occidentalis and α-thujone groups displayed good healing. According to the phytochemical analyses, 25 compounds were identified in the T. occidentalis oil. The main constituents of the oil were the monoterpene ketones α- and β-thujone, fenchone, and sabinene, as well as the diterpenes beyerene and rimuene. Conclusion T. occidentalis essential oil and its active component, α-thujone, can be used for the treatment of PCOS without inducing osteoporosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013849</affiliation-url><afid>60013849</afid><affilname>Gazi Universitesi</affilname><name-variant>Gazi University</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013849</affiliation-url><afid>60013849</afid><affilname>Gazi Universitesi</affilname><name-variant>Gazi University</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027222</affiliation-url><afid>60027222</afid><affilname>Afyonkarahisar Kocatepe Universitesi</affilname><name-variant>Kocatepe University</name-variant><affiliation-city>Afyonkarahisar</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114655790</affiliation-url><afid>114655790</afid><affilname>Bartin University</affilname><name-variant>Bartin University</name-variant><affiliation-city/><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55446863300</author-url><authid>55446863300</authid><authname>Küpeli Akkol E.</authname><surname>Küpeli Akkol</surname><given-name>Esra</given-name><initials>E.</initials><afid>60013849</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56020070400</author-url><authid>56020070400</authid><authname>Ilhan M.</authname><surname>Ilhan</surname><given-name>Mert</given-name><initials>M.</initials><afid>60013849</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56589956000</author-url><authid>56589956000</authid><authname>Ayşe Demirel M.</authname><surname>Ayşe Demirel</surname><given-name>Mürşide</given-name><initials>M.</initials><afid>60013849</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25649540400</author-url><authid>25649540400</authid><authname>Keleş H.</authname><surname>Keleş</surname><given-name>Hikmet</given-name><initials>H.</initials><afid>60027222</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:16317954800</author-url><authid>16317954800</authid><authname>Tümen I.</authname><surname>Tümen</surname><given-name>Ibrahim</given-name><initials>I.</initials><afid>114655790</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35099613700</author-url><authid>35099613700</authid><authname>Süntar I.</authname><surname>Süntar</surname><given-name>Ipek</given-name><initials>I.</initials><afid>60013849</afid></author><authkeywords>Cupressaceae | Osteoporosis | PCOS | Thuja occidentalis | α-Thujone</authkeywords><intid>1535634464</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929379346"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929379346?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929379346&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929379346&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929379346</prism:url><dc:identifier>SCOPUS_ID:84929379346</dc:identifier><eid>2-s2.0-84929379346</eid><dc:title>Real-time Imaging of Stress-induced Cardiac Autonomic Adaptation During Realistic Force-on-force Police Scenarios</dc:title><dc:creator>Brisinda D.</dc:creator><prism:publicationName>Journal of Police and Criminal Psychology</prism:publicationName><prism:issn>08820783</prism:issn><prism:eIssn>19366469</prism:eIssn><prism:volume>30</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>71-86</prism:pageRange><prism:coverDate>2015-06-18</prism:coverDate><prism:coverDisplayDate>18 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11896-014-9142-5</prism:doi><dc:description>© 2014, Society for Police and Criminal Psychology. Operational stress is a complex matter. It requires a better understanding based on scientific knowledge of the psychophysiology of stress to improve training methods for officer’s survival and prevention of post-traumatic stress disorders. This study aimed to assess the reliability and sensitivity of heart rate and of heart rate variability (HRV) as possible objective methods to quantify police operational stress (OS) in the real world and to differentiate the contribution of overlapping physical stress (PhS) during realistic training scenarios. 12-lead ECG of 113 police officers (POs) were continuously monitored during rest, daily activity (control state), and during 172 realistic tactical training scenarios requiring the use of force and/or of shooting firearms (OS, with or without associated PhS). Baseline physiological and psychological measurements were collected on the days of the training session. POs behavior and tactical outcome were rated by police instructors and documented with multiple video cameras. Real-time imaging of tactical stress was tempted with time-varying (TV) spectral HRV analysis (HRVa). Quantitative estimates of time-domain (TD), frequency-domain (FD), and nonlinear HRV parameters were computed from standard (300 and 120 seconds) and very short-term (60 and 30 seconds) intervals. The study was approved by a local Institutional Review Board. TV spectral HRVa provided dynamic imaging of transient cardiac autonomic adaptation induced by OS and/or PhS. Quantitative estimation of the majority of TD and FD HRV parameters were not significantly affected by shortening the length of the explored time-segments from 300 to 30 seconds, as demonstrated by the intraclass correlation coefficient analysis (&gt; 0.70). Discrimination analysis of HRV parameters allowed a differentiation between rest and stress conditions and between mental and physical stress. HRVa provides dynamic imaging and quantification of transient stress-induced autonomic adaptation in police officers during realistic tactical training scenarios.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031984</affiliation-url><afid>60031984</afid><affilname>Universita Cattolica del Sacro Cuore, Rome</affilname><name-variant>Catholic University</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602206929</author-url><authid>6602206929</authid><authname>Brisinda D.</authname><surname>Brisinda</surname><given-name>Donatella</given-name><initials>D.</initials><afid>60031984</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37121084700</author-url><authid>37121084700</authid><authname>Venuti A.</authname><surname>Venuti</surname><given-name>Angela</given-name><initials>A.</initials><afid>60031984</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56644646100</author-url><authid>56644646100</authid><authname>Cataldi C.</authname><surname>Cataldi</surname><given-name>Claudia</given-name><initials>C.</initials><afid>60031984</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644647800</author-url><authid>56644647800</authid><authname>Efremov K.</authname><surname>Efremov</surname><given-name>Kristian</given-name><initials>K.</initials><afid>60031984</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56644811300</author-url><authid>56644811300</authid><authname>Intorno E.</authname><surname>Intorno</surname><given-name>Emilia</given-name><initials>E.</initials><afid>60031984</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004646657</author-url><authid>7004646657</authid><authname>Fenici R.</authname><surname>Fenici</surname><given-name>Riccardo</given-name><initials>R.</initials><afid>60031984</afid></author><authkeywords>Autonomic nervous system | Heart rate variability | Operational stress | Realistic tactical training | Very short-term analysis</authkeywords><intid>1035940083</intid><source-id>12100155619</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929311057"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929311057?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929311057&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929311057&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929311057</prism:url><dc:identifier>SCOPUS_ID:84929311057</dc:identifier><eid>2-s2.0-84929311057</eid><dc:title>Self-Regulation of Breathing as a Primary Treatment for Anxiety</dc:title><dc:creator>Jerath R.</dc:creator><prism:publicationName>Applied Psychophysiology Biofeedback</prism:publicationName><prism:issn>10900586</prism:issn><prism:volume>40</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>107-115</prism:pageRange><prism:coverDate>2015-06-18</prism:coverDate><prism:coverDisplayDate>18 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10484-015-9279-8</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Understanding the autonomic nervous system and homeostatic changes associated with emotions remains a major challenge for neuroscientists and a fundamental prerequisite to treat anxiety, stress, and emotional disorders. Based on recent publications, the inter-relationship between respiration and emotions and the influence of respiration on autonomic changes, and subsequent widespread membrane potential changes resulting from changes in homeostasis are discussed. We hypothesize that reversing homeostatic alterations with meditation and breathing techniques rather than targeting neurotransmitters with medication may be a superior method to address the whole body changes that occur in stress, anxiety, and depression. Detrimental effects of stress, negative emotions, and sympathetic dominance of the autonomic nervous system have been shown to be counteracted by different forms of meditation, relaxation, and breathing techniques. We propose that these breathing techniques could be used as first-line and supplemental treatments for stress, anxiety, depression, and some emotional disorders.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101208169</affiliation-url><afid>101208169</afid><affilname>Augusta Women's Center</affilname><name-variant>Augusta Women's Center</name-variant><affiliation-city>Augusta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024399</affiliation-url><afid>60024399</afid><affilname>Medical College of Georgia</affilname><name-variant>Medical College of Georgia</name-variant><affiliation-city>Augusta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14019920000</author-url><authid>14019920000</authid><authname>Jerath R.</authname><surname>Jerath</surname><given-name>Ravinder</given-name><initials>R.</initials><afid>101208169</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56030335000</author-url><authid>56030335000</authid><authname>Crawford M.</authname><surname>Crawford</surname><given-name>Molly W.</given-name><initials>M.W.</initials><afid>101208169</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7007007218</author-url><authid>7007007218</authid><authname>Barnes V.</authname><surname>Barnes</surname><given-name>Vernon A.</given-name><initials>V.A.</initials><afid>60024399</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56030320400</author-url><authid>56030320400</authid><authname>Harden K.</authname><surname>Harden</surname><given-name>Kyler</given-name><initials>K.</initials><afid>101208169</afid></author><authkeywords>Anxiety | Autonomic nervous system | Membrane potential | Slow deep breathing | Stress</authkeywords><intid>1535943985</intid><source-id>12041</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929302039"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929302039?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929302039&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929302039&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929302039</prism:url><dc:identifier>SCOPUS_ID:84929302039</dc:identifier><eid>2-s2.0-84929302039</eid><dc:title>Aligning Policy to Promote Cascade Genetic Screening for Prevention and Early Diagnosis of Heritable Diseases</dc:title><dc:creator>George R.</dc:creator><prism:publicationName>Journal of Genetic Counseling</prism:publicationName><prism:issn>10597700</prism:issn><prism:eIssn>15733599</prism:eIssn><prism:volume>24</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>388-399</prism:pageRange><prism:coverDate>2015-06-18</prism:coverDate><prism:coverDisplayDate>18 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10897-014-9805-5</prism:doi><dc:description>© 2015, National Society of Genetic Counselors, Inc. Cascade genetic screening is a methodology for identifying and testing close blood relatives of individuals at increased risk for heritable conditions and follows a sequential process, minimizing testing costs and the number of family members who need to be tested. It offers considerable potential for cost savings and increased awareness of heritable conditions within families. CDC-classified Tier 1 genomic applications for hereditary breast and ovarian cancer syndrome (HBOC), Lynch Syndrome (LS), and familial hypercholesterolemia (FH) are recommended for clinical use and support the use of cascade genetic screening. Most individuals are unaware of their increased risk for heritable conditions such as HBOC, LS, and FH. Consistent implementation of cascade genetic screening could significantly increase awareness and prevention of heritable conditions. Limitations to effective implementation of cascade genetic screening include: insufficient genetic risk assessment and knowledge by a majority of healthcare providers without genetics credentials; a shortage of genetic specialists, especially in rural areas; a low rate of reimbursement for comprehensive genetic counseling services; and an individual focus on prevention by clinical guidelines and insurance coverage. The family-centric approach of cascade genetic screening improves prevention and early diagnosis of heritable diseases on a population health level. Cascade genetic screening could be better supported and augmented through changes in health policy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110049898</affiliation-url><afid>110049898</afid><affilname>Oregon Health Authority</affilname><name-variant>Oregon Health Authority</name-variant><affiliation-city>Portland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016733</affiliation-url><afid>60016733</afid><affilname>Oregon Health and Science University</affilname><name-variant>Oregon Health and Science University</name-variant><affiliation-city>Portland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643952000</author-url><authid>56643952000</authid><authname>George R.</authname><surname>George</surname><given-name>Rani</given-name><initials>R.</initials><afid>110049898</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507420630</author-url><authid>6507420630</authid><authname>Kovak K.</authname><surname>Kovak</surname><given-name>Karen</given-name><initials>K.</initials><afid>110049898</afid><afid>60016733</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507420630</author-url><authid>6507420630</authid><authname>Kovak K.</authname><surname>Kovak</surname><given-name>Karen</given-name><initials>K.</initials><afid>110049898</afid><afid>60016733</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55545862992</author-url><authid>55545862992</authid><authname>Cox S.</authname><surname>Cox</surname><given-name>Summer L.</given-name><initials>S.L.</initials><afid>110049898</afid></author><authkeywords>Cascade genetic screening | Familial hypercholesterolemia | Genetic counseling | Healthcare reform | Hereditary breast and ovarian cancer syndrome | Hereditary conditions | Heritable disease | Lynch syndrome | Policy change</authkeywords><intid>2035940651</intid><source-id>15509</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929299169"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929299169?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929299169&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929299169&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929299169</prism:url><dc:identifier>SCOPUS_ID:84929299169</dc:identifier><eid>2-s2.0-84929299169</eid><dc:title>Influence of extremely low frequency electromagnetic fields on growth performance, innate immune response, biochemical parameters and disease resistance in rainbow trout, Oncorhynchus mykiss</dc:title><dc:creator>Nofouzi K.</dc:creator><prism:publicationName>Fish Physiology and Biochemistry</prism:publicationName><prism:issn>09201742</prism:issn><prism:volume>41</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>721-731</prism:pageRange><prism:coverDate>2015-06-18</prism:coverDate><prism:coverDisplayDate>18 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10695-015-0041-1</prism:doi><dc:description>© 2015, Springer Science+Business Media Dordrecht. The effects of extremely low frequency electromagnetic fields on rainbow trout growth performance, innate immunity and biochemical parameters were studied. Rainbow trout (17–18 g) were exposed to electromagnetic fields (15 Hz) at 0.01, 0.1, 0.5, 5 and 50 µT, for 1 h daily over period of 60 days. Growth performance of fish improved in different treatment groups, especially at 0.1, 0.5, 5 and 50 µT. Immunological parameters, specifically hemagglutinating titer, total antiprotease and α&lt;inf&gt;1&lt;/inf&gt;-antiprotease levels in treatment groups, were also enhanced. Total protein and globulin contents in the serum of fish exposed to 0.1, 0.5, 5 and 50 µT were significantly higher than those in the control group. No significant differences were found in serum enzyme activities, namely aspartate aminotransferase and alanine aminotransferase of fish in all treatment groups. Conversely, alkaline phosphatase level decreased in fish exposed to 0.01 and 50 µT electromagnetic fields. Meanwhile, electromagnetic induction at 0.1, 0.5, 5 and 50 µT enhanced fish protection against Yersinia ruckeri. These results indicated that these specific electromagnetic fields had possible effects on growth performance, nonspecific immunity and disease resistance of rainbow trout.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006622</affiliation-url><afid>60006622</afid><affilname>Daneshgahe Tabriz</affilname><name-variant>University of Tabriz</name-variant><affiliation-city>Tabriz</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006622</affiliation-url><afid>60006622</afid><affilname>Daneshgahe Tabriz</affilname><name-variant>University of Tabriz</name-variant><affiliation-city>Tabriz</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006622</affiliation-url><afid>60006622</afid><affilname>Daneshgahe Tabriz</affilname><name-variant>University of Tabriz</name-variant><affiliation-city>Tabriz</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25230122500</author-url><authid>25230122500</authid><authname>Nofouzi K.</authname><surname>Nofouzi</surname><given-name>Katayoon</given-name><initials>K.</initials><afid>60006622</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35367013500</author-url><authid>35367013500</authid><authname>Sheikhzadeh N.</authname><surname>Sheikhzadeh</surname><given-name>Najmeh</given-name><initials>N.</initials><afid>60006622</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56644835200</author-url><authid>56644835200</authid><authname>Mohamad-Zadeh Jassur D.</authname><surname>Mohamad-Zadeh Jassur</surname><given-name>Davood</given-name><initials>D.</initials><afid>60006622</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:10840119900</author-url><authid>10840119900</authid><authname>Ashrafi-Helan J.</authname><surname>Ashrafi-Helan</surname><given-name>Javad</given-name><initials>J.</initials><afid>60006622</afid></author><authkeywords>Biochemical parameters | Extremely low frequency electromagnetic fields | Growth performance | Nonspecific immunity | Rainbow trout | Yersinia ruckeri</authkeywords><intid>1785946833</intid><source-id>21930</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929164563"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929164563?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929164563&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929164563&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929164563</prism:url><dc:identifier>SCOPUS_ID:84929164563</dc:identifier><eid>2-s2.0-84929164563</eid><dc:title>A Controlled Evaluation of Mindfulness-Based Cognitive Therapy for Patients with Coronary Heart Disease and Depression</dc:title><dc:creator>O’Doherty V.</dc:creator><prism:publicationName>Mindfulness</prism:publicationName><prism:issn>18688527</prism:issn><prism:eIssn>18688535</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>405-416</prism:pageRange><prism:coverDate>2015-06-16</prism:coverDate><prism:coverDisplayDate>16 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12671-013-0272-0</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. This study evaluated the effectiveness of an eight-session mindfulness-based cognitive therapy (MBCT) group intervention programme for treating depression in coronary heart disease (CHD) patients. Thirty-two depressed CHD patients were assigned to an MBCT treatment group, and a demographically and clinically similar group of 30 cases were assigned to a waiting list control group. Participants were evaluated at baseline, 8 weeks, and 6-month follow-up with the Hospital Anxiety and Depression Scale (HADS), Brief Symptom Inventory (BSI), Profile of Mood States (POMS), Psychosocial Adjustment to Illness Scale (PAIS) and the Mindful Attention Awareness Scale (MAAS). After each session, MBCT participants completed the post-session Questionnaire on helpful aspects of therapy and after the programme, completed the Client Satisfaction Questionnaire. At follow-up, 71 % of the MBCT group was clinically recovered from depression compared with 50 % of the control group. The MBCT group showed significantly greater improvement than the control group on all measures with effect sizes at follow-up of d = 0.43–1.0. Increases in mindfulness on the MAAS correlated significantly with improvements on the HADS, BSI, POMS and PAIS. Key helpful aspects of therapy identified by MBCT participants included learning meditation, obtaining group support and developing optimism. There was a high level of satisfaction with the MBCT programme. These results indicate that a randomized controlled trial of MBCT for depressed CHD patients is now warranted.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005141</affiliation-url><afid>60005141</afid><affilname>University College Dublin</affilname><name-variant>University College</name-variant><affiliation-city>Dublin</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021430</affiliation-url><afid>60021430</afid><affilname>Connolly Hospital Blanchardstown</affilname><name-variant>Connolly Hospital</name-variant><affiliation-city>Dublin</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100417218</affiliation-url><afid>100417218</afid><affilname>Tallaght Hospital</affilname><name-variant>Tallaght Hospital</name-variant><affiliation-city>Tallaght</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56641712500</author-url><authid>56641712500</authid><authname>O’Doherty V.</authname><surname>O’Doherty</surname><given-name>Veronica</given-name><initials>V.</initials><afid>60005141</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7402236848</author-url><authid>7402236848</authid><authname>Carr A.</authname><surname>Carr</surname><given-name>Alan</given-name><initials>A.</initials><afid>60005141</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56641598600</author-url><authid>56641598600</authid><authname>McGrann A.</authname><surname>McGrann</surname><given-name>Alison</given-name><initials>A.</initials><afid>60021430</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56520340500</author-url><authid>56520340500</authid><authname>O’Neill J.</authname><surname>O’Neill</surname><given-name>James O.</given-name><initials>J.O.</initials><afid>60021430</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56641525600</author-url><authid>56641525600</authid><authname>Dinan S.</authname><surname>Dinan</surname><given-name>Siobhan</given-name><initials>S.</initials><afid>100417218</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56640714300</author-url><authid>56640714300</authid><authname>Graham I.</authname><surname>Graham</surname><given-name>Ian</given-name><initials>I.</initials><afid>100417218</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7101603639</author-url><authid>7101603639</authid><authname>Maher V.</authname><surname>Maher</surname><given-name>Vincent</given-name><initials>V.</initials><afid>100417218</afid></author><authkeywords>Coronary heart disease | Depression | Mindfulness | Mindfulness-based cognitive therapy</authkeywords><intid>1785917476</intid><source-id>19600166326</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929192651"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929192651?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929192651&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929192651&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929192651</prism:url><dc:identifier>SCOPUS_ID:84929192651</dc:identifier><eid>2-s2.0-84929192651</eid><dc:title>Selective homocysteine-lowering gene transfer attenuates pressure overload-induced cardiomyopathy via reduced oxidative stress</dc:title><dc:creator>Muthuramu I.</dc:creator><prism:publicationName>Journal of Molecular Medicine</prism:publicationName><prism:issn>09462716</prism:issn><prism:eIssn>14321440</prism:eIssn><prism:volume>93</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>609-618</prism:pageRange><prism:coverDate>2015-06-16</prism:coverDate><prism:coverDisplayDate>16 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00109-015-1281-3</prism:doi><dc:description>© 2015, Springer-Verlag Berlin Heidelberg. Abstract: Plasma homocysteine levels predict heart failure incidence in prospective epidemiological studies. We evaluated whether selective homocysteine-lowering gene transfer beneficially affects cardiac remodeling and function in a model of pressure overload-induced cardiomyopathy induced by transverse aortic constriction (TAC). Female C57BL/6 low-density lipoprotein receptor (Ldlr&lt;sup&gt;−/−&lt;/sup&gt;) cystathionine-β-synthase (Cbs&lt;sup&gt;+/−&lt;/sup&gt;) mice were fed standard chow (control mice) or a folate-depleted, methionine-enriched diet to induce hyperhomocysteinemia (diet mice). Three weeks after initiation of thisdiet, mice were intravenously injected with 5 × 10&lt;sup&gt;10&lt;/sup&gt; viral particles of an E1E3E4-deleted hepatocyte-specific adenoviral vector expressing Cbs (AdCBS), with the same dose of control vector, or with saline buffer. TAC or sham operation was performed 2 weeks later. AdCBS gene transfer resulted in 86.4 % (p &lt; 0.001) and 84.6 % (p &lt; 0.001) lower homocysteine levels in diet sham mice and diet TAC mice, respectively. Mortality rate was significantly reduced in diet AdCBS TAC mice compared to diet TAC mice during a follow-up period of 8 weeks (hazard ratio for mortality 0.495, 95 % CI 0.249 to 0.985). Left ventricular hypertrophy (p &lt; 0.01) and interstitial myocardial fibrosis (p &lt; 0.001) were strikingly lower in control TAC mice and diet AdCBS TAC mice compared to diet TAC mice. Diastolic function in diet AdCBS TAC mice was similar to that of control TAC mice and was significantly improved compared to diet TACmice. AdCBS gene transfer potently reduced oxidative stress as evidenced by a reduction of plasma TBARS and a reduction of myocardial 3-nitrotyrosine-positive area (%). In conclusion, selective homocysteine lowering potently attenuates pressure overload-induced cardiomyopathy via reduced oxidative stress. Key message: Plasma homocysteine levels predict heart failure incidence in epidemiological studies.Transverse aortic constriction (TAC) induces pressure overload.Selective homocysteine-lowering gene therapy reduces mortality after TAC.Selective homocysteine lowering attenuates cardiac hypertrophy and fibrosis after TAC.Decreased homocysteine levels enhance diastolic function and lower oxidative stress.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025063</affiliation-url><afid>60025063</afid><affilname>Katholieke Universiteit Leuven</affilname><name-variant>University of Leuven</name-variant><affiliation-city>Leuven</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54384001200</author-url><authid>54384001200</authid><authname>Muthuramu I.</authname><surname>Muthuramu</surname><given-name>Ilayaraja</given-name><initials>I.</initials><afid>60025063</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35393983700</author-url><authid>35393983700</authid><authname>Singh N.</authname><surname>Singh</surname><given-name>Neha</given-name><initials>N.</initials><afid>60025063</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23972361900</author-url><authid>23972361900</authid><authname>Amin R.</authname><surname>Amin</surname><given-name>Ruhul</given-name><initials>R.</initials><afid>60025063</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36782736000</author-url><authid>36782736000</authid><authname>Nefyodova E.</authname><surname>Nefyodova</surname><given-name>Elena</given-name><initials>E.</initials><afid>60025063</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56641627400</author-url><authid>56641627400</authid><authname>Debasse M.</authname><surname>Debasse</surname><given-name>Mirjam</given-name><initials>M.</initials><afid>60025063</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56641682600</author-url><authid>56641682600</authid><authname>Van Horenbeeck I.</authname><surname>Van Horenbeeck</surname><given-name>Isa</given-name><initials>I.</initials><afid>60025063</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:16052564500</author-url><authid>16052564500</authid><authname>Jacobs F.</authname><surname>Jacobs</surname><given-name>Frank</given-name><initials>F.</initials><afid>60025063</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603625669</author-url><authid>6603625669</authid><authname>De Geest B.</authname><surname>De Geest</surname><given-name>Bart</given-name><initials>B.</initials><afid>60025063</afid></author><authkeywords>Cardiomyopathy | Gene transfer | Heart failure | Homocysteine | Transverse aortic constriction</authkeywords><intid>35917553</intid><source-id>15984</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929169266"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929169266?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929169266&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929169266&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929169266</prism:url><dc:identifier>SCOPUS_ID:84929169266</dc:identifier><eid>2-s2.0-84929169266</eid><dc:title>Can Virtual Reality Effectively Elicit Distress Associated with Social Anxiety Disorder?</dc:title><dc:creator>Owens M.</dc:creator><prism:publicationName>Journal of Psychopathology and Behavioral Assessment</prism:publicationName><prism:issn>08822689</prism:issn><prism:eIssn>15733505</prism:eIssn><prism:volume>37</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>296-305</prism:pageRange><prism:coverDate>2015-06-16</prism:coverDate><prism:coverDisplayDate>16 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10862-014-9454-x</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. This study examined the ability of a Virtual Reality (VR) environment to elicit the physiological and subjective arousal typically associated with public speaking. Using 21 adults with Social Anxiety Disorder (SAD) and 24 adults with no disorder, this study had three objectives: (a) to determine whether speaking to a virtual audience elicited significant increases in physiological response (e.g., heart rate, electrodermal activity, and respiratory sinus arrhythmia) and subjective distress over baseline resting conditions (b) to determine if individuals with SAD had a greater increase in physiological arousal and subjective distress when speaking in front of a live audience vs. the virtual environment and (c) to determine whether individuals with SAD had greater changes in physiological and self-reported arousal during each speech task compared to controls. All participants gave an impromptu speech in front of an in vivo and VR audience while measures of physiological arousal and self-reported distress were obtained. Results demonstrated that the VR task elicited significant increases in heart rate, electrodermal activity, and respiratory sinus arrhythmia, and self-reported distress over baseline conditions but was less anxiety-producing than the in vivo speech task. In addition, participants reported a moderate level of presence in the VR task, but significantly less than in the in vivo task. No group differences were found on physiological measures. Clinical implications of these findings and the role of VR in the treatment of SAD are discussed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022144</affiliation-url><afid>60022144</afid><affilname>University of Central Florida</affilname><name-variant>University of Central Florida</name-variant><affiliation-city>Orlando</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56640746400</author-url><authid>56640746400</authid><authname>Owens M.</authname><surname>Owens</surname><given-name>Maryann E.</given-name><initials>M.E.</initials><afid>60022144</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006749171</author-url><authid>7006749171</authid><authname>Beidel D.</authname><surname>Beidel</surname><given-name>Deborah C.</given-name><initials>D.C.</initials><afid>60022144</afid></author><authkeywords>Exposure therapy | Physiological arousal | Public speaking | Social anxiety disorder | Subjective distress | Virtual reality</authkeywords><intid>35916810</intid><source-id>30065</source-id></entry></search-results>
